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ABSTRACT

Investigation of Dynamic Biological Systems Using Direct Injection
and Liquid Chromatography Mass Spectrometry
Adam Clayton Swensen
Department of Chemistry and Biochemistry, BYU
Doctor of Philosophy
In biological systems, small changes can have significant impacts. It is, therefore, very important
to be able to identify these changes in order to understand what is occurring in the organism. In
many cases, this is not an easy task. Mass spectrometry has proven to be a very useful tool in
elucidating biological changes even at a very small scale. Several different mass spectrometry
based techniques have been developed to discover and investigate complex biological changes.
Some of these techniques, such as proteomics, have been through years of development and have
advanced to the point that anyone can complete complex analyses of global protein identification
and measurement with relative ease. Other techniques are still developing and still have some
ground to cover in terms of experimental outcome and ease of execution. Herein we show
improvements we have made in high-throughput high-resolution mass spectrometry based
techniques to identify and quantify small molecules that are involved in significant biological
changes. To begin, we show that our improved high-resolution mass spectrometry based
lipidomics techniques are capable of identifying small changes in diseased states that are
associated with inflammation, mitochondrial shape and function, and cancer. With our
techniques we have been able to extract, identify, and quantify several thousand unique lipid
species from complex samples with confidence. Our initial studies looked at global lipidome
profiles of differing tissue types from human and mouse biopsies. This was then adapted to
compare the global lipidomes of diseased states against healthy states in asthmatic lung tissue,
cigarette smoke treated cells, high fat high sugar (HFHS) stressed animals (with and without
additional treatment), and in signaling lipids associated with cell death resistance and growth
signaling in pancreatic cancer. As a result of our success with lipidomic method improvement we
then adapted our techniques and knowledge for use in elucidating small molecule signaling
peptides and oxidation changes in proteins. We were able to show that our improved liquid
chromatography mass spectrometry based small molecule assays are capable of identifying and
quantifying small peptides and protein modifications that would otherwise be undetectable using
traditional techniques. This work resulted in the development of a scalable method to detect and
quantify the small iron-regulatory hormone known as hepcidin from a variety of samples such as
blood, urine, and cell-culture media. We were also instrumental in evaluating and revising a new
ultra-high pressure liquid chromatography (UHPLC) system that allows for better separation of
analytes from complex mixtures for identification and quantification. Through these advances we
hope to aid researchers and clinicians to enable them to use mass spectrometry to further our
knowledge about the small but significant changes that regulate complex biological systems.
Keywords: mass spectrometry, proteomics, lipidomics, metabolomics, cancer research, liquid
chromatography, sphingosine kinase, hepcidin, ceramide
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CHAPTER 1:
Introduction to Mass Spectrometry Based Global –Omics Techniques and the Development of
Novel Detection and Quantification Assays

Introduction:
Even very small changes in a cell can result in significant consequences. These
consequences could only affect the cell itself, or affect the tissue in which it resides, or even
affect the organism as a whole. For example, a relatively small change in the activity of lipid
signaling enzyme can trigger a cell to grow, metastasize, resist cell death, and eventually become
cancer; or another change could elicit the exact opposite response and make it so that the cell
becomes sensitive to cell death signaling and can be removed from the organism before problems
arise. Knowing what causes these changes and what exactly these changes are is paramount to
understanding the underlying biological process. Ever since ancient Greek philosophers began
their systematic study of anatomy and biology it has been the goal of scientists to discover what
it is that makes things live and how they are regulated.
Many techniques have been employed to study complex biological systems. Some of
these techniques have been around for hundreds of years. Most of these techniques relied on
large scale observations of the entire organism. While these studies were helpful most did not
address or even comprehend the complex chemical nature of the changes that resulted in their
observations. The advent of mass spectrometry and the ability to detect, identify, and measure
very small molecules from complex biological systems has made it possible for scientists to now
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truly understand the underlying mechanisms that regulate life processes at a scale that was not
even imagined a century ago.
Mass spectrometry is extremely useful and versatile. We can use mass spectrometry to
study single molecules from simple chemical reactions or use it to study millions of complex
molecules from complex matrices. For studying complex biological systems several techniques
have been developed to look at molecules involved in complex biological systems. It is now
possible to extract proteins from cells and tissues and identify thousands of unique proteins and
their quantification. This technique is known as proteomics. The root of the word proteomics
refers to what is being observed the “prote-”, proteins, and the neo-suffix “-omics” which comes
from the Greek –ωμα denoting a totality. We are observing the totality of the proteins from a
sample. From proteomics we can determine expression differences or regulatory differences
between proteins or even how they interact within the cell. Proteins are actually some of the
largest molecules found within cell. Smaller molecules can also be extracted and identified on a
global scale. These studies are most often known as metabolomics or the totality of metabolites
in a sample. One of the sub-categories of this technique involves the isolation and identification
of lipids from complex biological samples. This technique is known as lipidomics.
My initial research delved into the study of lipidomics and the isolation, identification,
and quantification of lipids. The field of lipidomics really has not been around for very long. It is
a complex process to extract lipids (in a non-biased way) from biological samples. It is an even
harder process to separate and give identities to these lipids species especially since their
characteristic fragmentation patterns in mass spectrometry are not as easily predicted as they are
with proteins. In this work I will demonstrate the processes I developed and improved for the
complete non-biased extraction of global lipidomes (the collection of all lipids in a cell or
2

organism) their identification and quantification. My research first identified dozens of existing
extraction techniques which I evaluated and compared to determine the best approaches to avoid
biases in extraction. From there I developed techniques that could be employed with the mass
spectrometer that minimize concentration bias in the ionization and detection of lipids through
high-resolution direct injection mass spectrometry. These techniques involved the use of ionizing
adducts doped into the complex mixtures and the use of intra-source separations. I was also
participated in the development of new software that greatly enhanced the throughput, speed,
versatility, and efficiency of our new processes. Using this toolkit of techniques, I was able to
answer many biological questions that were the result of lipid regulation. I identified lipids that
were crucial in the mechanism of mitochondrial fission, crucial in metabolic disruptions, crucial
to receptor signaling molecules, and to the regulation of cancer growth and death. Herein I
demonstrate some of the great advances we made in progressing the field of lipidomics.
During the course of my research, we found that our techniques were not only useful for
isolating small lipid molecules but they were useful in isolating other small molecules as well,
including peptide hormones. Small peptide hormones can be difficult to detect and quantify from
complex mixtures but they have many of the same chemical characteristics as lipids. Cysteinerich peptides for example contain a strongly electronegative thiol group that prevents the peptide
from ionizing well using traditional electrospray mass spectrometry techniques. Using our
knowledge gained from lipid isolations and their ionization properties we were able to isolate a
cysteine-rich key iron-regulatory hormone, hepcidin-25, from complex matrices. Then through
chemical covalent modifications we were able to overcome much of the ionization resistant
character of the molecule and allow it to be detected on common mass spectrometers even in
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very low concentrations. This technique made it possible to detect small changes that occurred in
hepcidin-25 regulation in animal models of chronic inflammation.
One of the key instrumental components required to detect small concentration changes
in proteins and peptides is a high pressure liquid chromatography (HPLC) system.
Chromatography allows for the separation of compounds in a mixture based on their chemical
characteristic and their affinity to the column material. In order for a chromatography column to
operate at its highest potential and achieve the greatest separations it needs to operate with low
volumes at very high pressure. This is especially true for small, low abundance, hard to ionize
molecules. Herein we also demonstrate our involvement with the development of an ultra-highpressure liquid chromatography system that can allow for full baseline chromatographic
separations of similar molecules for identification by mass spectrometry.
The highly efficient chromatographic separations of similar molecules can then afford to
us the ability to identify and quantify small chemical changes that occur to proteins either within
or without a biological context. Herein we show the ability to distinguish specific oxidation
differences in a protein shell, ferritin, due to the action of a previously unknown iron reducing
chemical, ophen.
Mass spectrometry has really opened the door to complex global analyses of biological
systems. Through mass spectrometry based techniques we are able to pinpoint the exact
biological mechanism that is resulting in the macroscopic changes we observe. We demonstrated
the ability to identify thousands of lipids from a single sample and use that to find an active
oncogenic pathway as well as discovering the lipid contribution to several diseased states. We
developed a technique to identify and quantify a key compound involved in iron regulation.
Additionally, we helped develop and evaluate powerful new HPLC system for sample
4

separations. Our techniques are always improving and in time and through the contribution of
thousands of scientists these techniques hold the potential to provide fast, simple, robust assays
that can be used to evaluate biological systems and treat disease.
In Depth Introduction to Lipidomics and Technique Development:
Lipids function in diverse cellular roles including: maintenance of cellular structure and
electrochemical gradients, subcellular partitioning, energy storage, first and second messenger
cell signaling, protein trafficking and membrane anchoring. These important small molecules are
often discounted and understudied. Compared to the information available for nucleic acids and
proteins, there exists a void of information regarding lipid global composition, quantitation, and
regulation. Until recently the most common experiments involving lipids only targeted single
lipid categories and/or species for study, but this gives an incomplete picture of the global
dynamic state of the cell. A more comprehensive picture of the dynamic lipidome allows for
greater in-depth study of global categorical and single lipid species regulation. Lipid species can
be identified and tracked as cellular conditions change to give an indication of underlying
regulatory processes such as metabolic disorders and disregulation of energy storage
homeostasis. Key to the analysis of the global lipidome is the ability to elucidate hundreds, and
at times thousands, of high-confidence lipid identities across all lipid categories allowing for
accurate study of the dynamic state of the lipidome and the important roles that lipids play in the
cell.
As one of the newest of the emerging “omics” fields, lipidomics has already produced
very insightful and useful data that have increased our knowledge of the cell. The causative
effect of insulin resistance1, 2, metabolic syndrome3, cardiovascular disease4, and some cancers
have been discovered through studying lipids.5 Correlations with many other varied diseases
5

including Alzheimer’s disease6, atherosclerosis7, and obesity8 have been described using a
lipidomics approach. One of the most promising areas of lipidomics research in diseases today is
the elucidation of compositional lipidome changes as a result of cancer. As cancerous cells
develop and mature, they undergo a morphological plasticity change in their cellular
membranes9. Cancerous cells show other changes that include self-regulated growth, resistance
to inhibitory and apoptotic signals, angiogenesis, immortality, and metastasis. Collectively, these
have become known as the “Hallmarks of Cancer”.9, 10 The role of lipid metabolism and the use
of lipidomics are proving to be crucial to our ability to understand some of these hallmark
characteristics of cancer. The observable cellular morphological changes can often be associated
to the cellular membrane whose composition is more than fifty percent by mass composed of
lipids.11 The morphological changes that are observed in subcellular compartments of a cancer
cell have also been correlated with compositional changes in the lipid membrane.3 These help
illuminate our understanding of observable theories such as the Warburg effect12. Compositional
changes in membrane lipids in a cancer cell are required to bestow some of the characteristics
observed in cancerous tissue or in other diseases. For example, Chenais et al. and colleagues
have demonstrated that breast cancer proliferation will only occur when coupled to membrane
lipid compositional changes.13 Legembre et al. demonstrated that lipid raft micro-domains play a
crucial role in Fas-mediated apoptosis14 which is suppressed in cancer cells. There are many
more lipid related discoveries waiting to be made.
Previous experimentation has shown that cancer cells isolated from similar tissues show
many related hallmark characteristics and behaviors.9, 10 We propose there are many similarities
in the cellular lipid compositions among many cancerous cell types. For example, when cancer
metabolism shifts to favor glycolysis under anaerobic conditions, the NADH molecular reserves
6

must be recycled. Lipogenesis is one of the cellular pathways in which the cell oxidizes and
recycles the NADPH molecular reserves without the use of the electron transport chain and
oxidative phosphorylation. In effect, cells in a state of metabolic disregulation exhibit lipogenesis
patterns that have universal similarities. We developed and outlined an approach to elucidate
lipid species that are related to the effects of cancer stress on lipid metabolism in many cancerous
cell types. There are several oncogenic pathways that could present similar behaviors in lipid
metabolism and de novo synthesis that could present a general compartmentalized sub-lipidome
fingerprint common to many if not all cancerous cell types.
The effects of diet can also have a great impact on the ability of cancer to grow. Intake of
high levels of saturated fats have been positively correlated with prostate15, ovarian16, breast17,
colon18, and other cancers. In the human pancreatic cancer cell line Capan1 it has been shown
that cancer cells deprived of serum lipids cannot sustain proliferative growth.19 Other unusual
dietary effects are seen in cancer as well. Like all cells, fast-growing cancer cells must produce a
phospholipid bilayer for their membrane. Dietary sources alone are not enough to fuel the
demand for membrane lipid species and cancerous cells must produce these lipids through de
novo anabolic pathways. It is estimated that nearly 95% of the lipids required for cell
proliferation in tumor cells are made de novo. Human cells are only capable of making certain
fatty acid chain lengths through lipogenesis and certain lipid species are favored under the
stressful conditions of a cancer cell. This leads to a heavily biased lipid membrane composition
favored toward those even-number chain length fatty acid containing de novo synthesized lipids.
Our techniques are capable of elucidating the lipid species created de novo and detect their
global signature within the cellular lipidome.

7

Disease

Lipid

Sample

Lysophosphatidylcholines, Ether
phospholipids

Monozygotic Twin Study20

Phosphatidylcholine, Phosphatidic acid,
Ceramide, Sphingomyelin,
Phosphatidylethanolamine

Monozygotic Twin Study21

Ceramide, Triacylglycerol

Mouse liver22

Hypertension

Ether lipids, Cholesterol

Blood plasma23

Diabetes

Cardiolipin

Mice myocardial sample 24

Triacylglycerol

Murine myocardium 25

Alzheimer

Sulfatide

Human Brain 26

Transient
Cerebral ischemia (stroke)

Phosphatidylcholine,
Phosphatidylinositol, Phosphatidylserine,
Sphingomyelin, Cardiolipin

Gerbils Brain 27

Breast cancer

Phosphatidylcholine

Clinical breast cancer
tissues28

Chronic
glomerulonephritis

Phosphatidylinositol, Phosphatidylserine,

Blood plasma29

Cystic fibrosis

Lysophosphatidylcholine,
Phosphatidylcholine,

Blood plasma30

Obesity

Fabry disease

Lactosylceramide, Ceramide,
Glucosylceramide, Sphingomyelin

Urine samples31

Mitochondrial dysfunction

Cardiolipin

Mouse heart32

Epithelial barrier
dysfunction

n-3 Polyunsatyrated Fatty acids

Epithelial cell33

Gaucher disease

Ceramide-monohexoside

pericardial fluid34

Hepatic steatosis

Phosphatidylcholine, Cholesteryl ester,
Triacylglycerol

Mice liver35

Neuro-degeneration

Sulfatide

Mice brain36

Ovarian cancer

Asthma

Lysophosphatidicacid,
Lysophosphatidylinositol,
Sphingosylphosphorylcholine.
Lysophosphorylcholine
Phosphatidylcholine ,
Phosphatidylglycerol

Ascitic fluid37
Sputum, bronchoalveolar
lavage fluid 38, 39

8

Heart failure

Tetralinoleoylcardiolipin

Rat and explanted human
heart 40

Mitochondrial dysfunction
and disease

Cardiolipin

Many studies with mouse,
rat, human samples For
review 41

Rheumatoid arthritis

Phosphatidylcholine,
lysophosphatidylcholine

Human plasma 42

Barth syndrome

Monolysocardiolipin, Cardiolipin

Dried bloodspots43, 44

Table 1: Lipid Associated Diseases. Fluctuations in lipid homeostasis have been associated
with many diseases and their progression. This table helps demonstrate the important role that
lipids play in cellular health and maintenance and the diversity of diseases that are assiociated
with disregulation of lipids.

Lipids have been proven to be excellent biomarkers for a variety of diseases (Table 1.1).
Previous experimentation in the field of lipidomics has already identified significant lipid species
changes that are associated with ovarian45 and prostate46 cancers. Experimentation has also
shown that many cells, especially those under cellular stress or undergoing prolific growth, are
known to shed lipid molecules into blood serum.47
Lipidomics provides a detailed fingerprint of the unique composition of lipids in a cell.
We have been able to differentiate tissues solely by fingerprinting the cells unique lipid
compositions. The lipid composition of a muscle cell varies greatly from the composition of a
brain cell and also varies greatly from the composition of a liver cell. Conversely, differences in
lipid composition of the same type of tissue from individual to individual shows little variance.
Indeed it is much harder to distinguish lipidome fingerprints of liver tissue samples from two
individuals than it is to distinguish the differences between liver and lung tissues in the same
9

individual. Some of these same lipidome fingerprinting characteristics can also be observed with
cancerous tissues. Based on our preliminary results, the lipidome profile of a rapidly growing
pancreatic cancer cell is very distinct from the lipidome profile of a healthy pancreatic cell.
Using a lipidomics approach to obtain the unambiguous identification of cancerous tissue could
prove to be invaluable for physicians treating cancer patients. Similar techniques have already
seen limited intraoperative clinical use by measuring lipid smoke vapors and identifying lipid
profile changes on the fly that can differentiate cancerous and healthy tissues.48

Figure 1: Principle component analysis of lipidomics data The shotgun lipidomics data of
lipid extracts of lung, heart, liver samples from mice. The results were subjected to PCA
analysis. The analysis contains 3 sets of biological, sample and technical replicates each.

The Importance of Complete Lipid Extraction
In order to obtain a complete and accurate snapshot of the complete global lipidome it is
vital that all of the lipids are successfully extracted from the cells or tissue that are being
analyzed. This doesn’t just apply to the lipids in the cellular membrane but also to the organelles
10

and cellular compartments and the lipids that can be found not associated with bilayers or
membranes. There are many varied extraction techniques for isolating and concentrating lipids
from samples. While these methods do extract and concentrate lipids, is there a bias in the lipid
categories and classes that are removed? In order to answer this question, we set out to test 30
popular methods for extracting lipids from simple and complex matrices. Some of the methods
claimed to extract complete lipid profiles while other techniques specialized in certain lipid
categories and classes.
Extraction Techniques
Method Name

Extraction Chemicals

Reference

Folch Method

Chloroform/Methanol

(Folch et al., J Biol Chem 1957,
226, 497)*49

Bligh and Dyer Method

Chloroform/Methanol/Isopropanol

(Can J Biochem Physiol 1959, 37,
911)*50

NaCl added

(Hajra, lipids, 1974, 9, 502)51

Acetic Acid added

(Weerheim AM et al., Anal
Biochem 2002, 302, 191)52

Two Step Bligh and Dyer

Chloroform/Methanol/Isopropanol

Method

From bacteria with focus on fatty
acids (Lewis T et al., J Microbiol
Meth 2000, 43, 107)53

Chloroform/Methanol/Isopropanol

Miniaturized method (Burja AM
et al., J Agric Food Chem 2007,
55, 4795)54

Cequier-Sanchez Method

Dichloromethane/methanol

(Cequier-Sanchez et al., J Agric
Food Chem 2008, 56, 4297)55, 56
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Hexane/isopropanol

(Anal Biochem 1978, 90, 420)57
(Eder K et al. Clin Chim Acta
1993, 219, 93)58
For Sphingolipids (Markham JE
et al., J Biol Chem 2006, 281,
22684)59
Total Lipids from Algae
(Ryckebosch E et al., JAOCS
2012, 89, 189)60

MTBE

MTBE/Methanol/Water

(Matyash V et al., J Lipid Res
2010, 49, 1137)61
Blood Lipids (Ichihara K et al.,
Lipids 2011, 46, 297)62

Hexane only

Hexane

(Baümler ER et al., JAOCS 2010,
87, 1489)63

Dry-column method

NaSO 4 (an)/Celite diatomaceous

(Marmer WN et al. Lipids 1981,

earth/dichloromethane/methanol

16, 365)64
(Elmer-Frohlich K et al., JAOCS
1992, 69, 243)65, 66

Patented Multi-Column

C-18 bonded silica column

(Lewis T et al., J Microbiol Meth
2000, 43, 107)53

“matrix solid-phase
dispersion”
Extraction of lipids from
unicellular organisms

NaCl/chloroform/methanol/water

(Axelsson, M et al., PLOS One,
2014, v.9(2), e89643)67
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Extraction of highly polar

Chloroform/methanol/water

(Dreyfus et al., Anal Biochem
1977, 249, 67-78)68

lipids
Chloroform/methanol/water/butanol

(Bodennec J et al., J Lipid Res
2003, 44, 218) Recovery after
Folch method69

Total Plasma lipids

KH 2 PO 4 /Chloroform/methanol

(Ferraz TPL et al., J Biochem

Triton X-114 detergent (Use

Biophys Meth 2004, 58, 187)70

proteins later)
Lipid extraction from

EDTA/butanol/di-isopropyl ether

(Cham BE et al., J Lipid Res
1976, 17, 176)71

serum, plasma, plant seeds
TCA/Acetone added

To remove lipids from protein
samples. (Wang R et al., J
Biological Chemistry 2004, 279,
46835)72

Plasma fatty acids and

Isopropanol/heptane/H 2 SO 4 /Silica

(Dole, V.P. et al., J Clin Invest

acylglycerols

gel

1956, 37, 350)73

Chloroform/methanol/HCl

(Honeyman et al., Biochem J
1983, 212, 489)74

Add proteinaceous disk

(Lloyd et al., Br J Haematol 1972,
23, 571-585)75

Extraction of lipids from

Chloroform/butanol/methanol/

(Kumari P et al., Anal Biochem

plant material

Heptane/NaCl

2011, 415, 134)76 Comparison
paper.
(Zheng G et al., JAOCS 2012, 89,
561) Comparison paper.
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Mineralized samples

EDTA/HCl after other methods

(Wu L et al., J Biol Chem 2002,
277, 5126)77

Skin Surface

Lipid free absorbent paper/medical

(Michael-Jubeli R et al., J Lipid

tape/diethyl ether

Res 2011, 52, 143)78

Table 2: Lipid Extraction Techniques. A list of popular lipid extraction techniques used for
total and specialized lipid extractions from various tissues. Many techniques do to the nature of
the extraction or the solvents used introduce a bias to the categories and classes of lipids that are
extracted. In order to get a complete unbiased global snapshot of lipid composition these biases
must be eliminated. We used many of the techniques listed in this table to establish our own
extraction technique with the least perceived bias we could establish.
In order to evaluate the effectiveness of each extraction technique we prepared a
representative mixture in lipid standards of known concentration and formed an emulsion from
which we attempted extraction of the lipids. This proved useful to evaluate some of the methods
but is not representative of normal extraction conditions. Most samples we use for global
lipidomics contain several thousand lipid species across all eight lipid categories. In order to test
extractions in complex samples we prepared several mouse tissue types including brain, lung,
liver, fat, and heart. We added a cocktail of lipid standards of known concentration. These lipids
contained odd-chain fatty acids, deuterium labels, or unnatural moieties in order to minimize
overlap with exogenous lipid types. We performed lipid extractions on the tissues using the
techniques listed in Table 1.2. Lipid identification and quantitation was completed using a direct
inject IonMax ESI with a flow rate of 8 microliters per minute. Collection of high-resolution
spectra (100,000 resolution) was completed using a Thermo Scientific LTQ Orbitrap XL tandem
14

mass spectrometer. Spectra were collected in positive and negative modes (intra-source
separation) with representative fragmentation spectra collected for identification and verification
purposes. Only identifications with less than 3 ppm deviations were considered for this study.
Post-run alignment was completed by realigning the spectra to match the known internal
standards that were identified from each run.
We found that the extraction techniques that were published for total lipid extractions still
have some categorical biases. Most methods rely on the hydrophobic lipid interaction and
thereby miss some of the more hydrophilic lipid species. The opposite is true for the hydrophilic
extraction techniques that do not successfully extract the lipid species with hydrophobic
character. This was determined through comparison of the different extraction quantitation
results. Since there is not a comprehensive complete database for all lipid types with
concentration data for each tissue type we needed to find another method to determine what total
concentrations we should expect in representative samples. We used a “boot-strapping” method
by which we would add lipid identifications and quantitation to a database for each method that
yielded a high detected concentration for each lipid category. Then we were able to compare
each method individually to the “boot-strapped” total to see which technique was the closest. We
determined that the Bligh and Dyer and two-step Bligh and Dyer techniques yielded the closest
percentage match to the “boot-strapped” database total. We therefore chose this method and
made only minor modifications to this technique for our future global lipidome extractions used
for future study.
Lipidomic Analysis Software, a Complex Problem:
Without additional computational help it would take years to evaluate a single complex
global lipidomic sample. One complex lipidomic sample that we analyzed in our lab had
15

~200,000 unique peaks ranging from ~50 m/z up to ~2,700 m/z. Lipids often contain one or
more neutromer peak (inclusion of a naturally occurring heavy isotope in the lipid structure).
However, the most difficult problem resulted when two different lipids had the same chemical
composition but differing structures. We can overcome some of these problems with the
inclusion of adduct species that preferentially bind to certain functional groups or through
fragmentation of the lipid to ascertain identity through fragmentation patterning. To put this
simply, it is a complex exhausting process that requires some automation in order to make the
analysis feasible.
To address this complex analysis problem, we developed a suite of lipidomic analysis
software that takes advantage of the high-resolution capabilities of the LTQ Orbitrap mass
spectrometer. This software is under the MSpire family of Ruby based mass spectrometry
software and is available freely through GitHub under the name MSpire-Lipidomics. When scans
are completed at a resolution of 100,000 or greater we see separation of peaks based on mass
defect and high-confidence identification of chemical formula. Work in our lab and in other labs
has shown that identifications made at a resolution of 100,000 or greater and with error less than
3 ppm categorical assignments of lipid identities can be made with greater than 95% accuracy in
complex samples. We aid the confidence of these assignments by making a cocktail of lipid
standards with at least one artificial (odd-chain lipid when possible) standard for each of the
eight lipid categories. We have also developed a number of confidence filters that we apply after
the initial analysis in order to decrease the number of false positive identifications. Using our
specialized and adapted extraction techniques and our suite of software tools with confidence
filters it has become common for us to identify and quantify several thousand lipid species from
a single sample. This data can then be used to look at specific targets within the lipidome or to
16

allow comparison of global characteristic changes that occurred in the entire lipidome. This data
can also be searched repeatedly for new information without need to find or develop new
specialized extractions and analyses for each experiment.
Conclusion:
The wealth of knowledge that can be gained through global and targeted lipidomic
studies is tremendous. We can learn so much about metabolism, signaling, and disease by
studying and identifying lipids. Lipids are not the simple bi-layer only molecules they were once
thought to be. Lipids have many functions that are only now being fully appreciated. But in order
for lipidomics to continue to grow and develop it is vital that confident identifications be made
and that quantitation data be accurate. This is not a simple task and unfortunately is not as simple
as other established fields such as genomics and proteomics. At this point in time the software
tools are not as robust in the lipidomics field because of the complex nature of the samples and
their varying characteristics and the complexity of the analysis. Hopefully in the future we will
have better tools and more robust software as to allow us to tap into this vital wealth of
knowledge we can gain by understanding the complex world of lipids.
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CHAPTER 2:
Global Lipidomics of Diseased States

Introduction:
Once I had established a methodical, reliable, and reproducible model for extracting lipid
species from complex biological matrices with an accompanying high-throughput highconfidence lipid identification software suite for use with high-resolution mass spectrometry data
it was time to use this knowledge to answer important scientific questions. These techniques
were used to gather data for our own research and also to help other research groups that were
trying to answer questions about lipid identifications and quantitation.
The first work that was attempted with these new techniques was a tissue-by-tissue global
lipidomics database for a mouse model. One of our collaborators provided us with mice from a
control group of one of their experiments. Mice were dissected in order to collect skin, adipose,
liver, kidney, stomach, pancreas, intestines, heart, lung, bone marrow, and brain. Samples were
treated with our extraction technique and then high-resolution mass spectrometry data was
collected in both positive and negative ion modes with intra-source separation with ammonium
acetate. Over 1500 high-confidence lipid identities were generated for each tissue type. Each
tissue type identification and quantification data point was analyzed using a principle component
analysis. Tissue type identifications could be clearly separated in a three-dimensional PCA plot.
Interestingly we found that the lipid identifications had greater variation between tissue types
than the difference that was observed between samples of the same tissues between different
individuals of the control group. Also through this experiment we were able to establish expected
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lipid concentrations within tissues because we utilized a cocktail of lipid standards of known
concentration. This database proved to be helpful for experience and also for comparison with
our future experiments.
Our developed lipidomic techniques would then be used most significantly in
collaborative efforts where I was heavily involved in experimental direction and design and
helped several lab groups and individuals identify and quantify biologically significant lipids
from complex matrices. Lipids were collected from cell tissue culture, from extracted muscle
fibers, and from whole animal organs. These collaborative efforts resulted in the publication of
four lipidomics dependent papers which follow.
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Mitochondrial fission mediates ceramide-induced metabolic disruption in skeletal muscle

Summarizing my Contribution: I was approached by the primary author and her advisor due to
my experience with global lipidomics. The hypothesis at the time was that ceramide
accumulations inside the cell and especially in mitochondria were leading to mitochondrial
fission thereby causing metabolic disruption. These accumulations were due to metabolic stress
of a high-fat high-sugar (HFHS) diet that the mice were given. I contributed in the development
of the experiment and helped develop a model to induce ceramide accumulations by adding short
chain ceramides (C2-ceramide). These short chain ceramides are cell membrane permeable and
could be added to cell through simple fluid addition. Through my work with global lipidomics
we were able to confirm that the short-chain ceramides were involved in trans-esterification
reactions resulting in fatty-acid swapping to form longer chain length functional ceramides. I
completed all of the lipid identifications and quantitation using high-resolution mass
spectrometry based lipidomics. I also contributed to the writing process, formatting, and editing
of this manuscript.
Melissa E. Smith, Trevor S. Tippetts, Eric S. Brassfield, Braden J. Tucker, Adelaide Ockey,
Adam Clayton Swensen, Tamil S. Anthonymuthu, Trevor D. Washburn, Daniel A. Kane, John T.
Prince, Benjamin T. Bikman
Biochemical Journal Dec 15, 2013, 456 (3) 427-439; DOI: 10.1042/BJ20130807

Abstract
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Ceramide is a sphingolipid that serves as an important second messenger in an increasing
number of stress-induced pathways. Ceramide has long been known to affect the mitochondria,
altering both morphology and physiology. We sought to assess the impact of ceramide on
skeletal muscle mitochondrial structure and function. A primary observation was the rapid and
dramatic division of mitochondria in ceramide-treated cells. This effect is likely to be a result of
increased Drp1 (dynamin-related protein 1) action, as ceramide increased Drp1 expression and
Drp1 inhibition prevented ceramide-induced mitochondrial fission. Further, we found that
ceramide treatment reduced mitochondrial O2 consumption (i.e. respiration) in cultured
myotubes and permeabilized red gastrocnemius muscle fibre bundles. Ceramide treatment also
increased H2O2 levels and reduced Akt/PKB (protein kinase B) phosphorylation in myotubes.
However, inhibition of mitochondrial fission via Drp1 knockdown completely protected the
myotubes and fibre bundles from ceramide-induced metabolic disruption, including maintained
mitochondrial respiration, reduced H2O2 levels and unaffected insulin signalling. These data
suggest that the forced and sustained mitochondrial fission that results from ceramide accrual
may alter metabolic function in skeletal muscle, which is a prominent site not only of energy
demand (via the mitochondria), but also of ceramide accrual with weight gain.
Introduction
The current worldwide trends of increasing prevalence of obesity and Type 2 diabetes
suggest the complexity of the problem and the need for intensive research to discover effective
therapeutic interventions. The perfect metabolic storm of dietary excess, poor nutrient quality
and reduced physical activity combine to increase the risk of developing insulin resistance,
which is not only the foundation of Type 2 diabetes, but is also a contributing cause and
consequence of obesity 1,2. These causal factors (i.e. poor diet and sedentary living) lead to two
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distinct theories regarding the aetiology of obesity-induced metabolic disruption, namely altered
mitochondrial function and ceramide accumulation.
Despite being commonly represented as small segmented structures, mitochondria are
highly dynamic organelles undergoing continuous fission and fusion. Indeed, the word
mitochondrion itself reveals the typical state of the mitochondrion (mitos means thread) as
reticular rather than segmented. Increasingly, evidence suggests that mitochondrial structure
determines mitochondrial function 3, including substrate metabolism 4,5 and mitochondrial
bioenergetics 6. Given that obesity and Type 2 diabetes have been considered a malady of
maladaptive mitochondria, it is not surprising that interventions to stimulate mitochondrial
fission or fusion elicit disparate effects on metabolic function, such as mitochondrial respiration 6
and insulin signaling 5. A consensus suggests mitochondrial fusion as beneficial in maintaining
insulin sensitivity and resisting fat gain with dietary challenge 4,5.
In addition to altered mitochondrial function, the second factor that may explain obesityinduced metabolic disruption is the accumulation of the sphingolipid ceramide. Ceramide is
known to accumulate in insulin-sensitive 7, as well as high-metabolic-rate, organs 7–10, eliciting a
potentially powerful impact on whole-body metabolic function. Ceramide is known to induce
insulin resistance via decayed Akt/PKB (protein kinase B) phosphorylation, as well as to
increase the generation of mitochondria-derived ROS (reactive oxygen species) 11,12, which are
increased with mitochondrial fission 13.
With these two distinct theories in mind (i.e. altered mitochondrial function and ceramide
accrual), we sought to test the unifying hypothesis that ceramide forces mitochondrial fission,
which is a critical mediator of ceramide-induced metabolic disruption. In support of this
hypothesis, we observed that exogenous and endogenous ceramide levels increased
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mitochondrial fission in cultured cells via Drp1 (dynamin-related protein 1). Increased fission
was associated with reduced mitochondrial respiration, likely at complex II, and increased
production of ROS. Moreover, we found that mitochondrial fission is important in ceramideinduced insulin resistance, as cells co-treated with a Drp1 inhibitor maintained insulin signalling
despite the presence of ceramide. Lastly, mice fed a HFHS (high-fat high-sugar) diet experienced
glucose and insulin intolerance relative to SD (standard diet)-fed mice and HFHS-fed mice
supplemented with myriocin to inhibit serine palmitoyltransferase, the rate-limiting enzyme in
ceramide biosynthesis. Moreover, the myriocin-treated HFHS-fed mice did not gain excess
weight. Additionally, mitochondrial respiration was partially blunted in the RG (red
gastrocnemius) muscle of the HFHS-fed mice, but not of those receiving myriocin. In the end,
the present study suggests the potential efficacy of therapies that reduce excess ceramide accrual
and/or prevent ceramide-induced mitochondrial fission in the treatment of obesity and insulin
resistance.
Materials and Methods
Animals
Male C57Bl/6 mice were separated at 8 weeks into one of four treatment groups for 12
weeks: (i) SD (Harlan Teklad 8604), (ii) HFHS diet [Harlan Taklad 2018+15% (w/v) sucrose
water], (iii) SD with myriocin (SD+Myr) and (iv) HFHS diet with myriocin (HFHS+Myr). For
myriocin supplementation, myriocin was supplied in drinking water at 2.5 μg/ml, which, with
average drinking patterns, equates to approximately 0.3 mg/kg of body weight per day 14.
Following the treatment period, mice underwent intraperitoneal glucose (Sigma–Aldrich; G7021)
and insulin (Actrapid; Novo Nordisk) tolerance tests. For both tests, mice were fasted for 6 h and
received an injection of either glucose (1 g/kg of body weight) or insulin (0.75 unit/kg of body
34

weight). Blood glucose was determined at the times indicated in the Figures using the Bayer
Contour glucose meter. Studies were conducted in accordance with the principles and procedures
outlined in the National Institutes of Health Guide for the Care and Use of Laboratory Animals
and were approved by the IACUC (Institutional Animal Care and Use Committee) at Brigham
Young University.
Cell culture
C2C12 murine myoblast cells were maintained in DMEM (Dulbecco's modified Eagle's
medium) plus 10% FBS (Invitrogen). For differentiation into myotubes, C2C12 myoblasts were
grown to confluency and the medium was replaced with DMEM plus 10% horse serum
(Invitrogen). Myotubes were used for experiments on day 4 of differentiation. For fatty acid
treatment, palmitic acid (Sigma–Aldrich; catalogue number P5585) was dissolved in EtOH
(ethanol) and diluted to the desired concentration in DMEM containing 2% (w/v) BSA (Sigma–
Aldrich; A9576) and added to the cell culture at 0.5 mM, which is a physiological post-prandial
fatty acid concentration 15. For ceramide treatment, C2 (C2-ceramide; N-acetyl-D-sphingosine;
Sigma–Aldrich; A7191) was diluted in EtOH in a 10 mM stock solution. For Mdivi-1
(mitochondrial division inhibitor 1) treatment, Mdivi-1 (Sigma–Aldrich; M0199) was diluted in
DMSO in a 50 mM stock solution. For sptlc2 (serine palmitoyltransferase, long chain base
subunit 2; also known as SPT2) knock down, procedures were followed according to the
manufacturer’s instructions (Santa Cruz Biotechnology; sc-77377).
Lipid analysis
For isolation of lipids, pellets were re-suspended in 900 μl of ice-cold
chloroform/methanol (1:2), incubated for 15 min on ice, then briefly vortex-mixed. Separation of
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aqueous and organic phases required addition of 400 μl of ice-cold water and 300 μl of ice-cold
chloroform. The organic phase was collected into a fresh vial, and lipids were dried in a vacuum
centrifuge (Eppendorf Concentrator Plus). Lipids were characterized and quantified using a
shotgun lipidomics technique on a Thermo Scientific LTQ Orbitrap XL mass spectrometer.
Evaporated lipid samples were re-suspended in a 2:1 chloroform/methanol Folch solution (200
μl). The re-suspended lipids were then combined with a modified 2:1:1.25
chloroform/methanol/propan-2-ol Bligh and Dyer solution (800 μl) with 15 mM ammonium
acetate acting as an ionizing adduct. A 1.74 μM phosphatidylethanolamine internal standard (1
μl) was spiked into each sample for mass calibration and characterization data alignment.
Samples were analysed using a 2.5 min mass-window-scanning method in positive-ion mode at a
resolution of 60000 [fwhm (full width at half maximum) at 400 m/z] for all primary MS1 scans.
MS2 (tandem MS) fragmentation data were also collected and manually verified for each mass
window to give additional confidence to the correct identification of abundant lipid species.
Three technical replicate mass spectrometer runs were performed on each sample. Samples were
injected at 10 μl/min using a direct-inject ESI soft-ionization spray head from a Hamilton
GASTIGHT glass syringe. The spray voltage and capillary temperature were maintained at 5.0
kV and 275°C respectively. Each technical replicate was run in random order to reduce
systematic bias. Data were analysed using in-house-developed peak summarization, recalibration
and lipid identification software using lipid database information from the Lipid MAPS (LIPID
Metabolites and Pathways Strategy) Lipidomics Gateway database 16. To ensure high-confidence
identifications, an intensity threshold estimated to be 5% above the instrumental static signal was
implemented. Lipid identities were only assigned when significantly observable peaks were
identified in at least two of the three technical replicate runs. Non-zero lipid quantities were
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averaged from the replicate runs. The lipid species identified across different ionization states or
with adducts were totalled together. Quantification was completed by normalizing total ion
counts to the relative abundance of the internal standard that was spiked into each sample.
Mitochondrial morphology
C2C12 myoblasts were grown to confluence in chamber slides (NUNC Lab-Tek II
Chambered Coverglass System; 155382) and differentiate at day 4. The mitochondrial dye
MitoTracker Red CMXRos (Molecular Probes; M7512), dissolved in anhydrous DMSO, was
added to cultured myotubes at a concentration of 250 nM. The cells were incubated for 30 min at
37°C in the dark and then visualized using a confocal microscope (Olympus IX81). For muscle
mitochondrial imaging, the RG muscle was extracted and fixated in 0.1 M sodium cacodylate
and 3% gluteraldehyde at pH 7.3 for 3 h. The tissues were washed in 0.1 M sodium cacodylate
(six times for 10 min) and then washed in ddH2O (double-distilled water; six times for 10 min).
Post-fixation occurred in 1% OsO4 (0.1 M for 2h at 22°C). The samples were then soaked
overnight in 0.5% uranyl acetate at 4°C. The tissues were dehydrated in a graded series of
acetone (10 min steps of 10%, 30%, 50%, 70%, 95% and 100% three times) then embedded in
Spurrs® resin. Ultrathin sections (90 nm thick) were cut with a microtome and diamond blade
then stained with 0.4% lead citrate. The samples were then imaged with transmission electron
microscopy.
Quantitative real-time PCR
Total RNA was extracted and purified from tissues using TRIzol® (Invitrogen) according
to the manufacturer's recommendations. cDNA was synthesized from mRNA via reverse
transcription–PCR using a commercial cDNA synthesis kit with oligo(dT) primers (iScript Select
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cDNA Synthesis; Bio-Rad Laboratories). Quantitative real-time PCR was performed with
Evagreen Ssofast (Bio-Rad Laboratories) using a Bio-Rad Laboratories CFX Connect Real-Time
PCR Detection system. Primer sequences were 5′-ACAGGATGCAGAAGGAGATTAC-3′ and
5′-CACAGAGTACTTGCGCTCAGGA-3′ as the forward and reverse primers respectively for
actin, 5′-ACTTGACCTCCCTACTGGC-3′ and 5′-TCCTCTATCCCGTTGACACC-3′ as the
forward and reverse primers respectively for Drp1, and 5′-AAGTCCGGGAAGCTGAAAGT-3′
and 5′-TCTCGGTTATGGAACCAACC-3′ as the forward and reverse primers respectively for
Mfn2 (mitofusin 2). β-Actin reactions were performed side by side with every sample analysed.
Changes in the mRNA level of each gene for each treatment were normalized to that of the βactin control mRNA according to Pfaffl 17.
Protein analysis
Tissue and cell extracts lysed and protein content was determined using a BCA protein
assay (Pierce) and the sample volumes were adjusted so that precisely 50 μg of protein was
loaded into each lane. After the addition of sample buffer, samples were resolved by SDS/PAGE
(10% gel), transferred on to nitrocellulose membranes and immunoblotted using methods
described previously 18. After incubation with primary antibody, blots were incubated with an
HRP (horseradish peroxidase)-conjugated secondary antibody. HRP activity was assessed with
ECL solution (Thermo Scientific) and exposed to film. The primary antibodies used were: antiSPT2 (Abcam; ab23696), anti-phospho-Akt (Cell Signaling Technology; 4058S), anti-Akt/PKB
(Sigma–Aldrich; 217005), the OxPhos Complex Kit (Invitrogen; 457999) and anti-actin (Cell
Signaling Technology; 8457S). The secondary antibodies used were: anti-(mouse IgG) (Cell
Signaling Technology; 7076S) and anti-(rabbit IgG) (Cell Signaling Technology; 7074S).
Cell and muscle fibre bundle permeabilization
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For the cells, C2C12 myotubes were detached in culture dishes with 0.05%
trypsin/EDTA (Sigma) and growth medium was added to the culture. Contents were transferred
into a tube and centrifuged for 10 min at 1500 g at room temperature (25°C). After removal of
the supernatant, cells were resuspended in mitochondrial respiration buffer 05 [MiR05; 0.5 mM
EGTA, 10 mM KH2PO4, 3 mM MgCl2·6H2O, 60 mM K-lactobionate, 20 mM Hepes, 110 mM
sucrose and 1 mg/ml fatty-acid-free BSA (pH 7.1)] plus 1 mg/ml digitonin and gently rocked at
room temperature for 5 min before centrifugation at 10 min at 1500 g for 5 min. After discarding
the supernatant, cells were then suspended in 2.2 ml of warm MiR05 and transferred into
chambers in a O2K respirometer (Oroboros Instruments). Following the respiration protocol
(outlined below), cells were removed from the chambers and used for further analysis, including
protein quantification. For skeletal muscle use, the RG muscle was quickly removed from mice
following cervical dislocation and immediately placed in ice-cold buffer X [60 mM K-Mes, 35
mM KCl, 7.23 mM K2-EGTA, 2.77 mM CaK2-EGTA, 20 mM imidazole, 20 mM tuarine, 5.7
mM ATP, 15 mM PCr (phosphocreatine) and 6.56 mM MgCl2·6H2O (pH 7.1)] and trimmed of
connective tissue. Small fibre bundles were prepared and gently separated along their
longitudinal axis under a surgical scope (Olympus, ST) to a size of around 1 mg. Bundles were
then transferred into a tube with chilled buffer X and 50 μg/ml saponin, rocked at 4°C for 30
min, and then washed in buffer Z [105 mM K-Mes, 30 mM KCl, 10 mM KH2PO4, 5 mM
MgCl2·6H2O and 0.5 mg/ml BSA (pH 7.1)] at 4°C for at least 15 min.
Mitochondrial respiration
High-resolution O2 consumption was determined at 37°C in permeabilized cells (MiR05)
and fibre bundles (buffer Z) using the Oroboros Instruments O2K oxygraph. Before the addition
of the samples into the respiration chambers, a baseline respiration rate was determined. After
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addition of the sample, the chambers were hyperoxygenated to ~350 nmol/ml. Following this,
respiration was determined according to two SUIT (substrate-uncoupler-inhibitor titration)
protocols 5. For SUIT1, to determine the general electron transport system function, electron
flow through complex I was supported by GM (glutamate+malate; 10 and 2 mM respectively) to
determine O2 consumption from proton leak (GML). Following stabilization, ADP (2.5 mM)
was added to determine oxidative phosphorylation capacity (GMP). The integrity of the outer
mitochondrial membrane was then tested by adding cytochrome c (10 μM; GMcP). Succinate
was added (GMSP) for complex I+II electron flow into the Q-junction. To determine the full
ETS (electron-transport system) capacity over oxidative phosphorylation, the chemical uncoupler
FCCP (carbonyl cyanide p-trifluoromethoxyphenylhydrazone) was added (0.05 μM, followed by
0.025 μM steps until maximal O2 flux was reached). Complex II-supported ETS was then
measured by inhibiting complex I with Rot (rotenone; 0.5 μM). Lastly, residual O2 consumption
was measured by adding antimycin A (2.5 μM) to block complex III action, effectively stopping
any electron flow. This provides a rate of respiration that is used as a baseline and all presented
values are controlled for by using this baseline. SUIT2 was used to determine complex IIspecific respiration. This SUIT involved succinate (10 mM) with the addition of Rot (0.5 μM),
for complex II-mediated leak respiration [S(Rot)L], and then ADP (2.5 mM), for complex IImediated oxidative phosphorylation. Lastly, maximal ETS was determined by the addition of
FCCP as above. Similarly, residual O2 consumption was determined by antimycin A (2.5 μM)
addition and all values were controlled for using this value.
H2O2 emission
H2O2 emission was measured using an Amplex Red Hydrogen Peroxide/Peroxidase
Assay kit (Molecular Probes; A22188). A reaction mixture containing 50 μM Amplex Red and
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0.1 unit/ml HRP in KRPG (Krebs-Ringer phosphate glucose) buffer was prepared (145 mM
NaCl, 5.7 mM sodium phosphate, 4.86 mM KCl, 0.54 mM CaCl2, 1.22 mM MgSO4 and 5.5
mM glucose). The reaction mixture was pre-warmed in a 96-well plate with 100 μl of mixture
per well. A 20 μl aliquot of cells suspended in KRPG buffer (~1.5×104 cells) were added to each
well. Samples were incubated for 1 h. Fluorescence was measured with a microplate reader
(Molecular Devices; Gemini EM).
Statistics
Data are presented as means±S.E.M. Data were compared by ANOVA with Tukey's posthoc analysis (Graphpad Prism). Significance was set at P<0.05.
Results
Ceramide increases mitochondrial fission via Drp1
Drp-1 is a mitochondrial fission protein that induces outer membrane ‘pinching’ in the
division of tubular mitochondria. Drp1 mRNA expression was significantly increased in C2C12
myotubes within 4 h of C2 (20 μM) treatment, and peaked after 8 h with a 3-fold increase
compared with the baseline (Figure 1B). Further, C2 treatment (20 μM) caused mitochondrial
fission in mouse C2C12 myotubes after 16 h of treatment (Figure 1A). However, pre-treatment
with Mdivi-1, an inhibitor of Drp1 19, prevented mitochondrial fission (Figure 1A). Functionally,
C2-induced mitochondrial fission led to significantly reduced complex II-supported respiration
(GMSP), as determined by O2 consumption in permeabilized C2C12 myotubes in the presence
of glutamate, malate, succinate and ADP (Figure 1C). This was completely prevented by the cotreatment of Mdivi-1 in cell culture (Figure 1C).

41

Figure 1: Ceramide induces mitochondrial fission and reduces mitochondrial respiration
(A) C2C12 myotubes were treated with vehicle (EtOH), C2 (40 μM) or C2 and Mdivi-1 (150
μM) for 16 h. MitoTracker Red was then added to visualize mitochondria via confocal
microscopy (n=5). (B) Following treatment with C2 (40 μM) for the indicated time points, Drp1
gene expression was quantified via quantitative real-time PCR (n=5). (C) Myotubes were treated
with C2 (40 μM) or vehicle (EtOH) in the presence or absence of Mdivi-1 (150 μM) for 16 h.
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Following treatment, the rate of O2 consumption was determined using SUIT1 (see the Materials
and methods section for details) (n=3). *P<0.05 for C2 compared with EtOH; #P<0.05 for Mdivi
compared with the control (Con).

To further confirm the effect of ceramide on mitochondrial fission, we explored the role
of endogenously produced ceramides in response to fatty acid treatment. Accordingly, the sptlc2
gene was knocked down via siRNA (Santa Cruz Biotechnology) to prevent ceramide
biosynthesis. Complete loss of the SPT2 protein was found at 120 h (Figure 2A) and subsequent
experiments occurred at this time. The functionality of knock down was confirmed by the
observed prevention of increased ceramide accrual with PA (palmitate) treatment (Figure 2B).
Similar to ceramide treatments, PA resulted in mitochondrial fission (Figure 2C). Drp1 gene
expression was elevated approximately 3-fold in the PA-treated cells, but not in SPT2knockdown cells (Figure 2D), suggestive of the importance of ceramide in Drp1 expression.
Moreover, mitochondria in cells lacking SPT2 were more fused than control cells receiving PA
(Figure 2C). Although not as dramatic as in C2-treated cells, PA treatment also blunted
respiration from complex-II-supported oxidative phosphorylation (GMSP; Figure 2E).
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Figure 2: PA mimics the effects of ceramide on mitochondrial structure and function
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(A) SPT2 was knocked down using Sptlc2 siRNA in C2C12 myotubes (n=3). (B) The functional
effect of the SPT2 knockdown was confirmed by treating control (Con) and SPT2-knockdown
(KD) myotubes (n=5). (C) C2C12 myotubes were treated with BSA and BSA-conjugated PA
(0.5 mM) for 16 h and the mitochondrial network was visualized with MitoTracker Red via
confocal microscopy and compared with PA-treated SPT2-knockdown cells (n=5). (D)
Following treatment with PA, Drp1 gene expression was quantified from control and SPT2knockdown cells via quantitative real-time PCR (n=5). (E) Control and SPT2-knockdown
myotubes were treated with BSA alone (BSA) or BSA-conjugated PA (PA) for 16 h. Following
treatment, the rate of O2 consumption was determined with SUIT1 (see the Materials and
methods section for details) (n=3). *P<0.05 for PA compared with BSA; #P<0.05 for SPT2knockdown compared with control cells.

Ceramide inhibits complex II-supported mitochondrial respiration
Given our observations of a preferentially greater inhibition of complex II-supported
mitochondrial respiration with ceramide treatment, we sought to elucidate this effect more
directly. Accordingly, C2C12 myotubes were treated overnight with C2 or vehicle (EtOH).
Although no significant difference was observed with succinate and Rot alone to determine leak
respiration [S(Rot)L], the addition of ADP to induce oxidative phosphorylation elicited a robust
increase in respiration in vehicle-treated cells that was less evident in ceramide-treated cells
(Figure 3A). The same discrepancy was observed with the addition of the uncoupler FCCP,
which collapses the chemiosmotic gradient via proton transport. This change in complex IIsupported respiration occurred independent of a change in the amount of complex II (Figure 3B,
CII – Fp subunit).
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Figure 3: Complex II-mediated mitochondrial respiration is adversely affected by ceramide
treatment
(A) Vehicle- (EtOH) and C2- (40 μM) treated cells were permeabilized and O2 consumption was
determined with SUIT2 (see the Materials and methods section for details) (n=6). *P<0.05 for
C2 compared with EtOH. (B) Complex II (CII) Fp subunit levels were determined in C2-treated
cells over various time points as an assessment of complex II presence in the cells (n=2).
Inhibition of mitochondrial fission prevents reduced mitochondrial respiration with ceramide ex
vivo
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Next, we sought to replicate our findings in whole muscle. Accordingly, the RG muscle
was dissected from C57Bl6 mice and permeabilized. After permeabilization, fibre bundles were
washed and placed in oxygraph sample chambers (O2K, Oroboros Instruments) filled with 2 ml
of buffer Z and vehicle (EtOH) or C16-ceramide (20 μM). Further analyses included the addition
of Mdivi-1 to inhibit Drp1-mediated mitochondrial fission. Upon placement in the chambers,
fibre bundles were incubated in the buffer at 37°C for 10 min. Following this, respiration was
determined according to the indicated SUIT protocol 5. We observed a significant increase in
leak respiration (GML) in those fibres treated with Mdivi-1, although this difference did not
linger with the addition of ADP (Figure 4). We are not the first to note increased proton-leakdependent respiration with increased mitochondrial fusion 20. In contrast with Mdivi-1 treatment,
ceramide-treated muscle fibre bundles exhibited a significantly blunted respiration with complex
I- and II-supported respiration. No effect was observed when fibre bundles were treated with C2
or C6-ceramide (results not shown).
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Figure 4: Mitochondrial fission is a requisite for ceramide-induced decayed mitochondrial
respiration
O2 consumption was determined in permeabilized RG muscle treated with vehicle (EtOH),
vehicle with Mdivi-1 (EtOH+Mdivi) to inhibit Drp1, C16-ceramide (C16) alone or with Mdivi-1
(C16+Mdivi) using SUIT 1 (see the Materials and methods section for details) (n=5). *P<0.05
for C16 compared with EtOH; #P<0.05 for Mdivi compared with the control (Con).

Mitochondrial fission is necessary for ceramide-induced ROS generation and insulin
resistance in muscle
Mouse myotubes were treated with C2 or PA in the presence or absence of Mdivi-1 for
12 h. Following treatment, cells were washed with PBS and exposed to Amplex Red to quantify
H2O2 production. Although C2 alone elicited an increase in fluorescence with Amplex Red
treatment, this effect was mitigated by inhibition of mitochondrial fission by Mdivi-1 co48

treatment (Figure 5A). Considering the evidence suggesting redox-sensitive phosphorylation
events in the regulation of the insulin signalling pathway 21, we explored the effect of blocking
mitochondrial fission, with its subsequent reduction in H2O2 formation, on muscle insulin
signalling. Inhibition of mitochondrial fission with Mdivi-1 protected Akt/PKB phosphorylation
with insulin stimulation in C2-treated myotubes (Figure 5B).

Figure 5: Mitochondrial fission inhibition prevents ceramide-induced H2O2 generation
and insulin signaling
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(A) C2C12 myotubes were treated with vehicle (EtOH), Mdivi-1 (Mdivi), C2 and C2 with
Mdivi-1 (C2+Mdivi) followed by incubation with Amplex Red (n=5). (B) Following a 16 h
treatment with C2 without (C2) or with (C2+Mdivi) Mdivi-1, cells were treated with 100 nM
insulin for 10 min (n=3). Inhibition of mitochondrial fission prevented both C2-induced H2O2
and the loss of insulin signalling. *P<0.05 for C2 compared with EtOH; #P<0.05 for C2+Mdivi
compared with C2.

ROS generation is not necessary for mitochondrial fission or altered mitochondrial
respiration with PA and ceramide treatments
To address whether ROS are necessary for the mitochondria-specific effects of both
ceramide and PA, we replicated earlier experiments with the addition of the glutathione
precursor NAC (N-acetylcysteine), an effective reducing agent known to neutralize H2O2 22,23.
We found that C2-treated cells that were pre-treated with NAC appeared to experience a similar
degree of mitochondrial fission as the C2 treatment alone (Figure 6A). Functionally, NAC pretreatment likewise failed to prevent reduced mitochondrial respiration in ceramide- and PAtreated myotubes (Figures 6B and 6C respectively).
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Figure 6: NAC does not prevent ceramide-induced mitochondrial alterations
(A) C2C12 cells were treated with vehicle (EtOH), C2 (40 μM) and C2 with NAC (5 mM;
C2+Mdivi) followed by incubation with Amplex Red (n=2). (B) Myotubes were treated with
vehicle (EtOH) or C2 (40 μM) in the presence or absence of NAC (5 mM) for 16 h (n=3). (C)
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Myotubes were treated with vehicle (BSA) or PA (0.5 mM) in the presence or absence of NAC
(5 mM) for 16 h (n=3). Following both treatments in (B) and (C) the rate of O2 consumption was
determined with SUIT1 (see the Materials and methods section for details). *P<0.05 for C2 and
PA compared with EtOH and BSA.

Inhibition of ceramide biosynthesis prevents metabolic disruption with dietary challenge
Male 8-week-old C57Bl6 mice were separated into one of four treatment groups for 12
weeks: (i) SD, (iii) HFHS diet, (iii) SD with myriocin (SD+Myr) and (iv) HFHS diet with
myriocin (HFHS+Myr). No differences in food or water consumption were noted between the
SD and SD+Myr groups and the HFHS and HFHS+Myr groups, although both the HFHS and
HFHS+Myr groups consumed more water than the SD groups (results not shown). Marked
differences in body weight were noted early in the dietary intervention, which lingered until the
conclusion of the study period. Specifically, the HFHS group, but not the HFHS+Myr group,
gained significantly greater body weight over the course of the study (Figure 7A). Further, the
HFHS group experienced a significant reduction in glucose and insulin tolerance, but the
HFHS+Myr group did not have a reduced response (Figures 7B and 7C respectively).
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Figure 7: Ceramide inhibition prevents diet-induced weight gain and improves insulin
sensitivity
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(A) Following a 12 week dietary intervention, mice fed a HFHS diet weighed significantly more
than mice fed a SD without (SD) or with (SD+Myr) myriocin. Mice fed a HFHS diet with
myriocin supplementation (HFHS+Myr) did not gain excess weight. Following the treatment
period, intraperitoneal glucose [(B) 1g/kg of body weight] and insulin [(C) 0.75 unit/kg of body
weight] tolerance tests were conducted. In every case, myriocin improved the metabolic profile
(n=6). *P<0.05 for the HFHS diet compared with the HFHS diet and myriocin.

Owing to insufficient samples of RG muscle, full statistical analyses were not performed
for ceramides and Drp1 expression in the RG. Thus, to determine the effect of intervention in a
similarly highly oxidative mitochondria-rich tissue, the soleus muscle was used as a surrogate for
a complimentary analysis. Both muscles are commonly used in analyses of muscle mitochondrial
capacity 24. Ceramide levels were significantly elevated in the soleus of the HFHS group
compared with the SD groups, but not in the HFHS+Myr group (Figure 8B). As mentioned
above, statistical analysis of RG ceramide levels (Figure 8A) was not possible, although a trend
appears to suggest a difference exists. Analysis of Drp1 expression in the soleus muscle revealed
a robust increase in Drp1 expression with the HFHS diet over the other groups (Figure 9B),
suggesting a role for Drp1 in mediating diet-induced mitochondrial fission. A lack of tissue for
RG muscle analysis prevented statistical analysis, although the given data suggested a similar
trend in the RG as noted in the soleus muscle (Figure 9A). Analysis of mitochondrial O2
consumption in permeabilized muscle (RG) fibre bundles revealed a selective reduction in
respiration in the HFHS group (Figure 9C). Specifically, both myriocin-treated groups had
slightly higher leak respiration in the presence of GM alone (GML). This trend of myriocin to
increase respiration continued to various degrees throughout the protocol, but was most apparent
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in the HFHS group. Moreover, respiration was blunted with both complex I- and II-mediated
oxidative phosphorylation, although the difference was once again amplified with complex IIsupported respiration. A portion of each RG muscle was prepared for electron microscopy to
determine mitochondrial morphology with the various interventions (Figure 10). Little difference
in size of both the subsarcolemmal (Figure 10, left-hand panels) and intramyofibrillar (Figure 10,
right-hand panels) mitochondrial populations was noted between the SD-fed animals (Figure
10A) and those with myriocin supplementation (Figure 10B). In contrast, the HFHS diet
appeared to result in markedly smaller and more segmented mitochondria than the SD groups
(Figure 10C). However, long-term treatment of HFHS-fed animals with myriocin prevented this
(Figure 10D). In particular, the subsarcolemmal mitochondria in the RG from the HFHS+Myr
group appeared larger than those from any other group.
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Figure 8: Skeletal muscle ceramide levels with treatments
Ceramides were measured in the RG (A) and soleus (B) muscles. Owing to a shortage of
samples, statistical analysis was not possible for the RG muscle (n=2–3). As a surrogate for RG
muscle, levels of ceramide were analysed in the soleus muscle, which is a similarly highly
oxidative muscle fibre type. Ceramide levels were significantly elevated in the soleus muscle
after the HFHS compared with the SD treatment (n=6). Although the reduction in ceramides was
not significant with the addition of myriocin (Myr) in the HFHS group, the trend is suggestive of
an effect. *P<0.05 for the HFHS compared with the SD.
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Figure 9: Ceramide inhibition protects diet-induced alterations in mitochondrial function
Drp1 expression was determined in the RG (A) and soleus (B) muscles from mice following a 12
week dietary intervention. Owing to insufficient samples of RG muscles (n=2–3), the soleus
muscle was used as a surrogate (n=6). Mice fed a HFHS diet expressed significantly higher
levels of Drp1 in the soleus muscle than all other groups. (C) O2 consumption was determined in
permeabilized RG muscles from the four dietary interventions using SUIT1 (see the Materials
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and methods section for details) (n=6). *P<0.05 for the HFHS diet compared with the SD.
#P<0.05 for HFHS diet and myriocin compared with the HFHS diet alone.

Figure 10: Ceramide inhibition prevents diet-induced alterations in mitochondrial
morphology
58

Visualization of subsarcolemmal (left-hand panels) and intramyofibrillar (right-hand panels) RG
muscle mitochondrial fractions suggest that myriocin supplementation increased mitochondrial
size [(B) compared with (A) and (D) compared with (C)] (n=3). In particular, the HFHS
intervention appeared to result in markedly smaller mitochondria (C), but not with myriocin
supplementation (D). Scale bars, 1 μm.

Discussion
The basic conclusion of the present study is that division of the cellular mitochondrial
network in muscle cells mediates the reduced mitochondrial respiration and loss of insulin
signalling that accompanies ceramide accumulation. Given the widespread finding of skeletal
muscle ceramide accumulation with weight gain 8,25–27, this conclusion invites a novel
perspective in understanding the observations that defective mitochondrial fusion may cause,
exacerbate, or is certainly related to, obesity and insulin resistance 4,5,20,28,29.
The metabolic ramifications of the physical structure of mitochondria have appropriately
received more attention in recent years and may assist in understanding metabolic disruption
with obesity. Indeed, mitochondrial morphology may be relevant in the altered fuel handling
evident in the muscle of obese and diabetic humans. The observation by Kelley et al. 30,31 of a
‘metabolic inflexibility’ in obese and diabetic subjects stemmed from the inability of these
subjects to oxidize glucose when provided with a glucose load. Interestingly, these same groups
of subjects have been found to carry reduced proteins that drive mitochondrial fusion, namely
Mfn2 20,28,32. A lack or overexpression of Mfn2 decreases or increases glucose oxidation
respectively 33. Thus the observed metabolic inflexibility with obesity/diabetes may in reality
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stem from a shift towards mitochondrial fission and reduced mitochondrial fusion. Although our
report focuses on Drp1, which we consistently found elevated in response to ceramide, we have
also explored the effect of ceramide on Mfn2. Whereas the HFHS diet had no effect on soleus
muscle Mfn2 expression, myriocin supplementation had a dramatic effect. Mfn2 expression was
increased significantly in both the SD+Myr and HFHS+Myr groups (Supplementary Figure S1 at
http://www.biochemj.org/bj/456/bj4560427add.htm). It is tempting to speculate that ceramide
accumulation in skeletal muscle would force mitochondrial fission, which would subsequently
result in reduced mitochondrial capacity and function, as well as insulin resistance, ultimately
exacerbating weight gain.
Myriocin is usually administered every 24–48 h by intraperitoneal injection. Given the
efficacy of oral myriocin supplementation, the findings of the present study reveal a novel and
effective delivery method for myriocin. Regardless of the delivery, ceramide inhibition with
myriocin has consistently led to an improved metabolic profile and resistance to metabolic
insults, such as diet-induced obesity. Indeed, we observed a similar resistance to the deleterious
effects of dietary challenge on glucose and insulin tolerance as that noted by the Lopaschuk and
co-workers 34. Moreover, it is tempting to speculate that the reduced whole-body O2
consumption in the HFD (high-fat diet) group, but not in the myriocin-treated HFD group, in
their study 34 is partly a result of the more dramatic and disparate O2 consumption rates we
observed in permeabilized ceramide-depleted and -replete muscle cells and fibre bundles
(Figures 1, 2, 4 and 8). We also noted a lack of body weight gain with myriocin supplementation
in spite of an HFHS diet intervention (Figure 8A). These results support similar findings of an
obesity-resistant effect of myriocin 35 and other inhibitors of ceramide biosynthesis 36, be they
pharmacological 37 or genetic 38.
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The results from the present study support those by Jheng et al. 5 that recently explored
the effect of lipid overload and dietary challenge on mitochondrial fission and function.
Although they did not elucidate the role of ceramides, Jheng et al. 5 found that PA, but not
unsaturated oleate, increased mitochondrial fission. Interestingly, they found that addition of
oleate to PA-treated cells prevented the mitochondrial fission evident with PA alone. Given our
previous observation that oleate prevents PA-induced ceramide accrual 8, the findings by Jheng
et al. 5 support ceramide's role as an activator of mitochondrial fission. Further, Jheng et al. 5
observed that Drp1 expression was increased with PA treatment and was an essential mediator of
PA-induced mitochcondrial fission. Critically, although we similarly found an increase in Drp1
expression with PA treatment, inhibition of ceramide synthesis blunted the effect (Figure 2D).
These studies suggest a paradigm wherein ceramide leads to altered mitochondrial
dynamics, with subsequent changes in mitochondrial function, including altered respiration and
ROS generation. However, oxidative stress from ROS is among the numerous cellular insults
known to induce ceramide biosynthesis 36, which invites the theory that ROS are both a cause
and consequence of the observed mitochondrial dysfunction. To address the possibility that ROS
mediate, and thus precede, ceramide-induced changes in mitochondrial function, multiple
experiments with ceramide treatment were replicated with the addition of NAC, a glutathione
precursor known to reduce levels of H2O2 22,23,39. Pre-treatment with NAC failed to protect cells
from ceramide-induced mitochondrial fission (Figure 6A) as well as reduced mitochondrial
respiration with both C2 and PA treatment (Figures 6B and 6C). Altogether, these findings
suggest that ROS do not mediate the mitochondria-specific effects of ceramide accumulation.
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The site of ceramide biosynthesis in the cells may be relevant in the ability of ceramide to
induce mitochondrial fission. Interestingly, the two organelles involved in mitochondrial fission,
namely the mitochondria and the ER (endoplasmic reticulum), are two prominent sources of
intracellular ceramide 11,40,41. Physical coupling between the ER and mitochondria is necessary
for mitochondrial fission, which may explain the somewhat disparate findings that have studied
ceramide and mitochondrial function. Previous work that has explored the specific effect of
ceramide on mitochondrial respiration has been performed largely, perhaps exclusively, in
isolated mitochondria 36,42–44. Our observation of a ceramide-induced reduction in mitochondrial
respiration in intact cells and muscle fibers is the first we know of. The different sources and
state of the mitochondria (i.e. isolated heart mitochondria compared with mitochondria in
permeabilized skeletal muscle cells and fibers) may explain differences in the effects of ceramide
on specific aspects of mitochondrial O2 consumption. In particular, we consistently found a
decay in complex II-mediated respiration, whereas Gudz et al. 43 found complex III to be highly
affected by ceramide accrual, although complex II involvement in respiration was not
determined in that study. Di Paolo et al. 42, in contrast, found a complex II-specific inhibition of
ceramide with state 3 (ADP supported) respiration, which corroborates the findings of the
present study (Figure 3). It is important to note that given the necessity of physical interaction
between the ER and mitochondria for mitochondrial fusion and fission, isolated mitochondria
seem to be a less ideal model with which to explore the role of mitochondrial structure in altering
mitochondrial respiration. Indeed, we have found that treating isolated heart mitochondria with
Mdivi-1 is not effective at preventing a loss of respiration with ceramide (T.S. Tippetts and B.T.
Bikman, unpublished work). Given that ceramide reduces respiration in isolated mitochondria
42,43

, and presumably in the absence of any known fusion–fission events, these observations
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introduce the possibility of a fission-independent mechanism. However, we believe our
consistent findings in whole cells and muscle fibres that fission is required for ceramide-induced
loss of mitochondrial respiration represents the likely physiological event, where changes in
mitochondrial structure can occur very rapidly. Indeed, significant mitochondrial fission can
occur in minutes in response to PA 5. Perhaps related to this, we found that waiting 5–10 min
was necessary to observe a reduction in respiration in muscle fibre bundles treated with C16ceramide (Figure 4), which is sufficient time for ceramide to cause mitochondrial fission
(Supplementary Figure S2 at http://www.biochemj.org/bj/456/bj4560427add.htm).
To confirm the specificity of ceramide to modify mitochondrial structure and function,
we regularly used dihydroceramide as a negative control. Dihydroceramide (C2, C6 and C16 in
permeabilized muscle fibres and C2 in permeabilized C2C12 myotubes) had no effect on altering
mitochondrial respiration, a finding supported by others 42,43. Nevertheless, dihydroceramides,
the immediate precursor to ceramides, may regulate respiration. Siddique et al. 45 recently found
that cells deficient in Des1 (dihydroceramide desaturase 1), which lack the enzyme that
introduces the distinguishing double bond in the sphingolipid backbone, accumulate
dihydrosphingolipids, including dihydroceramides, exhibit reduced mitochondrial respiration 45.
A critical difference may be the experimental protocols used in the various studies. Whereas the
present study and others 42,43, which found no effect of dihydroceramides, used exogenous (and
mostly non-biological, e.g. C2 and C6) dihydroceramides, the results by Siddique et al. 45 were
observed under conditions of endogenously altered dihydrosphingolipid levels where a variety of
dihydroceramides are increased, including C18, C24 and C24:1.
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Ceramide has long been known to inhibit insulin signaling via a two-pronged attack on
Akt/PKB action, inhibiting Akt/PKB translocation to the cell membrane as well as activating a
protein phosphatase that prevents sufficient Akt/PKB phosphorylation46,47. The observation in
the present study, and others5, of the insulin-sensitizing effect of inhibited mitochondrial fission
may lend credence to the theory that redox-sensitive alterations in phosphorylation of proteins
relevant in insulin signal transduction may mediate insulin resistance21.
Inhibition of ceramide-induced mitochondrial division may have diverse clinical
applications, from acutely protecting against ischaemia/reperfusion injury48 to chronically
treating insulin resistance5. Ultimately, however, an erroneous assumption from these results
would be that mitochondrial fusion is better for the cell than mitochondrial fission. In reality,
maintaining freedom for both fusion and fission is a fundamental factor to ensure adequate
bioenergetic utility of the mitochondria. The results of the present study suggest that ceramide
may prevent the healthy dynamic cycling of mitochondria, essentially forcing sustained fission.
Given the relevance of mitochondrial morphology to obesity and insulin resistance/diabetes29,
these findings add to the mounting obvious applications and benefits of pharmaceutical therapies
aimed at preventing excess ceramide biosynthesis. Nonetheless, and importantly, on-going
efforts should explore the most effective combination of physical activity and, especially,
improved nutritional intervention to prevent excess ceramide accumulation and alleviate
subsequent metabolic disruption.
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Abstract
Background
Cigarette smoking is a common and lethal worldwide habit, with considerable mortality
stemming from its deleterious effects on heart function. While current theories posit altered
blood lipids and fibrinogen metabolism as likely mediators, none have explored the role of the
sphingolipid ceramide in exacerbating heart function with smoke exposure. Ceramide production
is a consequence of cigarette smoke in the lung, and considering ceramide’s harmful effects on
mitochondrial function, we sought to elucidate the role of ceramide in mediating smoke-induced
altered heart mitochondrial respiration.
Methods
Lung cells (A549) were exposed to cigarette smoke extract (CSE) and heart cells (H9C2)
were exposed to the lung-cell conditioned medium. Adult male mice were exposed sidestream
cigarette smoke for 8 wk with dietary intervention and ceramide inhibition. Ceramides and heart
cell or myocardial mitochondrial respiration were determined.
Results
Lung cell cultures revealed a robust response to cigarette smoke extract in both
production and secretion of ceramides. Heart cells incubated with lung-cell conditioned medium
revealed a pronounced inhibition of myocardial mitochondrial respiration, though this effect was
mitigated with ceramide inhibition via myriocin. In vivo, heart ceramides increased roughly
600% in adult mice with long-term sidestream cigarette smoke exposure. This resulted in a
significant ceramide-dependent reduction in left myocardial mitochondrial respiration, as heart
mitochondria from the mice exposed to both smoke and myriocin injections respired normally.
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Conclusions
These results suggest ceramide to be an important mediator of altered myocardial
mitochondrial function with cigarette smoke exposure. Thus, anti-ceramide therapies might be
considered in the future to protect heart mitochondrial function with smoke exposure.
Introduction
Cigarette smoke exposure is the leading cause of preventable deaths worldwide1 and is
among the top ten contributors to the worldwide health burden2. Despite concerted social efforts
to reduce smoking prevalence, current trends suggest the number of smokers will increase
worldwide3,4. Moreover, cigarette smoke is a common inhaled toxin—almost half of the U.S.
population is regularly exposed to cigarette smoke5,6 and approximately 20% of young children
live with someone who smokes in the home7. Much of smoking’s health burden stems from the
increased risk of chronic diseases like cancer, emphysema, and cardiovascular disease8,9,
including cardiomyopathy—a deterioration of heart muscle.
Cardiomyocytes are highly oxidative cells with a tremendous reliance on mitochondrial
capacity 10, and altered mitochondrial function can lead to heart failure11,12,13, a common
consequence of cardiomyopathy. Considering the importance of healthy mitochondrial function
in cardiomyocyte homeostasis, a valuable area of study is to elucidate the factors that mediate
altered heart mitochondrial physiology and its effects with cigarette smoke exposure. Previous
studies have observed that cigarette smoke exposure inhibits mitochondrial respiratory function
in blood cells14 and myocardium15, but a mediating mechanism has yet to be identified.
Cigarette smoke has long been known to robustly activate inflammatory pathways in the
lung16, which increases ceramide biosynthesis17,18. Importantly, ceramides are known to disrupt
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mitochondrial structure and function19,20, possibly increasing risk of cardiomyopathy21. Thus, the
purpose of these studies was to determine whether the sphingolipid ceramide mediates
cardiomyocyte mitochondrial disruption with cigarette smoke exposure. Considering the lung’s
apposition with the environment, the lung is a logical site of external pathogen-induced stress, a
product of which is ceramide biosynthesis17. Moreover, given the heart’s location relative to
pulmonary blood flow, the heart is a reasonable site of lung-derived ceramide uptake.
Materials and Methods
Cell culture
Cigarette smoke extract (CSE) was generated as previously described with slight
modifications22. Briefly, one 2RF4 research cigarette (University of Kentucky, Lexington, KY)
was continuously smoked by connecting the filtered end of the cigarette to a vacuum pump,
pulling the particles into 5 ml of DMEM/F12 and the resulting medium was defined as 100%
CSE. The total particulate matter content of 2RF4 cigarettes is 11.7 mg/cigarette, tar is 9.7
mg/cigarette, and nicotine is 0.85 mg/cigarette. Dilutions were made using DMEM/F12 + 10%
FBS. Human type II–like pulmonary adenocarcinoma cells (A-549; passage 10-15) were
maintained in DMEM/F12 supplemented with 10% FBS (Invitrogen) and antibiotics. Cells were
split into 6-well dishes and grown to 80% confluence. H9C2 cardiomyocytes were maintained in
DMEM +10% FBS. For differentiation into myotubes, cells were grown to confluency and the
medium was replaced with DMEM +10% horse serum (Invitrogen, Grand Island, NY).
Myotubes were used for experiments on day 3 of differentiation. A-549 cultures were exposed to
media supplemented with 10% CSE or media alone for 4 h, after which the medium was
transferred to differentiated H9C2 cardiomyocytes (termed “conditioned medium”) for 12 h.
Where indicated, cells were treated with myriocin (10 μM, Sigma, M1177), a known and widely
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used inhibitor of ceramide biosynthesis. Muscle cells were harvested for RNA, protein, and lipid
isolation following treatments. Cell survival during treatments was confirmed by trypan blue
exclusion.
Animals
Male C57Bl6 mice were housed in a conventional animal house and maintained on a 12hour light–dark cycle. Two animal studies were conducted. In the first study, animals received
standard diet chow (Harlan Teklad 8604) and water ad libitum. At 12 wk of age, animals were
randomly divided into room air and cigarette smoke (CS)-exposed groups. Mice were placed in
soft restraints and connected to the exposure tower of a nose-only exposure system (InExpose
System, Scireq, Canada). Animals were nasally exposed to sidestream CS generated by research
cigarettes where a computer-controlled puff was generated every minute, leading to 10 min of
CS exposure followed by 10 min of fresh air, repeated once. The CS-exposed group inhaled CS
from two cigarettes per day for one week, at which point the dosage was increased to two
cigarettes twice daily. Control animals were similarly handled and restrained in fresh air for the
same duration. For the second study, 12-wk-old mice were separated into one of eight treatment
groups for eight weeks. Each of the following groups were duplicated to have one group receive
vehicle or myriocin injections (0.3 mg/kg) every other day for a total of eight groups: 1) control
– standard diet chow, no smoke; 2) cigarette smoke exposure (two cigarettes, twice daily) with
standard diet chow; 3) high-fat, high-sugar diet (Harlan Teklad 45F30S); 4) high-fat, high-sugar
diet with cigarette smoke exposure. Tissues were harvested at the conclusion of the study period.
Studies were conducted in accordance with the principles and procedures outlined in the
National Institutes of Health Guide for the Care and Use of Laboratory Animals and were
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approved by the Institutional Animal Care and Use Committee (IACUC) at Brigham Young
University.
Lipid analysis
For isolation of lipids, cell pellets or tissue were suspended in 900 μl ice-cold
chloroform/methanol (1:2) and incubated for 15 minutes on ice, then briefly vortexed. Separation
of aqueous and organic phases required addition of 400 μl of ice-cold water and 300 μl of icecold chloroform. The organic phase was collected into a fresh vial, and lipids were dried in a
vacuum centrifuge (Eppendorf Concentrator Plus). Lipids were characterized and quantified
using a shotgun lipidomics technique on a Thermo Scientific LTQ Orbitrap XL mass
spectrometer. Evaporated lipid samples were re-suspended in a 2:1 chloroform: methanol Folch
solution (200 μL). The re-suspended lipids were then combined with a modified 2:1:1.25
chloroform: methanol: isopropanol Bligh and Dyer solution (800 μL) with 15 mM ammonium
acetate acting as an ionizing adduct. A 1.74 μM phosphatidylethanolamine, 1 μM C-17 ceramide,
1 μM tripalmitin internal standard cocktail (1 μL) was spiked into each sample for mass
calibration and characterization data alignment. Samples were analyzed using a 2.5-minute masswindow scanning method in positive-ion mode at a resolution of 100,000 (FWHM at 400 m/z)
for all primary MS1 scans. MS2 fragmentation data was also collected (PQD at relative intensity
of 35) and manually verified for each mass window to give additional confidence to the correct
identification of abundant lipid species. Three technical replicate mass spectrometer runs were
performed on each sample. Samples were injected at 8 μL/min using a direct-inject electrospray
ionization (ESI) soft-ionization spray head from a Hamilton GASTIGHT glass syringe. A
nitrogen sheath gas spray flow rate of 8 (arb. Units) was used for all runs. The spray voltage and
capillary temperature were maintained at 5.0 KV and 275°C respectively. Each technical
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replicate was run in random order to reduce systematic bias. Data were analyzed using in-house
developed peak summarization, recalibration, and lipid identification software using lipid
database information from the LIPID Metabolites and Pathways Strategy (Lipid MAPS)
Lipidomics Gateway database23. To ensure high-confidence identifications, an intensity
threshold estimated to be 5% above instrumental static signal was implemented. Lipid identities
were only assigned when significantly observable peaks were identified in at least two of the
three technical replicate runs. Non-zero lipid quantities were averaged from the replicate runs.
The lipid species identified across different ionization states or with adducts were totaled
together. Quantification was completed by normalizing total ion counts to the relative abundance
of the internal standard that was spiked into each sample.
Cell and myocardium permeabilization
For cells, H9C2 cardiomyocytes were detached in culture dishes with 0.05% trypsinEDTA (Sigma) and growth medium was added to the culture. Contents were transferred to a tube
and centrifuged for 10 min at 1000 × g at RT. After removal of supernatant, cells were lifted in
MiR05 [0.5 mM EGTA, 3 mM MgCl2, 60 mM K-lactobionate, 20 mM taurine, 10 mM
KH2PO4, 20 mM HEPES, 110 mM sucrose, and g/l BSA (Sigma; A3803) adjusted to pH 7.1]
plus 1 mg/ml digitonin and gently rocked at RT for 5 min before centrifugation at 1000 × g for 5
min. After discarding supernatant, cells were then suspended in 2.2 ml warm MiR05 and
transferred to chambers in the O2K (Oroboros Instruments, Innsbruck, Austria). Following
respiration protocol (outlined below), cells were removed from the chambers and used for further
analysis, including protein quantification. For myocardial mitochondrial respiration, left ventricle
was quickly removed from euthanized mice and immediately placed in ice-cold buffer X (60 mM
K-MES, 35 mM KCl, 7.23 mM K2EGTA, 2.77 mM CaK2EGTA, 20 mM imidazole, 20 mM
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tuarine, 5.7 mM ATP, 15 mM PCr, 6.56 mM MgCl2-6H2O, pH 7.1) and trimmed of connective
tissue. Small fiber bundles were prepared and gently separated along their longitudinal axis
under a surgical scope (Olympus, ST) to 1-2 mg. Bundles were then transferred to a tube with
chilled buffer X and 50 μg/ml saponin and rocked at 4°C for 30 min, then washed in buffer Z
(105 mM K-MES, 30 mM KCl, 10 mM KH2PO4, 5 mM MgCl2-6H2O, 0.5 mg/ml BSA, pH 7.1)
at 4°C for at least 15 min. Samples were then blotted dry and weighed.
Mitochondrial isolation
To isolate mitochondria from left ventricle myocardium, the whole heart was placed in
isolation buffer (300 mM sucrose, 10 mM Na-HEPES, 0.2 mM EDTA, pH 7.2) and the left
ventricle isolated. After finely mincing the sample, trypsin (Sigma T9935) was added for two
minutes before adding trypsin inhibitor (Sigma T9003). The sample was then transferred to a
conical tube and allowed to settle. After removal of supernatant, samples were resuspended in
isolation buffer with BSA (Sigma A3803) and homogenized with Teflon pestle before
centrifugation (600 × g for 10 min at 4°C). Supernatant was then transferred to a new tube and
centrifuged (8000 × g for 15 min at 4°C), then washed by gently adding isolation buffer and
rotating the tube. A portion of this suspension is used for protein quantification. The pellet was
then resuspended with isolation buffer + BSA.
Mitochondrial respiration protocol
High-resolution O2 consumption was determined at 37°C in permeabilized cells and fiber
bundles using the Oroboros O2K Oxygraph with MiR05 respiration buffer. Before addition of
sample into respiration chambers, a baseline respiration rate was determined. After addition of
sample, the chambers were hyperoxygenated to ~350 nmol/ml. Following this, respiration was
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determined by all or parts of the following substrate-uncoupler-inhibitor-titration (SUIT)
protocol24: electron flow through complex I was supported by glutamate + malate (10 and 2 mM,
respectively) to determine basal oxygen consumption (GM B ). Following stabilization, ADP
(2.5 mM) was added to determine oxidative phosphorylation capacity (GM P ). Succinate was
added (GMS P ) for complex I + II electron flow into the Q-junction. To determine full electron
transport system (F) capacity over oxidative phosphorylation, the chemical uncoupler carbonyl
cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP) was added (0.05 μM, followed by 0.025
μM steps until maximal O2 flux was reached). Complex II-supported ETS was then measured by
inhibiting complex I with rotenone (Rot; 0.5 μM). Mitochondrial membrane integrity was tested
in all experiments by adding cytochrome c (10 μM; GMc P ). Lastly, residual oxygen
consumption was measured by adding antimycin A (2.5 μM) to block complex III action,
effectively stopping any electron flow, which provides a baseline rate of respiration. Where
indicated, C2-ceramide (Sigma A7191; 20 μM) was added to respiration chambers.
Statistics
Data are presented as the mean ± SEM. Data were compared by ANOVA with Tukey’s
post-hoc analysis (Graphpad Prism; La Jolla, CA). Significance was set at p <0.05.
Results
Ceramide inhibits cardiomyocyte mitochondrial respiration
To determine the effects of ceramide on cardiac mitochondrial respiration, we utilized
two models. First, mitochondria were isolated from left ventricle myocardium. During the course
of the respiration protocol in the isolated mitochondria, C2-ceramide was added to one oxygraph
chamber. The addition of ceramide (+C2) elicited a rapid and significant reduction in
81

mitochondrial respiration that was sustained through maximal respiration with FCCP (Figure 1A;
see Methods for protocol details). A second model was the use of permeabilized intact left
ventricle myocardium. One sample was incubated with C2-ceramide throughout the length of the
protocol, which elicited a sustained reduction in mitochondrial respiration throughout the entire
protocol (Figure 1B).

Figure 1: Ceramide inhibits left ventricle mitochondrial respiration.

82

A: Respiration rates of mitochondria isolated from left ventricle myocardium with addition of
C2-ceramide during respiration protocol (20 μM; n = 4). B: Mitochondrial respiration from
permeabilized left ventricle myocardium (30 min) with continuous incubation with C2-ceramide
(20 μM; n = 8). See Methods for more details on respiration protocol. *P <0.05.

Cigarette smoke extract increases lung cell ceramide production and secretion
The deleterious effect of cigarette smoking on heart function is undeniable, but the
mechanism communicating the pulmonary insult to the heart is not clear. As proof of concept
that the lung is capable of producing and secreting ceramides with smoke exposure, we treated
A549 alveolar type 2 cells with cigarette smoke extract (CSE). Relative to PBS treatment,
ceramides increased over 60% in CSE-treated lung cells, though this effect was mitigated with
myriocin co-treatment (Figure 2A). Further, CSE treatment elicited an almost three-fold increase
in ceramide secretion into medium compared with PBS treatment (Figure 2B). We also observed
an upward trend (P = 0.069) in circulating ceramides from whole blood following 5 d of
sidestream smoke exposure in adult mice (Figure 2C).
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Figure 2: Lung cells make and secrete ceramide in response to cigarette smoke extract.
A: Ceramide levels in A549 cells treated with PBS- or 10% cigarette smoke extract-containing
medium without (CSE) or CSE with myriocin (CSE + Myr), a ceramide inhibitor, for 12 h
(n = 6). B: Ceramides in culture medium of A549 cells following a 12-h treatment with PBS or
CSE (n = 6). C. Ceramides were determined from whole blood of adult mice following 5 d of
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room air (CON) or sidestream cigarette smoke (CS) (P =0.069; n = 5). *P <0.05 for CSE vs.
PBS.

Ceramide is necessary for smoke extract-induced altered cardiomyocyte mitochondrial
disruption
To determine the effects of lung cell-secreted ceramides on heart cell function, we
utilized a conditioned medium in vitro model. Briefly, following incubation with PBS- or CSEcontaining medium, with or without myriocin co-treatment, the conditioned medium from lung
cells was transferred to H9C2 cardiomyotubes for 12 h. Following the incubation with
conditioned medium, we determined cardiomyotube ceramide accrual and mitochondrial
respiration. Ceramides were significantly increased in cardiomyotubes treated with conditioned
medium from CSE-treated lung cells (Figure 3A). However, when lung cells received treatment
with myriocin in addition to CSE, the conditioned medium had no effect on heart cell ceramides
(Figure 3A). Mitochondrial respiration in the heart cells followed a similar trend as ceramides.
Namely, respiration in heart cells receiving CSE conditioned medium was negatively affected,
but not when myriocin was included in the lung cell culture medium (Figure 3B).
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Figure 3: Ceramide is necessary for decreased mitochondrial respiration in myocardial
cells following treatment with conditioned medium from CSE-treated lung cells.
A: Ceramide levels in H9C2 cardiomyocytes treated with conditioned medium from A549
alveolar type 2 cells following incubation with normal growth medium (Con), Con with myriocin
(Myr), cigarette smoke extract (CSE), and CSE with Myr (CSE + Myr) (n = 4). B: Mitochondrial
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respiration from H9C2 cardiomyocytes following treatment in identical conditions (n = 5). See
Methods for more details on respiration protocol. *P <0.05 for CSE vs. Con.

Ceramide inhibition prevents reduced myocardial mitochondrial respiration with cigarette
smoke
To more accurately determine the role of ceramides in mediating smoke-induced decayed
heart mitochondrial respiration, we exposed animals to CS for 1 wk while receiving injections of
PBS (vehicle) or myriocin every other day. Left ventricle ceramides increased four fold with CS
compared with room air-exposed mice (Figure 4A) with vehicle injections, though myriocin
prevented this effect. Moreover, respiration was protected from CS in myriocin-injected animals
(Figure 4B).
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Figure 4: Myriocin prevents left ventricle ceramide accrual and mitochondrial dysfunction
with cigarette smoke.
Mice were exposed to room air (Con) or cigarette smoke (CS) for 1 wk while receiving PBS
(vehicle) or myriocin injections every other day. A: Ceramides were measured from left ventricle
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following treatment period (n = 6). B: Mitochondrial respiration was reduced with CS treatment
in vehicle-injected animals (n = 6). *P <0.05 for CS vs all other treatments.

Given the evidence suggesting the role of diet in increasing heart complications25 and
ceramide accrual26, we provided a high-fat, high-sugar (Western diet; WD) to animals in
conjunction with smoke (or room air) exposure over the course of an 8-wk study. Similar to
before, animals received vehicle (PBS) or myriocin injections every other day. In addition to
observing a roughly 6-fold increase in heart ceramides with smoke exposure, we found an
equally great increase in heart ceramides in animals receiving WD diet and smoke (Figure 5A).
However, ceramide inhibition was only partially successful in the WD + CS group. In general,
ceramide accrual was associated with reduced myocardial mitochondrial respiration (Figure 5B).
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Figure 5 Western diet exerts a minimal effect on heart ceramides in smoke-exposed mice.
Mice were exposed to room air (Con) or cigarette smoke (CS) for 8 wk while receiving PBS
(vehicle) or myriocin injections every other day. Mice also received either a standard diet (SD)
or Western diet (WD). A: Ceramides were measured from left ventricle following treatment
period (n = 4). B: Mitochondrial respiration was determined from permeabilized left ventricle
myocardium (n = 8). *P <0.05 for treatment vs. Vehicle SD. #P <0.05 for WD + CS myriocin vs.
WD + CS vehicle.
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Discussion
Previous research demonstrated that smoke exposure contributes to cardiomyopathy27,28,
which can be a consequence of altered mitochondrial function21, and we have recently shown
that sidestream smoke alters mitochondrial function in skeletal muscle29. Considering current
worldwide smoking trends3,4, cardiomyopathy and other cardiovascular burdens mediated by
cigarette smoke are likely to increase. To date, the main instigators thought to mediate the heartspecific effects of smoking are altered blood lipids and changes in fibrinogen metabolism30,31,
though the actual impact of these mechanisms is unknown30. While ceramides are known to
mediate cellular disruption in the lung with smoking32, its impact on cardiomyocyte function
with smoking has not been adequately explored. Thus, the purpose of this project was to
determine the role of tobacco smoke-induced ceramides in disrupting cardiomyocyte
mitochondrial function. Our major discoveries were that lung cells secrete ceramide with
sidestream smoke exposure and that ceramide accumulates in heart tissue and alters
mitochondrial function.
To our knowledge, the first study to explore the effects of ceramide on mitochondrial
respiration was published by the Hoppel laboratory, where they observed a rapid and robust
inhibition of respiration in isolated heart mitochondria upon ceramide treatment20, and
subsequent work corroborates these findings33. We confirm those observations by Gudz et al.20
in isolated heart mitochondria and report similar findings in permeabilized left ventricle.
Additionally, we have previously shown that ceramides substantially inhibit complex II action
and that the general adverse effect of ceramides on mitochondrial respiration is dependent on
ceramide-induced mitochondrial fission24. Similarly, our findings of ceramide accrual in the lung
with smoking corroborate those from other laboratories34,35,36, but while previous work focused
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on ceramide generation via sphingomyelinase, our effective use of myriocin suggests the
importance of de novo ceramide synthesis in sidestream smoke-induced ceramide accumulation.
However, while myriocin injections were sufficient to completely block ceramide accrual with
smoking or diet separately, it was insufficient to prevent an increase in ceramides with combined
smoking and diet. This may be a result of insufficient myriocin action in the midst of an
overpowering stimulus (diet and smoke combined), or that sphingomyelinase may be particularly
relevant in our combined treatment.
Importantly, we not only find increased ceramide production in lung cells with smoke
exposure, but also ceramide release, providing proof of concept that the lung may be at least a
source of systemic ceramide accrual with smoke exposure. This is supported by our finding of an
upward trend in circulating ceramides with smoke exposure. Nonetheless, ongoing experiments
are testing the hypothesis that secreted ceramide by smoke-exposed pulmonary tissues travel and
accumulate in cardiac muscle. Related to this, our conclusions that ceramide is the relevant
component within the cultured medium upon transfer of medium from lung cells to
cardiomyocytes is based on our use of myriocin. However, due to the harmful cocktail of
molecules within the CSE, it is possible that a non-ceramide variable exists.
The level of ceramide accumulation we observe in the heart with smoking is substantial.
We have previously quantified ceramide in various tissues (i.e., skeletal muscle, liver, brain)
with dietary intervention17,24,37 and rarely observed greater than a roughly twofold increase in
ceramides; similar changes have been observed in the heart26. However, cigarette smoking
appears to be a more robust inducer of systemic ceramide accumulation compared with diet. We
found a roughly four-fold increase in heart ceramides after only 1 wk of smoke exposure (Figure
4) that increased to a six-fold change with an 8-wk exposure (Figure 4A). Interestingly,
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supplementing the smoking regimen with a dietary component (Western diet, Harlan Teklad
45F30S) had no additive effect on heart ceramides (Figure 5A).
Conclusions
In conjunction with our recent findings of altered skeletal muscle function with cigarette
smoke exposure29, the results of these studies implicate ceramide as an important mediator of
myriad systemic metabolic effects. In particular, we find evidence that ceramides are a mediator
of sidestream smoke-induced altered heart mitochondrial function. While interventions to
promote smoking cessation should continue, the increase in worldwide smoking and
cardiovascular complications highlights the need for immediate therapies. Our findings suggest
that ceramide inhibition may be a novel and potentially valuable therapeutic modality to protect
heart function for those who are unwilling or unable to vacate smoke environments.
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Ceramides mediate cigarette smoke-induced metabolic disruption in mice

Summarizing my Contribution: I was involved in the development of this experiment in all of
the aspects that involved ceramide identification and quantitation. I helped determine treatment
conditions for lipid accumulations. Our hypothesis for this paper was that cigarette smoke
exposure to lung cells was leading to inflammation induced production of ceramide lipids. The
subsequent accumulation of ceramide class lipids leads to lipid shedding and transport into the
blood stream of the treated individual. These shed lipids then work their way through the
circulatory system of the effected individual and accumulate in sensitive tissues such as the
heart. Using my lipidomic techniques I was able to track theses accumulations throughout the
body and tissues. The locations that had the greatest metabolic disruptions were also the
locations with greatest accumulations of ceramide. I helped develop and teach careful specialized
sphingolipid specific lipid extractions. I completed the extractions of lipids from cell pellets and
developed the internal standards that were spiked into each sample to aid in mass alignment in
the identification phase of the mass spectrometry based lipidomics I also conducted all highresolution mass spectrometry based lipidomic identifications and quantitation. I generated and
helped put together all of the figures that involved ceramide quantitation for the differing
treatment states. I was involved in the writing, formatting, and editing of this manuscript.
Mikayla O. Thatcher, Trevor S. Tippetts, Michael B. Nelson, Adam Clayton Swensen, Duane R.
Winden, Melissa E. Hansen, Madeline C. Anderson, Ian E. Johnson, James P. Porter, Paul R.
Reynolds, Benjamin T. Bikman
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Abstract
Cigarette smoke exposure increases lung ceramide biosynthesis and alters metabolic
function. We hypothesized that ceramides are released from the lung during cigarette smoke
exposure and result in elevated skeletal muscle ceramide levels, resulting in insulin resistance
and altered mitochondrial respiration. Employing cell and animal models, we explored the effect
of cigarette smoke on muscle cell insulin signaling and mitochondrial respiration. Muscle cells
were treated with conditioned medium from cigarette smoke extract (CSE)-exposed lung cells,
followed by analysis of ceramides and assessment of insulin signaling and mitochondrial
function. Mice were exposed to daily cigarette smoke and a high-fat, high-sugar (HFHS) diet
with myriocin injections to inhibit ceramide synthesis. Comparisons were conducted between
these mice and control animals on standard diets in the absence of smoke exposure and myriocin
injections. Muscle cells treated with CSE-exposed conditioned medium were completely
unresponsive to insulin stimulation, and mitochondrial respiration was severely blunted. These
effects were mitigated when lung cells were treated with the ceramide inhibitor myriocin prior to
and during CSE exposure. In mice, daily cigarette smoke exposure and HFHS diet resulted in
insulin resistance, which correlated with elevated ceramides. Although myriocin injection was
protective against insulin resistance with either smoke or HFHS, it was insufficient to prevent
insulin resistance with combined CS and HFHS. However, myriocin injection restored muscle
mitochondrial respiration in all treatments. Ceramide inhibition prevents metabolic disruption in
muscle cells with smoke exposure and may explain whole body insulin resistance and
mitochondrial dysfunction in vivo.
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Obesity and cigarette smoking are two of the largest causes of preventable deaths
worldwide, increasing the risk of multiple illnesses such as heart disease, stroke, airway
infections, and diabetes31,52. The incidences of smoking and obesity mirror each other in nations
across the globe; where one risk factor is increasing, the other follows31,52. This correlation has
elicited speculation of a causative association between toxin exposure, such as cigarette smoke,
and metabolic disruption6,11,42, which adds another layer of complexity to the already convoluted
search for a treatment for obesity and its comorbidities. Although cigarette smoke contains
chemicals that reportedly increase energy expenditure and promote weight loss29, smoke
exposure is associated with increased visceral adipose accumulation46,48 that increases with
greater smoking frequency46.
Two lines of evidence may support the theory that cigarette smoke causes metabolic
disruption leading to fat gain. First, cigarette smoke exposure is known to disturb mitochondrial
function and biogenesis3,37, which may compromise the cell's ability to use fat for fuel. Second,
insulin resistance and hyperinsulinemia are common features attending regular
smoking4,15,20,43,44, and insulin is a potent inducer of adipocyte expansion and fat gain30,36,50. How
smoke exposure causes both of these deleterious metabolic consequences is unclear. Of the
myriad mediators that may disrupt healthy metabolic function in response to cigarette smoke
exposure, the particular effects of the sphingolipid ceramide on cellular insulin sensitivity and
mitochondrial function elucidate a novel mechanism and potential therapeutic target9.
The lung produces ceramides in response to cigarette smoke exposure24,35, which may
explain the altered metabolic function evident with smoking7,18. Ceramide is a well-established
mediator of both insulin resistance12,49 and compromised mitochondrial function25,47. Based on
these observations, the purpose of our study was to test the hypothesis that cigarette smoke
102

exposure leads to ceramide accumulation in systemic tissues, particularly skeletal muscle, and
mediates insulin resistance and altered mitochondrial function. Additionally, by using a rodent
smoke exposure model, these studies provide evidence that long-term cigarette smoke
exacerbates weight gain.
Materials and Methods
Cell culture.
Cigarette smoke extract (CSE) was generated as previously described, with slight
modifications45. Briefly, one 2RF4 research cigarette (University of Kentucky, Lexington, KY)
was continuously smoked by connecting the filtered end of the cigarette to a vacuum pump,
pulling the particles into 5 ml of DMEM-F12, and the resulting medium was defined as 100%
CSE and diluted with culture medium to 10%. The total particulate matter content of 2RF4
cigarettes is 11.7 mg/cigarette, tar is 9.7 mg/cigarette, and nicotine is 0.85 mg/cigarette. Human
type II-like pulmonary adenocarcinoma cells (A-549) were maintained in DMEM-F12
supplemented with 10% FBS (Invitrogen, Grand Island, NY) and antibiotics. Cells were split
into six-well dishes and grown to 80% confluence. C2C12 muscle cells were maintained in
DMEM + 10% FBS. For differentiation into myotubes, myoblasts were grown to confluence,
and the medium was replaced with DMEM + 10% horse serum (Invitrogen). Myotubes were
used for experiments on day 4 of differentiation. A-549 cultures were exposed to serum-free
medium supplemented with 10% CSE or medium alone for 4 h, after which the medium was
transferred to differentiated C2C12 myotubes (termed “conditioned medium”) for 12 h. Where
indicated, cells were treated with myriocin (10 μM; Sigma, M1177). Muscle cells were harvested
for RNA, protein, and lipid isolation following treatments.
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Animals.
Male C57Bl/6 mice were housed in a conventional animal house and maintained on a
12:12-h light-dark cycle. Two animal studies were conducted. In the first study, animals received
standard diet chow (Harlan-Teklad 8604) and water ad libitum. At 12–14 wk of age, animals
were randomly divided into room air- and cigarette smoke (CS)-exposed groups. Mice were
placed in soft restraints and connected to the exposure tower of a nose-only exposure system
(InExpose System; Scireq, Canada). Animals were nasally exposed to mainstream CS generated
by research cigarettes where a computer-controlled puff was generated every minute, leading to
10 s of CS exposure followed by 50 s of fresh air. The CS-exposed group inhaled CS from two
consecutive cigarettes per day for 3 wk, at which point the dosage was increased to two
cigarettes twice daily. Control animals were similarly handled and restrained in fresh air for the
same duration. After the 6-wk course, mice underwent intraperitoneal glucose (G7021; SigmaAldrich, St. Louis, MO) and insulin (Actrapid; Novo Nordisk, Plainsboro, NJ) tolerance tests.
For both tests, mice were fasted for 6 h and received an injection of either glucose (1 g/kg body
wt) or insulin (0.75 U/kg body wt). Blood glucose was determined at the times indicated in the
figures, using the Bayer Contour glucose meter. For the second study, 12-wk-old mice were
separated into one of several treatment groups for 8 wk. Each of the following groups was
duplicated to have one group receive vehicle or myriocin injections (0.3 mg/kg) every other day
for a total of eight groups: 1) control: standard diet chow, no smoke; 2) cigarette smoke (CS)
exposure (two cigarettes, twice daily) with standard diet chow; 3) high-fat, high-sugar (HFHS)
diet (Harlan-Teklad 45F30S); 4) HFHS diet with CS exposure. Tissues were harvested at the
conclusion of the study period and following a 6-h fast. Insulin resistance was assessed using
fasting blood glucose and insulin (MP Biomedicals; Insulin RIA kit, 07260102) to compute a
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homeostatic model assessment (HOMA-IR) score, as previously described (8). Studies were
conducted in accordance with the principles and procedures outlined in the National Institutes of
Health Guide for the Care and Use of Laboratory Animals and were approved by the Institutional
Animal Care and Use Committee (IACUC) at Brigham Young University.
Lipid analysis.
Lipids were extracted and quantified as described previously47. Briefly, lipids were
isolated with chloroform-methanol (1:2), and after addition of water, the organic phase was
collected and dried. After resuspension, lipids were quantified using a shotgun lipidomics
technique on a Thermo Scientific LTQ Orbitrap XL mass spectrometer.
Protein quantification and quantitative real-time PCR.
Protein and message were quantified as described previously21,47. Primers were used as
listed previously21. β-Actin reactions were performed side by side with every sample analyzed.
The following antibodies were used: β-actin (Cell Signaling, no. 4967), Akt (no. 9272), p-AktSer473 (no. 9271), GSK3β (no. 9315), p-GSK3β-Ser9 (no. 9323), SPT2 (Santa Cruz
Biotechnology, no. sc-27500), anti-oxphos complex (Invitrogen, no. 457999).
Changes in the mRNA level of each gene following treatments were normalized to the βactin control mRNA according to Pfaffl (39).
Cell and muscle fiber bundle permeabilization.
Cells and tissue were prepared for the mitochondrial respiration assay as described
previously (47). Following the respiration protocol (outlined below), samples were removed
from the chambers and used for further analysis, including protein quantification.
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Mitochondrial respiration protocol.
High-resolution O2 consumption was determined at 37°C in permeabilized cells and fiber
bundles, using the Oroboros O2K Oxygraph (Innsbruck, Austria) with MiR05 respiration buffer
as described previously38,47. Respiration was determined by all or parts of the following
substrate-uncoupler-inhibitor-titration (SUIT) protocol32: electron flow through complex I was
supported by glutamate + malate (10 and 2 mM, respectively) to determine O2 consumption
from proton leak (GML). Following stabilization, ADP (2.5 mM) was added to determine
oxidative phosphorylation capacity (GMP). Where indicated, outer mitochondrial membrane
integrity was tested by adding cytochrome c (10 μM, GMcP). Succinate was added (GMSP) for
complex I+II electron flow into the Q-junction. To determine full electron transport system
(ETS) capacity over oxidative phosphorylation in cells, the chemical uncoupler carbonyl cyanide
4-(trifluoromethoxy) phenylhydrazone (FCCP) was added (0.05 μM followed by 0.025 μM steps
until maximal O2 flux was reached). Complex II-supported ETS was then measured by
inhibiting complex I with rotenone (Rot; 0.5 μM). Last, residual O2 consumption was measured
by adding antimycin A (2.5 μM) to block complex III action, effectively stopping any electron
flow. This value provides a rate of respiration that is used as a baseline.
Glycogen assay.
Glycogen was measured from cells where indicated, according to the manufacturer's
instructions (BioVision, Milpitas, CA).
Statistics.
Data are presented as mean ± SE. Data were compared by ANOVA with Tukey's post
hoc analysis (Graphpad Prism, La Jolla, CA). Significance was set at P < 0.05.
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Results
A549 cells produce and secrete ceramide in response to CS extract.
Compared to PBS-treated cells, ceramide was significantly elevated in alveolar type 2
A549 cells following treatment with cigarette smoke extract (CSE) for 4 h (Fig. 1A). However,
this effect was prevented when CSE treatment was supplemented with myriocin (CSE+Myr; Fig.
1A). Myriocin inhibits the initial and rate-limiting step in de novo ceramide biosynthesis, serine
palmityoltransferase (SPT) by preventing condensation of palmitoyl-CoA and serine. The
relevance of SPT was further determined by measuring the gene expression of SPT2. CSE
treatment elicited an over twofold increase in SPT2 gene expression and protein (Fig. 1, B and
C), providing evidence of the role of the de novo pathway in CSE-induced ceramide
biosynthesis. In addition to ceramide production, we sought to determine the ability of A549
cells to secrete ceramide. Accordingly, lipids were isolated and ceramides measured following 8h treatment with PBS and CSE medium (± myriocin; Fig. 2). Medium from CSE-treated cells
contained ∼60% more ceramide than PBS-treated cells.
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Figure 1: Cigarette smoke extract (CSE) increases ceramide biosynthesis.
Alveolar type 2 cells (A549) were treated with PBS or CSE without (CSE) or with myriocin
(CSE+Myr; 10 μM) suspended in growth medium. Following treatment period, ceramides (A; n
= 6) and serine palmityoltransferase 2 (Sptlc2) gene (B; n = 6), and protein (C; n = 3) levels were
measured. *P < 0.05 for CSE vs. other treatments.
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Figure 2: A549 cells secrete ceramide.
A549 cells were treated with PBS or CSE without (CSE) or with myriocin (CSE+Myr; 10 μM)
suspended in growth medium. Following 8 h, treatment medium was replaced with fresh growth
medium for 16 h, after which lipids were isolated from the medium and analyzed for ceramides.
*P < 0.05 for CSE vs. other treatments; n = 5.

Muscle cells treated with lung cell conditioned medium have higher ceramide levels.
To determine the effect of lung cell-secreted ceramides on muscle cell ceramide
metabolism, conditioned medium from PBS- and CSE-treated cells (± myriocin) was harvested
from A549 cells and placed on C2C12 myotubes for 12 h, as outlined in Fig. 3A. Myotubes
treated with conditioned medium from CSE-treated cells (SCM) had significantly higher levels
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of ceramide than both myotubes treated with PBS-conditioned medium (CCM) and addition of
myriocin to CSE treatment (SCM+Myr; Fig. 3B).

Figure 3: Smoke-treated lung cell conditioned medium increases muscle cell ceramide
biosynthesis.
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Skeletal muscle cells (C2C12) were treated with conditioned medium from A549 cells. A:
schema indicating culture medium handling. B: muscle cells treated with conditioned medium
from A549 cells following incubation with control (CCM), cigarette smoke extract medium
(SCM), and SCM with myriocin (SCM+Myr; 10 μM). *P < 0.05 for CSE vs. other treatments; n
= 5.

Muscle cells experience metabolic disruption following SCM treatment.
Two important aspects of metabolic disruption that may mediate obesity-related
morbidities and/or exacerbate weight gain are the reduction of muscle insulin sensitivity and
altered mitochondrial respiration. Similarly, to the above, C2C12 myotubes were treated with
conditioned medium from A549 cells previously treated with normal medium, CSE, or
CSE+Myr. Following 12-h serum-free conditioned medium treatment, myotubes were stimulated
with insulin for 10 min. As an indicator of insulin signaling, Akt and GSK3β phosphorylation
was determined. Whereas CCM myotubes experienced a marked increase in both Akt and
GSK3β phosphorylation in response to insulin, myotubes treated with SCM failed to respond to
insulin (Fig. 4A). However, when myotubes were treated with SCM+Myr, insulin responsiveness
was restored (Fig. 4A). These results were strengthened by determining glycogen accrual with
similar treatments (Fig. 4B).
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Figure 4: Inhibition of ceramide biosynthesis prevents lung cell conditioned mediuminduced loss of muscle cell insulin signaling.
Skeletal muscle cells (C2C12) were treated with conditioned medium from PBS- and CSEtreated A549 cells. C2C12 myotubes were treated with serum-free conditioned medium from
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CSE-treated A549 cells ± myriocin (10 μM) to block ceramide biosynthesis. At the end of the
treatment period, cells were treated with insulin (100 nM, 10 min) before being lysed for
immunoblotting (A; n = 4) and glycogen analysis (B; n = 6). *P < 0.05 for treatment vs. control.

To determine mitochondrial respiration, following similar treatments indicated above,
myotubes were permeabilized to undergo a substrate-uncoupler-inhibitor titration protocol
(protocol details provided in materials and methods). No difference in rates of mitochondrial O2
was observed between treatment conditions with addition of glutamate and malate (Leak state;
Fig. 5A). However, addition of ADP to measure respiration with complex I-mediated oxidative
phosphorylation (GMP) revealed a marked contrast, where O2 consumption failed to increase in
myotubes treated with SCM. Similar results were found with addition of succinate to introduce
complex II-mediated respiration GMSP, as well as FCCP addition to measure uncoupled
respiration (GMSE). Addition of rotenone (complex I inhibitor) resulted in a general reduction
and equalization of respiration rates regardless of treatment [S(Rot)E]. Addition of myriocin to
CSE treatment completely protected mitochondrial respiration (SCM+Myr), and rates were
comparable to control (CCM) throughout the assay. All together, these findings suggest a
severely compromised ability of muscle cell mitochondria to respire in the midst of the highceramide state caused by CS. The smoke-induced decrease in mitochondrial respiration may at
least partly result from the slight yet significant ceramide-dependent reduction in complex III
and IV protein evident in SCM-treated cells (Fig. 5B).
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Figure 5: Inhibition of ceramide biosynthesis protects muscle cell mitochondrial
respiration.
Skeletal muscle cells (C2C12) were treated with conditioned medium from A549 cells. A:
myotubes were treated PBS- and CSE-A549-conditioned medium ± myriocin (CCM, SCM,
SCM+Myr, respectively). Following treatment, muscle cell mitochondrial O2 consumption was
determined according to the protocol outlined in materials and methods (n = 6). GML, glutamate
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(10 mM) + malate (2 mM); GMP, +ADP (2.5 mM); GMcP, +cytochrome c (10 μM); GMSP,
+succinate (10 mM); GMSE, +FCCP (0.05 μM+); S(Rot)E, +rotenone (0.5 μM); and +antimycin
A (2.5 μM) as baseline. B: Western blot and quantification were performed on sample lysates to
determine levels of mitochondrial complexes (n = 3). *P < 0.05 for SCM vs. other treatments.

CS exposure causes metabolic disruption in mice.
In an effort to determine whether CS causes insulin resistance, adult male mice were
exposed to CS daily for 6 wk. Treatment period was determined by the length of time necessary
to observe differences in glucose tolerance and insulin sensitivity. We found that smoke-exposed
mice became less glucose tolerant (Fig. 6A) and less insulin sensitive (Fig. 6B) than control
mice. Furthermore, the insulin resistance was attended by altered ceramides; smoke-exposed
mice had significantly elevated ceramides in multiple tissues, including lung (Fig. 6D), blood
(Fig. 6E), and skeletal muscle (Fig. 6G), but not in liver (Fig. 6D). A portion of the
gastrocnemius was permeabilized to assess mitochondrial respiration (Fig. 6C). We found that
ADP-supported complex I-mediated respiration (GMP) was significantly blunted in smoked
animals. This difference was further exaggerated with succinate addition (GMSP) to introduce
complex II but was absent with uncoupling by the addition of FCCP (GMSE), suggesting that
maximal, but not submaximal, mitochondrial respiration rate in the muscle is unaffected by CS
exposure.
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Figure 6: Cigarette smoke (CS) increases tissue ceramides and causes insulin resistance and
reduced mitochondrial respiration.
Adult male C57Bl/6 mice were exposed to restraint (Control) or sidestream CS (Smoke) daily for
6 wk. Glucose (A; 1 g/kg body wt ip) and insulin (B; 0.75 U/kg body wt ip) tolerance tests were
performed and mitochondrial respiration analyzed in red gastrocnemius according to the protocol
outlined in materials and methods (C). Ceramides were determined in lung (D; P < 0.05, n = 4),
blood (E; P < 0.05, n = 4), liver (F; P = 0.07, n = 4), and soleus (P < 0.05, n = 8) and
gastrocnemius (P < 0.05, n = 7) (G). *P < 0.05 for smoke vs. control.

Ceramide inhibition prevents smoke-induced metabolic disruption, but not with combined
CS and HFHS diet.
The previous animal experiment provided proof of concept that CS exposure causes
insulin resistance. To elucidate the role of ceramides in smoke-induced metabolic disruption,
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mice received vehicle or myriocin injections every other day to inhibit ceramide biosynthesis.
Additionally, mice received a longer smoking regimen with the addition of a dietary
intervention. Namely, animals received standard diet (SD) chow or the HFHS diet. The rationale
for the dietary intervention was to more closely mimic current real world conditions, considering
that smokers tend to engage in less healthy eating habits than nonsmokers (28). Interestingly, CS
exposure (SD+CS) alone increased body weight (Fig. 7A), despite no apparent difference in
eating habits (Sup. Fig. 1). The HFHS diet also resulted in significantly higher body weight
compared with animals fed SD, although the HFHS+CS combination resulted in the highest
weight gain among all groups (Fig. 7A). However, myriocin injection prevented CS-induced
weight gain and mitigated HFHS-induced weight gain but was insufficient to prevent weight
gain with combined HFHS+CS (Fig. 7A). Ceramides increased in soleus with all interventions
(Fig. 7B). Myriocin injection prevented significant ceramide gains with all treatments. At the
conclusion of the study, fasting blood glucose and insulin levels were used to determine HOMAIR score following the 8-wk treatment period (Fig. 7C). HOMA-IR scores suggested pronounced
insulin resistance with smoke (SD+CS) and dietary intervention (HFHS, HFHS+CS), but this
was significantly mitigated with myriocin treatment. Last, red gastrocnemius fibers were
separated and permeabilized to determine mitochondrial respiration (Fig. 8). With vehicle
injections, CS exposure, regardless of diet, blunted mitochondrial respiration throughout the
protocol, although inhibition with HFHS diet alone became apparent only after addition of
succinate (GMSP). Myriocin injections failed to prevent reduced respiration with the various
treatments, but it offered some protection, considering that respiration was generally higher with
myriocin than the comparable vehicle-treated conditions.
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Figure 7: Effects of myriocin on metabolic parameters with smoking and diet.
Twelve-week-old mice were placed on 1 of 4 treatments [SD, standard diet; SD+CS, +daily CS
exposure; high-fat, high-sugar (HFHS) diet; and HFHS+CS] while receiving vehicle or myriocin
(0.3 mg/kg ip) injections every other day. Body weight (A), soleus ceramides (B), and fasting
blood glucose and insulin (C) were measured at the conclusion of the study period. *P < 0.05 for
treatment vs. SD within each group; #P < 0.05 for comparable treatment between myriocin vs.
vehicle; n = 6–12.
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Figure 8: Ceramide inhibition protects skeletal muscle mitochondrial respiration.
Red gastrocnemius fibers were separated and permeabilized from mice following one of four
treatments (SD: standard diet; SD+CS: + daily cigarette smoke exposure; HFHS: high-fat, highsugar diet; HFHS+CS) while receiving vehicle or myriocin (0.3 mg/kg) I.P. injections every
other day. Following treatment, muscle cell mitochondrial oxygen consumption was determined
according to the protocol outlined in the Methods section (A; n = 6). GML, glutamate (10 mM) +
malate (2 mM); GMP, +ADP (2.5 mM); GMcP, +cytochrome c (10 μM); GMSP, +succinate (10
mM); GMSE, +FCCP (0.05 μM+); S(Rot)E, +rotenone (0.5 μM); and +antimycin A (2.5 μM) as
baseline. Western blot was performed on sample lysates to determine levels of mitochondrial
complexes (B; n = 4). *p < 0.05 for treatment vs. SD within each group; #P < 0.05 for
comparable treatment between myriocin vs. vehicle.
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Discussion
Dr. Gerald Reaven was the first to identify a relationship between smoking and insulin
resistance over 20 years ago22, and his initial findings have been corroborated by multiple studies
since then4,10,19. Although previous findings may reveal a mechanism (i.e., insulin resistance)
whereby smoking results in systemic diseases17,27, the ensuing decades have failed to implicate a
mediating molecular process linking smoking and insulin resistance. In addition to insulin
resistance, smoking compromises mitochondrial function5,34,37. The purpose of this report was to
determine the role of the sphingolipid ceramide as a mediator of CS-induced metabolic
disruption, i.e., insulin resistance and reduced mitochondrial function.
Our first step was to determine whether lung cells, specifically alveolar type 2 cells or
bronchial epithelial cells (data not shown), produce and secrete ceramide in response to CSE. We
observed that both cells secrete ceramides with smoke exposure, but the response is greater in
alveolar type 2 cells. Previous studies exploring the source of blood ceramides have revealed a
prominent role for the liver in producing and packaging ceramides into lipoproteins for transport
from the liver throughout the body16. However, ceramides are able to cross the cell membrane
without lipoproteins16, which is our predicted mechanism for ceramides exiting lung cells.
However, once in the blood, ceramides are likely transported via albumin or, more likely,
lipoproteins51. Upon confirming ceramide secretion from lung cells, we utilized a cell culture
system of treating myotubes with conditioned medium from alveolar type 2 cells that were
treated with CSE with or without myriocin to inhibit ceramide synthesis. Our findings of a
protective effect on insulin signaling and mitochondrial respiration with myriocin-treated lung
cells suggest that ceramides are necessary for smoke-induced metabolic disruption in vitro.
Results from our animal studies are noteworthy, considering that chronic smoking caused insulin
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resistance. Importantly, the dose and method of cigarette smoke exposure we used has been
previously shown to yield similar levels of blood carboxyhemoglobin seen in human smokers53.
To determine the role of ceramides in insulin signaling and mitochondrial function in vivo, we
performed a second and similar smoking regimen that prolonged the smoke exposure (from 6 to
8 wk), and included a HFHS diet with regular myriocin injections. The rationale for the HFHS
diet was to more closely mimic real world conditions, considering smokers tend to engage in less
healthy eating habits than nonsmokers28. In general, the combination of CS and HFHS diet
tended to exacerbate the effects of smoke alone, including body weight, ceramides, and HOMAIR. Ceramide inhibition with myriocin treatment tended to mitigate these negative effects.
Together, our findings build upon the initial observations of smoking and disturbed metabolic
function13,22,44 and allow, for the first time, a definitive implication of ceramides as a mediator of
CS-induced metabolic disruption.
Similarly, to insulin resistance, CS elicits a host of negative effects on mitochondria,
including inhibition of respiration (34, 37) and increased ROS generation5. It is tempting to
speculate these effects may be a result of altered mitochondrial dynamics, which is affected by
smoke exposure23. We have recently shown that mitochondrial fission is necessary for ceramideinduced changes in mitochondrial function, including varied respiration and ROS production47.
CS is a common environmental toxin, with half of the US population being regularly
exposed40, 41 and ∼20% of young children living with someone who smokes in the home2. Every

day, almost 4,000 young adults smoke their first cigarette and 1,000 become habitual smokers1.

We intentionally utilized sidestream (i.e., second-hand) smoke in this study, given that it affects
both smokers and bystanders. Our findings, in conjunction with numerous observational
studies4,15,20,43,44 linking smoking with insulin resistance are relevant to current metabolic
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syndrome and obesity concerns, given that insulin resistance is the crux of the pathologies that
constitute the metabolic syndrome26. Previous animal studies have indicated weight loss in
smoke-exposed mice14, although the treatment length was considerably shorter than that used in
this study (4 days vs. 8 wk). However, whether smoking exerts an anti- or pro-obesogenic effect
in humans is unclear. Smoking is traditionally considered to prevent fat gain, but these
observations are exclusively cross-sectional15. In contrast, prospective studies following large
cohorts reveal that initiation of smoking promotes greater fat gain compared with nonsmokers48
and heavy smoking increases the fat gain33. Given insulin's potent actions in increasing fat
mass30,36,50, the hyperinsulinemia that accompanies insulin resistance may be an important
regulator of smoke-induced fat gain. Importantly, while cross-sectional studies suggest that
smokers may indeed weigh less (e.g., lower BMI), they also tend to have a higher waist-to-hip
ratio15, suggesting increased visceral fat, which is an additional feature of the metabolic
syndrome. Our data suggest that ceramide is an important mediator of the metabolic disruption
and weight gain that accompanies chronic smoke exposure.
This study presents the perspective that smoking disrupts healthy metabolic function and,
via ceramide accrual, increases risk of weight gain, especially when smoking is combined with a
typical Western diet. Future efforts are currently focused on exploring the role of ceramide in
other smoke-related pathologies, including the considerable smoke-induced cardiovascular
burden. These findings reveal a new metabolic concern for smokers who struggle to quit, but we
consider the concern even greater for those exposed to cigarette smoke as bystanders,
particularly at early ages. In the end, the results suggest a potential use for anti-ceramide
therapies in preventing at least some of the metabolic consequences of smoke exposure.
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Cardiomyocyte mitochondrial respiration is reduced by receptor for advanced glycation
end-product signaling in a ceramide-dependent manner

Summarizing my Contribution: I was involved in the development of this experiment in all of
the aspects that involved ceramide identification and quantitation. In this paper we treated
cardiomyocytes in vitro with advanced glycation end products (AGEs). When cells were treated
with an inhibitor of ceramide biosynthesis, myriocin, many of the detrimental side effects of
AGE treatment were ameliorated. We therefore set forth to measure the specific effect that
ceramide accumulations were having on the cells tested. In agreement with our hypothesis we
were able to show that the detrimental effects of AGE treatment were best observed when
ceramide concentrations were high. When ceramide biosynthesis was inhibited the negative
effects of AGE treated were reduced thereby restoring mitochondrial function. I helped
determine treatment conditions for lipid accumulations. I helped develop and teach careful
specialized sphingolipid specific lipid extractions. I completed the extractions of lipids from cell
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alignment in the identification phase of the mass spectrometry based lipidomics I also conducted
all high-resolution mass spectrometry based lipidomic identifications and quantitation. I
generated and helped put together all of the figures that involved ceramide quantitation for the
differing treatment states. I was involved in the writing, formatting, and editing of this
manuscript.
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Abstract
Cigarette smoke exposure is associated with an increased risk of cardiovascular
complications. The role of advanced glycation end products (AGEs) is already well established
in numerous comorbidities, including cardiomyopathy. Given the role of AGEs and their
receptor, RAGE, in activating inflammatory pathways, we sought to determine whether
ceramides could be a mediator of RAGE-induced altered heart mitochondrial function. Using an
in vitro model, we treated H9C2 cardiomyocytes with the AGE carboxy-methyllysine before
mitochondrial respiration assessment. We discovered that mitochondrial respiration was
significantly impaired in AGE-treated cells, but not when cotreated with myriocin, an inhibitor
of de novo ceramide biosynthesis. Moreover, we exposed wild-type and RAGE knockout mice to
secondhand cigarette smoke and found reduced mitochondrial respiration in the left ventricular
myocardium from wild-type mice, but RAGE knockout mice were protected from this effect.
Finally, conditional overexpression of RAGE in the lungs of transgenic mice elicited a robust
increase in left ventricular ceramides in the absence of smoke exposure. Taken together, these
findings suggest a RAGE-ceramide axis as an important contributor to AGE-mediated disrupted
cardiomyocyte mitochondrial function.
Receptors for advanced glycation end-products (RAGEs) are important mediators of
numerous chronic complications. Many of these conditions, including peripheral neuropathy2,
retinopathy1,8, nephropathy48, and cardiomyopathy6,15, reduce quality of life32 and often involve
macrovascular and microvascular complications7. RAGE was originally characterized for its
ability to bind advanced glycation end products (AGEs) and for its role as a prominent
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feedforward receptor involved in inflammation25. AGEs are derived via the nonenzymatic
combination of amino groups and reducing sugars19, and hyperglycemia-mediated induction of
protein glycosylation has been implicated in the production of systemic AGEs13,46. However,
independent of blood glucose, cigarette smoke exposure increases AGE formation through
Malliard chemical reactions involving smoke components and plasma proteins20. Whether
through chronic hyperglycemia or secondhand cigarette smoke exposure, cellular responses
provide abundant AGEs for RAGE signaling that causes enhanced expression of
proinflammatory cytokines and deleterious inflammatory responses17. Two AGEs often found in
increased abundance with diabetics and smokers are N(ε)-carboxy-methyllysine (CML)34 and
N(ε)-carboxy-ethyllysine45.
In addition to RAGE, sphingolipids are another factor increasingly recognized to play a
role in the progression of inflammatory disorders3,16. Ceramides, in particular, are a subset of
sphingolipid that have been linked to cardiometabolic disruption42, altered mitochondrial
dynamics and function4,36,39, increasing atheroma development5, and mediating insulin
resistance41. We have previously shown that ceramides are actively synthesized in the lung with
cigarette smoke exposure42.
Since activation of inflammatory signaling pathways has been shown to upregulate
ceramide biosynthesis3, it is plausible that RAGE-mediated inflammation can stimulate the
synthesis and elaboration of ceramides. RAGE functions as other pattern recognition receptors,
including Toll-like receptor (TLR)4, which increases ceramide biosynthesis upon activation14.
This paradigm involving a connection between RAGE and ceramide, however, has yet to be fully
investigated. Based on this intersection, we hypothesized that RAGE-AGE signaling would
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increase cardiomyocyte ceramide accrual, thereby increasing ceramide-mediated cardiomyocyte
mitochondrial dysfunction.
Materials and Methods
Cell culture.
Immortalized rat H9C2 cardiac myocytes were obtained from the America Type Cell
Culture (Manassas, VA) and used at passages 9–12. CML-BSA was purchased from MBL
(Woburn, MA), and myriocin was obtained from Sigma-Aldrich (St. Louis, MO). Cells were
split into six-well plates and grown to confluency. Myriocin-treated cells were pretreated for 1 h
with 1 μl of 10 mM myriocin. Cells were subsequently cotreated with either 30 μl CMLBSA/mL growth media or normal growth media for 24 h. All subsequent analysis took place
after the exposure period.
Mice
Wild-type (WT) C57BL/6 mice are in house and were obtained from Jackson
Laboratories (Bar Harbor, ME). RAGE knockout (KO) mice lacking membrane and soluble
RAGE were generated on a C57BL/6 background. Conditional RAGE transgenic mice were also
generated, which overexpress RAGE in the alveolar epithelium when fed doxycycline28,37.
Doxycycline incorporation into murine diets caused the upregulation of RAGE in the lungs of
transgenic mice from postnatal day 20 until the date of death at postnatal day 11038. Mice were
kept on normal light-dark cycles and had free access to food and water. Housing and treatment of
all mice were in accord with approved Institutional Animal Care and Use Committee protocols at
Brigham Young University.
Smoke exposure.
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For one study, WT and RAGE KO mice were randomly assigned to control and smokeexposed groups and acutely treated using an in-house nose-only smoke exposure system
(InExpose System, Scireq). Over the course of 1 wk, mice were restrained daily and connected to
an exposure tower for 10 min, where they were nasally exposed to secondhand cigarette smoke
from two cigarettes. Computer-generated puffs resulted in 10 s of secondhand exposure followed
by 50 s of fresh air. After exposure, mice were then allowed to rest for 10 min before repeating
the process two additional times until they had been exposed to a total of 6 cigarettes/day. The
smoke challenge chosen in the present study was associated with a good tolerance of mice to the
smoke sessions and an acceptable level of particulate density concentration according to
literature29,44. Control animals were similarly handled and restrained but kept under a smoke-free
environment. In a second chronic exposure study, WT mice were similarly assigned to control
and smoke-exposed groups and exposed to secondhand smoke. The procedure, however,
included exposure to 4 cigarettes/day for 8 wk. Studies were performed in accordance with
principles outlined in the National Institutes of Health Guide for the Care and Use of Laboratory
Animals.
Immunohistochemistry.
Heart tissue from control and cigarette smoke-exposed mice was fixed in 4%
paraformaldehyde, processed, embedded in paraffin wax, sectioned, and stained according to
standard immunohistochemical procedures27,30. The ceramide primary antibody used for
immunohistochemical detection was obtained from Sigma-Aldrich (C8104-50TST, 1:500).
Development in 3,3-diaminobenzidone revealed enhanced brown chromogen in tissues positive
for ceramide expression.
Mass spectrometry.
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In isolating lipids, pellets were suspended in ice-cold chloroform-methanol (1:2),
incubated for 15 min on ice, and then briefly vortexed. Aqueous and organic phases were
separated by the addition of ice-cold water and chloroform. The organic phase was collected in a
fresh vial and dried via vacuum centrifugation (Eppendorf Concentrator Plus). Lipids were then
characterized and quantified using shotgun lipidomics on a Thermo Scientific LTQ Orbitrap XL
mass spectrometer, as previously described12.
Mitochondrial respiration.
O2 consumption from H9C2 cardiomyocytes and cardiac muscle obtained from mice was
determined using an O2K oxygraph (Oroboros Instruments). Cells [digitonin (1 mg/ml)] and
tissue [saponin (50 μg/ml)] were then permeabilized. After permeabilization, samples were
transferred to respiration chambers. Respiration was determined using a substrate-uncouplerinhibitor titration protocol. Electron flow through complex 1 was assessed by supporting the
system with glutamate (G; 10 mM) and malate (M; 2 mM). After stabilization, ADP was added
to determine oxidative phosphorylation capacity (2.5 mM). Succinate (S; 10 mM) was then
added to assess complex 1 + 2 electron flow. To determine full electron transport system
capacity, the chemical uncoupler FCCP (E; 0.05 μM) was added. To assess complex 2 electron
flow, complex 1 was then inhibited by including rotenone (0.5 μM).
Real-time PCR.
RNA from cells was isolated using TRIzol (Invitrogen, Grand Island, NY) and quantified
via optical density measurement. Reverse transcription of RNA was performed using a
Superscript III First-Strand Synthesis System to obtain cDNA for PCR. Primers for serine
palmitoyltransferase (SPT)1, SPT2, and ceramide synthase (CerS)2 were obtained and diluted
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according to the manufacturer's protocol. Bio-Rad iQ SYBR Green Supermix was used to
perform real-time PCR along with previous cDNA, primers, and water. Values were assessed
using the ΔΔCT method (where CT is threshold cycle), and comparisons were made with
amplified actin. Control wells lacking template or reverse transcriptase were included to identify
primer-dimer products and to exclude possible contaminants.
Immunoblot analysis.
Total protein from H9C2 cardiac myocytes and heart tissue was obtained after
homogenization with RIPA buffer supplemented with protease inhibitors (Fisher Scientific,
Waltham, MA). Protein was then quantified using a BCA Protein Assay Kit (Fisher Scientific),
and 20 μg of the resulting lysate were blotted using a mouse polyclonal antibody (AF1179, R&D
Systems, Pittsburg, PA) against RAGE (1:1,000), as previously described (45). Western blots
were visualized and quantified using a LI-COR C-DiGit Blot Scanner (LI-Cor Biosciences).
Quantification of RAGE was performed by densitometry, and normalization with actin provided
comparisons between samples.
Statistics.
In vitro data presented are representative of experiments performed in triplicate and
animal experiments involved at least 4 samples/group. Data are presented as means ± SE. Data
were compared by ANOVA with Tukey's post hoc analysis (Graphpad Prism, La Jolla, CA).
Significance was set at P < 0.05.
Results
AGEs reduced cardiomyocyte mitochondrial function in a ceramide-dependent manner.
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CML is one of the most physiologically relevant AGEs in a diabetic context. To assess the
effects of AGEs on cardiomyocytes, we treated H9C2s with growth media containing CML-BSA
with and without myriocin, an inhibitor of SPT, the rate-limiting enzyme in de novo ceramide
biosynthesis. Compared with control cells, gene expression levels of SPT1, SPT2, and CerS2
were significantly elevated in CML-treated cells (Fig. 1A). Similarly, compared with control
conditions, cells exposed to CML-BSA showed a robust increase in ceramide production by
mass spectometry but not when pretreated with myriocin (Fig. 1B, CML + myriocin). The
increase in SPT and ceramides plausibly implicate RAGE as a factor contributing to de novo
ceramide biosynthesis.

Figure 1: Receptor for advanced advanced glycation end product (RAGE) signaling
increases do novo ceramide biosynthesis in cardiomyocytes.
Cardiac myocytes (H9C2) were treated for 24 h with either normal growth media [control
(CON)] or growth media infused with carboxy-methyllysine (CML)-BSA (30 μl/ml growth
media) with and without myriocin (Myr; 10 μM). After the treatment period, expression levels of
serine palmitoyltransferase (SPT)1, SPT2, and ceramide synthase (CerS)2 were quantified (A; n
= 3) in addition to ceramides (B; n = 3). *P < 0.05 for CML vs. other treatments.
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To determine the effect of RAGE-mediated inflammation on heart cell function, we
similarly exposed H9C2 cardiomyocytes to the same conditions described above and assessed
mitochondrial respiration using a substrate-uncoupler-inhibitor titration protocol (see materials
and methods). A significant reduction in respiration was elicited in cells treated with CML-BSA
upon the addition of glutamate and malate [leak state (GML); Fig. 2A]. Pretreatment with
myriocin, however, abolished the effects of CML-BSA and restored respiration to control levels.
Similar results were also found upon stimulation of complex 1-mediated oxidative
phosphorylation with ADP addition (GMP). The ddition of succinate to introduce complex IImediated respiration (GMSP) revealed a slight departure from the trend; whereas CML-treated
cells experienced a comparable increase in respiration as control cells, CML treatment appeared
to blunt the normal response to succinate addition. We further observed reduced complex II
function when analyzing the complex II control factor (GMSP less GMP; Fig. 2B). Similar to
succinate addition, the addition of FCCP (respiration uncoupler; GMSE) failed to increase
respiration with CML treatment to a level seen with control or myriocin treatment. Taken
together, these findings suggest that respiration in cardiomyocytes is impaired by RAGE
signaling and is mediated through increased ceramide accrual.
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Figure 2: RAGE signaling reduces cardiomyocyte mitochondrial respiration through
ceramide accrual.
Cardiac myocytes (H9C2, n = 3) were treated for 24 h with either normal growth media or
growth media containing CML-BSA with and without Myr. After treatment, heart cell
mitochondrial O2 consumption was assessed using a substrate-uncoupler-inhibitor titration
protocol (A). Complex (C)II control factor was used to determine the specific effect on succinate
addition on respiration (B). A description of the protocol is shown in C. ETS, electron transport
chain. *P < 0.05 for CML vs. other treatments.
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RAGE signaling contributed to cigarette smoke-induced ceramide accrual in
cardiomyocytes.
Because AGEs and smoke impact ceramide levels in vitro, we next assessed whether
similar effects occurred in vivo. Specifically, as RAGE expression is known to be elevated with
inflammation and exposure to cigarette smoke24,44, we sought to ascertain the expression profile
of RAGE in cardiac tissue under both control conditions and after smoke exposure. To establish
its expression in the heart, WT mice were restrained and exposed to either room air or
secondhand cigarette smoke for 1 or 8 wk. After the treatment, we assessed RAGE protein
expression in the left ventricular myocardium. Compared with control animals, RAGE
expression was significantly elevated in animals after 1 wk (Fig. 3A) or 8 wk of secondhand
cigarette smoke exposure (Fig. 3B). We next analyzed ceramide levels by mass spectrometry to
assess whether ceramides are also elevated in cardiomyocytes after secondhand smoke exposure.
WT mice exposed to acute cigarette smoke showed a significant increase in ceramides (Fig. 4A);
however, this effect was diminished in RAGE KO mice after 1 wk of exposure. To qualitatively
visualize these differences, we also performed immunohistochemistry on heart samples for
ceramides. WT mice exposed to secondhand cigarette smoke expressed pronounced 3,3diaminobenzidone-mediated staining for ceramides in heart tissue (Fig. 4B, arrow), but
ceramides were qualitatively diminished in exposed RAGE KO mice (Fig. 4B).
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Figure 3: Cigarette smoke increases RAGE expression in the heart with secondhand
cigarette smoke exposure.
Wild-type (WT) mice were restrained and exposed to either room air (n = 3) or secondhand
cigarette smoke (n = 3, see materials and methods) for 1 (A) or 8 (B) wk. After the exposure
period, Western blot analysis and quantification after normalization with actin were performed
on heart tissue lysates to determine relative expression levels of RAGE. *P < 0.05 for smoke vs.
room air.
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Figure 4: RAGE knockout (KO) prevents heart ceramide accrual with cigarette smoke.
WT and RAGE KO mice were restrained and exposed to either room air or acute secondhand
cigarette smoke for 1 wk. After the exposure period, lipids were isolated from heart tissue and
analyzed for ceramides (A). Immunohistochemical staining for ceramides was also performed to
qualitatively determine any differences in heart tissue between WT and RAGE KO mice under
the different exposure conditions (B). Ceramides were significantly increased in WT mice
exposed to tobacco smoke (arrows) compared with exposed RAGE KO mice. Scale bars = 200
nm. *P < 0.05 for smoke vs. room air within each group.

143

RAGE signaling was necessary for cigarette smoke-mediated reductions in myocardial
mitochondrial respiration.
After exposure to secondhand cigarette smoke, the left ventricular myocardium from WT
and RAGE KO mice was permeabilized and assessed for mitochondrial respiration. WT mice
showed altered mitochondrial respiration in response to acute cigarette smoke exposure (Fig.
5A). However, RAGE deletion was protective against secondhand smoke-induced respiration
defects (Fig. 5A). As with cells, we observed reduced complex II function when analyzing the
complex II control factor (GMSP less GMP; Fig. 5B).
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Figure 5: RAGE KO prevents cigarette smoke-induced reduced myocardial mitochondrial
respiration.
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WT and RAGE KO mice were restrained and exposed to either room air or acute secondhand
cigarette smoke for 1 wk. After the exposure period, mitochondrial O2 consumption of cardiac
myocytes was assessed (A). Complex II control factor was used to determine the specific effect
on succinate addition on respiration (B). *P < 0.05 for smoke vs. other treatments; #P < 0.05 for
smoke-exposed RAGE KO mice vs. room air-exposed RAGE KO mice.

Conditional pulmonary upregulation of RAGE increased biosynthesis of cardiomyocyte
ceramides.
The experiments shown in Figs. 3–5 considered the biology of RAGE and ceramide in
cardiomyocytes after controlled pulmonary exposure to secondhand smoke. To further assess the
role of RAGE in promoting cardiac accumulation of ceramide, experiments were designed in the
absence of smoke that compared control mice and conditional transgenic mice that genetically
overexpress RAGE in the peripheral lung. Upregulation of RAGE in these mouse models has
been validated by both immunoblot analysis and quantitative PCR (27, 29). Lipids were purified
from heart tissue obtained from RAGE transgenic mice after 90 days of RAGE upregulation and
age-matched nontransgenic control mice before subjection to mass spectrometry analysis.
Compared with control mice, hearts from transgenic mice showed a significant increase in
ceramides (Fig. 6), further supporting the notion that RAGE is a sufficient mediator of de novo
ceramide biosynthesis in cardiac tissue.
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Figure 6: Conditional upregulation of pulmonary RAGE expression increases heart
ceramides.
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Nontransgenic control and RAGE transgenic (TG) mice, which overexpress RAGE, were
euthanized and assessed for ceramide levels in cardiac tissue (A). Expression levels of SPT2,
CerS1, CerS2, CerS5, and CerS6 were also quantified in hearts from control and RAGE TG mice
(n = 3 mice/group) (B). *P < 0.05 for RAGE TG vs. control mice.

Discussion
This study assessed the effects of RAGE stimulation on cardiomyocyte ceramide accrual
and mitochondrial function. Because AGEs are established factors in the progression of
cardiovascular complications15,21, our goal was to assess whether RAGE signaling leads to
mitochondrial disruption in heart tissue and whether ceramide is an obligate mediator of these
effects. Our results demonstrated that cardiomyocytes respond to AGE treatment with a robust
increase in ceramide accrual. This increase may be due, at least in part, to increased expression
of the initial and rate-limiting enzymes of ceramide biosynthesis (i.e., SPT) as well as CerS2. To
our knowledge, our results are the first to establish a RAGE-ceramide axis within heart cells and
tissue.
Under normal physiological circumstances, RAGE serves a protective role by generating
a nonspecific inflammatory response to a host of heterogeneous compounds, but this process can
become pathological with sustained activation and chronic inflammation18. Although the scope
of our study was limited to the effects of RAGE and ceramides on cardiomyocyte mitochondrial
function, both have been implicated in a host of diabetic and smoke-induced cardiovascular
complications. However, AGEs inhaled by smokers may be chemically and functionally
different compared with de novo AGE synthesis in uncontrolled diabetics. Ma et al.15 revealed
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that AGE-RAGE ablation prevents diabetes-induced altered cardiovascular function, including
cardiomyopathy. Moreover, Park et al.23 found that ceramide inhibition through SPT ablation is
protective against dilated diabetes-induced cardiomyopathy. Thus, in light of our results of
increased ceramides with RAGE activation in heart tissue, future work will seek to determine
whether ceramides are necessary for altered heart function orchestrated by RAGE signaling.
Importantly, mitochondrial dysfunction may play a critical role in the pathogenesis of
cardiomyopathy11. This is relevant given our previous findings that ceramides directly disrupt
mitochondrial physiology, reducing respiration and increasing oxidative stress42, through a
mitochondrial fission-dependent process36. We have previously found that ceramide accrual
exhibited a widespread inhibition of mitochondrial respiration, but the effect appeared more
selective to inhibiting complex II-mediated respiration. We note similar findings in this report:
CML-treated cells did not experience the succinate-induced respiration increase evidenced in
both control and myriocin-treated cells. Our demonstration that AGEs induce ceramidedependent impairment in mitochondrial O2 flux may explain, at least in part, why diabetic hearts
are characterized by contractile impairment from anomalous energy metabolism.
Our rationale for targeting RAGE as an activator of ceramide accrual in the heart stems
from two observations: 1) as noted earlier, RAGE mediates cardiovascular complications15; and
2) RAGE shares common signaling intermediates in pathways known to activate ceramide
biosynthesis, namely, TLR4. We reported in 2011 that TLR4 is required for lipid- and
endotoxin-induced ceramide biosynthesis14. Interestingly, not only do TLR4 and RAGE share
common downstream signaling (e.g., IL-1 receptor-associated kinase)33, but also common ligand
activators (e.g., high-mobility group protein B1)10,35. Our use of cigarette smoke exposure as an
intervention to stimulate RAGE expression is based on our earlier reports of smoke exposure
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eliciting a robust increase in lung RAGE expression26,31, which is a necessary event in
transducing inflammation. However, the increase in heart RAGE expression is novel and
conveys the possible importance of RAGE modulation in heart complications. To our
knowledge, while Denis et al.9 were the first to find a ceramide-RAGE connection when they
noted a roughly twofold increase in ceramides in cultured bovine pericytes with AGE exposure,
our data may be the first to reveal this phenomenon in whole tissue. Moreover, our evidence of
RAGE-mediated increased ceramides in animals exposed to cigarette smoke and in the lungs of
RAGE transgenic mice speaks to the influence of lung RAGE signaling on heart ceramide
accrual. Despite the clear implication of RAGE in ceramide accrual, important questions remain,
such as to what extent RAGE signaling intermediates participate in ceramide biosynthesis and
mitochondrial function and how pulmonary RAGE upregulation impacts ceramide accrual in
heart tissue.
Given the considerable cardiovascular burden inherent to cigarette smoke exposure40,43,
our results provide a possible mechanism whereby smoke exposure leads to cardiovascular
complications. Ceramide has been shown to mediate cardiomyopathy22 and atherosclerosis5 and
inhibit nitric oxide-induced vasodilation47. Thus, our results may have broad implications for
cardiovascular therapies.
In conclusion, our results demonstrate that RAGE signaling reduces heart mitochondrial
respiration in a ceramide-dependent manner. Considering the dependence of the myocardium on
normal mitochondrial function, these results provide evidence for the utility of anti-ceramide
therapies in the treatment or prevention of multiple cardiovascular complications.
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CHAPTER 3:
The Discovery of an Oncogenic Enzyme in Pancreatic Cancer Involved in Cell-Fate Signaling

Introduction
Lipidomics of Pancreatic Cancer Pilot Study
Maintenance of cellular structure and electrochemical gradients, subcellular partitioning,
energy storage, first and second messenger cell signaling, protein trafficking and membrane
anchoring are all reliant on proper lipid concentrations and regulation. Using global lipid
analyses, the causative effect of insulin resistance1, metabolic syndrome2, cardiovascular
disease3, and some cancers have been described.4 Correlations between diseases and lipids have
been made with many other varied diseases including Alzheimer’s disease5, atherosclerosis6, and
obesity.7 Global analysis of lipids, known as lipidomics, is proving to be a powerful and
indispensable method for studying the dynamic state of any cell.
One of the most promising areas of lipidomics research today is the elucidation of
compositional lipidome changes as a result of cancer. We have shown through our own
experimentation that the lipid composition of cancerous cells is dramatically different than their
otherwise healthy counterparts. One of the differences we observe is the effect of metabolic
deregulation on the global lipid composition. Anabolic synthesis of membrane and signaling
lipids created as a result of oncogenic factors can be identified, detected, and tracked. One type
of signaling lipid that we have detected is lysophosphatidic acid. Interacting with at least five
known G-coupled protein receptors these signaling lipids are upstream activators of several
known oncoproteins including Ras.8
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Lipids are vital for cellular homeostasis and are often required for proper protein
function. Weise et al. has shown that some oncoproteins such as K-Ras4B are not active until
properly localized by lipid micro-domains.9 Gault et al. has even shown that oncogenic K-Ras
regulates sphingolipids in a sphingosine kinase 1 dependent manner.10
We collected and completed preliminary analysis of three pancreatic cell lines, hTERTHPNE (a telomerase immortalized pancreas cell line), PSN1 (ductal pancreatic cancer), and
PANC1 (ductal pancreatic cancer). We confirmed previous research based on lipidome profiling.
More importantly we have been able to elucidate new knowledge about underlying cellular
processes by analyzing lipidome changes. The abundant wealth of knowledge we can gain
through lipidomics is tantalizing.

Figure 1: Principle component analysis of lipidomics data. The shotgun lipidomics data of
lipid extracts of lung, heart, liver samples from mice. The results were subjected to PCA
analysis. The analysis contains 3 sets of biological, sample and technical replicates each.
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Figure 2: Primary MS1 Mass Spectra of A) telomerase immortalized pancreas cells (hTERTHPNE), B) pancreatic cancer cell line (PSN1), and C) pancreatic cancer cell line (PANC1).
Spectra were collected using a Thermo Scientific LTQ Orbitrap XL mass spectrometer and a
resolution of 100,000.

Lipid Composition Changes in Cancer
An estimated 5 x 106 lipid molecules are found per square µm of the cell membrane with
a total of 109 total lipid molecules in the full membrane of a small cell. Approximately half of the
mass of the outer cellular membrane is comprised of lipids.11
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Being the major molecular species of membranes and of energy storage, cellular lipids
play a crucial role for both physiological and cellular energy homeostasis. Perturbations in the
lipid composition of a cell can be indication of disease and disregulation. As shown in Figure 1,
we have demonstrated that samples from different tissues can be differentiated by using a
lipidomics approach. We have also shown that the same approach can be used to differentiate
cancerous tumor cells from healthy cells within the same tissue. Figure 2 illustrates some of the
distinctive lipidome mass spectra fingerprints we have collected. Balog et al. has already
demonstrated the usefulness of lipidome fingerprinting for the detection of cancer with the
introduction and commercialization of the iKnife.12 This technology cauterizes during surgical
procedures and ‘sniffs’ the ionized smoke that arises from the cut by fingerprinting the ionized
lipid cloud using mass spectrometry.
However, we are capable of taking this process one step farther by assigning specific
lipid identifications to the peaks seen in the mass spectra. This doesn’t only reveal a wealth of
useful information that helps us distinguish cell types and tissues, it reveals information about
the regulated state of the cell and can yield information about activated underlying metabolic and
anabolic pathways. Figure 3 shows the categorical lipid compositions of the three pancreatic cell
lines we have analyzed to date, as well as comparative lipid compositions of their fresh and used
growth media. We gain a wealth of knowledge even from this simple categorical grouping. We
observe that there is a drastic change in the most abundant lipid class found in healthy cells,
phospholipids. This is indicative of global deregulated metabolism.13 Additional lipid class
compositions also show similar drastic metabolic changes (data not shown). We are confident we
will be able to elucidate much more information about pancreatic cancer from the comprehensive
databases we plan to create.
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Figure 3: Categorical lipid compositions of hTERT-HPNE, PSN1, and PANC1. Data was
averaged from sample duplicates that were run in technical triplicate, with and without additional
ionizing adducts. Error bars indicate standard deviation.
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Ras activation through Lysophosphatidic acids
Lipids can act as primary and secondary cellular messengers. Lysophosphatidic acids
(LPAs) are a messenger lipid type that have only recently been discovered. Lin et al. and others
have shown that LPAs act to regulate cell proliferation, growth, survival, migration, invasion,
and promotion of angiogenesis.8 LPAs act through at least five known G-protein coupled
receptors that are capable of activating or deactivating many cellular processes. Acting through
the Rho/ROCK/actomyosin and Ras/MEKK1 pathways, LPAs enhance cancer cell migration and
accelerate focal adhesion formation.14 Our data indicate that LPA levels in pancreatic cancer are
grossly overexpressed. Figure 5 demonstrates some of the LPA species detected in our
preliminary analysis. One species of LPA worth further investigation is PA(17:2(9Z,12Z)/0:0).
No amount of this lipid was detected in hTERT-HPNE, but it was the most up-regulated
signaling lipid species in both PSN1 and PANC1.

Figure 4: GPCR pathways activated by the signaling lipid species LPA class. Adopted from
Lin et al.8
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Figure 5: Lysophosphatidic Acids (LPAs) in Pancreatic Cancer. LPAs were found to be
highly up-regulated in pancreatic cancer. Only one species of LPA was detected in hTERTHPNE. Multiple species were detected in the cancerous pancreatic cells, including one species,
PA(17:2(9Z,12Z)/0:0) that is observed up-regulated in both cancer cell types.
K-Ras Activation and Anchoring in Pancreatic Cancer

Figure 6: K-Ras4B contains a polybasic farnesylated lipid anchoring tail. It has been shown
that K-Ras is only active when clustered properly on lipid micro-domains. Adopted from Weise
et al.10
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K-Ras is a GTPase and is a major oncoprotein found in pancreatic cancer. In order to
function properly, K-Ras must be correctly localized to negatively-charged subcellular
membranes. It only becomes functional and active when it forms nano-clusters in the presence of
negatively charged acidic lipids found in membrane micro-domains.9 K-Ras4B localizes itself
with the use of a polybasic farnesylated C-terminal tail as illustrated in Figure 6. This tail is best
stabilized by interacting with acidic lipid species such as phophoserines, cardiolipins,
phosphoinositols, and phosphatidic acids. It has even been proposed that K-Ras activity is
changed in the presence of polyphosphoinositols (PIPs), and that the surface interactions with the
lipid membrane change the protein folding through interactions with the α5 helix. We have
completed an analysis of some of the acidic lipid species found in the pancreatic cell lines. More
experimentation is required to fully elucidate the effects of these acidic lipid micro-domains or to
potentially determine how to interrupt the plasma membrane targeting of these membrane
proteins.

Figure 7: Polyphosphoinositide (PIP) and General Acidic Lipid Classes in Pancreatic
Cancer. These lipid species have been shown to be important for the activity of oncoproteins
such as K-Ras.9
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Sphingosine Kinase (SphK1) Regulates Bioactive Sphingolipids
Gault et al. have shown that oncogenic K-Ras has the ability to regulate lipid member of
a class of bioactive sphingolipids known as sphingosine-1-phosphate (S1P). It does this by
regulating sphingosine kinase 1 (SK1). C-16 ceramide in particular is the target species that is
converted to S1P by oncogenic K-Ras. We were able to show this exact character among the
pancreatic cancer cell lines we studied. The cellular levels of S1P are observed to be highly upregulated in pancreatic cancer when compared to the immortalized healthy pancreatic cells. The
Gault et al. study was conducted in immortalized MEF cells. We were able to demonstrate
similar behavior in human pancreatic cancer.

Figure 8: Sphingosine Kinase 1 like activity of K-Ras in Pancreatic Cancer. Sphingosine-1phosphate levels rise as C-16 ceramide levels decrease in PSN1 and PANC1, suggesting that
oncogenic K-Ras is potentially directly involved in the sphingolipid regulation through
sphingosine kinase activity.
In-vitro Studies of Useful Pancreatic Cancer Metabolites
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Before plating and growing the cells for our study several aliquots of fresh growth media
were collected and used in a comparative study against used growth media. These samples were
analyzed using a lipidomic method. Through our experimentation we have discovered that each
cancer cell type subsists on and excretes distinct lipid species. We could use this information to
discover unique novel pancreatic cancer lipid biomarkers using a simple in vitro technique.
Completing lipidomic analyses of growth media could also allow us to do future studies to
discover specifically how diet affects the growth and lipid composition of pancreatic cancer. We
have shown that this could potentially lead to new dietary treatment methods once we learn
which lipids and metabolites most exacerbate cancer growth.

Figure 9: Metabolite Studies in Pancreatic Cancer. Fresh (left top: hTERT-HPNE, left
middle: PSN1, left bottom: PANC1) and used (right top: hTERT-HPNE, right middle: PSN1,
right bottom: PANC1) growth media from pancreatic cancer cells. Samples of fresh growth
media were collected at the same time the cells grown. More growth media was collected before
removing the cells from the plates. These samples will be analyzed to observe lipid composition
changes affected by growth in the media.
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Conclusion:
We have established that the use of lipidomics is indispensable in the study of cancer. We
have demonstrated that cancerous cells can be differentiated from healthy cells based on their
lipidome composition. This technique can greatly speed cancer detection and differentiation from
health tissue. We have shown that the effects of oncoproteins found in pancreatic cancer can be
observed using lipidomics, thereby indicating which oncongenes are active. We can can also
quickly determine the phenotype of cancer on a patient by patient basis. Our work proves that
lipidomics is a technique that can verify active oncogenes, help lipid biomarker discovery, We
have greatly increased our knowledge about pancreatic cancer through the use of lipidomics.
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Lipidomic profiling identifies modified sphingosine kinase 1 regulation, and cell-fate
signaling in pancreatic cancer

Summarizing my Contribution: This project began as a collaboration with Dr. David Bearss’
lab at BYU in the life science’s department. Preliminary analysis of pancreatic cancer using
genomic analysis, epigenomic analysis, and proteomic analysis did not yield any significant data
for targeted drug treatment of the cancer. At the time I was beginning to have success with global
lipidomic extractions, identifications, and quantitation using high-resolution mass spectrometry.
For this reason, I was approached to see if I could find anything significant lipid differences in
the pancreatic cancer cell lines. From this point on I managed the process and drove the direction
of experimentation. Using data analysis tools we developed, I was able to discover several
significant differences between healthy control cells and cancerous cells and ultimately chose the
pathways that were deemed to be most significant in the cancer cells.
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Abstract
Many bioactive lipid species play key roles in cellular signaling. These lipid signals can
evoke rapid and wide-ranging changes to cell metabolism and morphology. Here we show that a
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mass spectrometry based lipidomic analysis of human ductal pancreatic cancer identified an
imbalance in C16-ceramide and sphingosine-1-phosphate (S1P) molecules. This perturbation
increases the growth rate, and protects these cells from the mitochondrial mediated apoptotic
cell-signaling cascade. Regulation of sphingosine kinase 1 (SphK1) seems to be a major
component of this alternate regulation of lipid signals. Importantly, we observed that different
pancreatic cancer lines utilized unique alterations in SphK1 concentration and/or activation to
alter regulation of sphingosine kinase activity, suggesting that SphK1 is an important regulatory
node for the cancerous phenotype. Modified SphK1 activity resulted in pro-apoptotic signals
changing into anti-apoptotic signals. This imbalance in the ‘rheostat’ between pro- and antiapoptotic signals may, in part, explain the frequently aggressive and chemoresistent nature of
pancreatic cancers.
Introduction
Lipids in the cell are separated into categories and classes based on their chemical
structure. There is a large diversity of chemical structure and function among the lipids within
these classes. The presence of different lipid classes in a membrane can be used to distinguish
different structures in the cell (Figure 1A). Many lipids also act as messenger signals for cellular
communication. These structural and signaling roles of the lipid classes can be coopted to
support a cancerous phenotype. Signaling molecules like sphingolipids are of particular
importance in supporting changes that lead to cancer1-3.
Separation of the different species within each class can be difficult because biologically
distinct lipids can share very similar chemical structures. Differentiation between structurally
similar lipids is important, because they can have vastly different biological effects4. Cholesterol
metabolism is a well-described example of lipid signaling and represents a good example of the
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challenge5, because widely divergent signals like cortisol and aldosterone vary only by the
position of an oxygen and a proton in the structure.
Use of mass spectrometry has recently provided important insight into lipids as inducers
of cancers6, the importance of signaling lipid concentrations in response to drug treatment7, and
regulation of oncogenic proteins through lipid raft formation and anchoring1, 8. Mass
spectrometry enables the simultaneous measurement of many lipid types (lipidomics), which has
helped identify some of these roles, and reaffirmed that lipids are not just the passive structural
molecules.
Here we used an unbiased lipidomics assay (Figure 1B) to compare concentrations of
~3000 lipid species between healthy and cancerous cells. Lipidomics methods are still in
development and we found, similar to the work of Reis et al., that chemical extraction could bias
the number of lipid species we observed9. In our experiments, using a modified form of Bligh
and Dyer extraction, we could observe the maximum number of lipid species with a more
balanced view of the major lipid classes. We also incorporated adduct formation, to maximize
the ionization of the lipid species we extracted. Although we observed changes in many
individual lipids, changes in sphingolipid concentrations were particularly interesting. We
identified connected changes in two sphingolipids, which are major contributors to the cancerous
phenotype in pancreatic cells. This is due to the strong role that sphingolipids play in cellular
signaling and regulation. Cell fate can change based on the balance and regulation of key
sphingolipid molecules3.
Many sphingolipid species are second-messenger molecules that play a critical role
in cellular homeostasis. Membrane sphingolipids are bioactive regulators of a diverse array of
processes: cell growth, death, inflammation, adhesion, migration, angiogenesis, intracellular
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trafficking, and senescence2, 10, 11(Figure S2). Ceramide, a sub-class of sphingolipid, is a central
molecule in sphingolipid metabolism, and important in anti-proliferative processes, such as
senescence modulation, cell growth inhibition, endoplasmic reticulum stress responses, apoptosis
induction12, 13 and/or autophagy14. Ceramide is a required mediator of both extrinsic and intrinsic
pathways of apoptosis15. It has been shown that endogenous ceramide generation is essential for
apoptotic signaling in CD95- and TNFα-treated conditions16. Inhibition of the ceramide
producing sphingomyelinase (SMase) effectively blocks cell death17-19. Elevated C16-ceramide
levels increase mitochondrial outer membrane permeability, which mediates cytochrome c
release20. Ceramide species are also direct regulators of many BCL-2 family proteins through
multiple mechanisms12, 21. Without these vital second-messenger lipid molecules, the ability of
the cell to undergo programmed cell death becomes severely impaired or in some cases disabled
entirely21, 22.
Competing sphingolipid signals. Interestingly, by removing the fatty acyl tail from
ceramide the free sphingosine backbone can become another potent cellular signal. If the
sphingosine is phosphorylated by the conserved lipid kinase, sphingosine kinase (SphK1), it
creates sphingosine-1-phosphate (S1P) another important lipid secondary messenger which
mediates motility, cell survival, and proliferation (Figure S3). In addition, S1P has an important
paracrine signaling role because it potently stimulates angiogenesis23. Tests in human umbilical
vein endothelial cells showed that adding S1P was sufficient to protect them from apoptosis,
while inhibition of sphingosine kinase, which makes S1P, sensitized these cells to apoptosis22.
Importantly, most sphingolipid metabolites (like ceramide and sphingosine) are predominantly
located in membranes, while S1P can diffuse throughout the cell24.
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The effect of increased anti-apoptotic S1P is particularly important, because S1P is often
created from ceramide11. This means that not only is there increased signaling for cellular
motility and proliferation, but signals to arrest growth and initiate apoptosis through ceramidelinked pathways are reduced. Our lipidomics assay identified concurrent changes in C16ceramide and S1P which point to SphK1 as a major contributor to lipid signaling imbalances and
cell-fate signaling.
It is our hypothesis that this ceramide/S1P imbalance is present generally in pancreatic
cancer cells and that it imparts some of the cell death resistant nature to the cancerous cells. We
show that regulation of the sphingosine kinase enzyme is important to the accelerated growth
rate and the resistance to apoptotic signaling in five different pancreatic cancer lines.

Materials and Methods
Experiments were collected using eight ductal adenocarcinoma pancreatic cancer cell
lines including; PSN1, PANC1, BxPC3, and Capan1 (additional supplemental data available for
HS766T, MiaPACA2, CfPAC1, and HPAC). The measured lipid concentrations in the cancerous
cell lines were compared to the detected lipid concentrations in the telomerase immortalized
healthy pancreatic cell line hTert-HPNE.
Cell culturing:
Cells were obtained from Dr. David Bearss at Tolero Pharmaceuticals and were not tested
for mycoplasma contamination after arrival. Cells were cultured for ~ 6 months total in T-75
and T-25 cell culture flasks at 37oC with 5.0% carbon dioxide in RPMI 1640 with L-glutamine
and high glucose with amphotericin B (1 unit per mL) and penicillin/streptomycin (1x). Cells
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were allowed to grow to 95% confluence before hard-splitting into new culture flasks. Assays
were completed only after each cell line reached a consistent log phase growth rate to ensure
consistent treatment.
Cells were harvested by incubating with 0.5% trypsin (Thermo), the soluble cells were
then spun down at 2500 G. The pellet was rinsed in PBS and flash frozen in liquid N 2 and stored
at -80°C until needed for the various assays.
Lipidomics assay development:
In order to achieve maximum breadth of lipid species identified and high reproducibility
between samples we tested multiple sample preparation methods (supplemental Table 1). Cell
pellets were re-suspended in 1.5 mL cell lysis buffer (0.1M Tris-HCl @ pH 7.6) and
homogenized by circular cut tissue homogenizer (Omni) and vortex (30 seconds at 850 RPM).
The homogenate was then transferred to glass vial (4.5 dram) where a two-phase extraction was
completed to remove the lipid constituents. We found the modified Bligh and Dyer extraction
method25 to be the most reproducible method to achieve a large diversity of lipid classes. Sample
collection and homogenization steps were performed under cold collection environments and
under nitrogen to reduce oxidation. The final extraction mixture contained the 1.5 mL aqueous
homogenate and then an additional 3 mL of chloroform/methanol/isopropanol (3:1:1.25, v/v/v).
A larger extraction batch with the Bligh and Dyer was extracted over 24 hours with shaking gave
the closest match a spiked standard. The organic lipid containing layer was then concentrated
under reduced pressure at room temperature. The concentrated lipid extract was divided into two
separate samples for comparison of adduct effects. The half sample analyzed without adduct was
diluted with organic phase solution chloroform/methanol/isopropanol (3:1:1.25, v/v/v) with 0.1%
formic acid (Thermo) at a 9-fold dilution by volume (9:1, solution: organic layer extraction) to a
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total volume of 250 μL immediately prior to data collection. The half sample analyzed with
adduct was diluted with the same organic phase solution with 0.1% formic acid and ammonium
acetate (1.5 mM) to promote ionization of some of the neutral lipid species. The sample (with
and without adduct) was run in both positive and negative instrument modes to increase
specificity and variety of lipids through intra-source selection of differentially ionizable species.
During sample dilution and immediately prior to data collection a 1 μL aliquot of 15 mM internal
standard cocktail was added to aid in quantitation and mass alignment during the analysis phase.
The internal cocktail contained at least 1 lipid from each category as classified by the LIPID
MAPS database26, 27. When possible heavy isotope labeled or odd-chain length lipids were
selected as standard to reduce biological overlap (see supplemental for recipe).
To reduce the influence of time-dependent fluctuation or cross contamination from run to
run, the sample analysis schedule was randomized using a random number generator. In this way
if the wash cycle between sample runs did not remove all the contaminants from the capillary
line, the contaminated peak should not appear more than once in the technical replicates and is
thereby removed by the data analysis filters. Sample (250 L) was infused at 10 L/min onto a
Thermo LTQ-Orbitrap XL mass spectrometer using an IonMax ESI soft-ionization direct inject
technique. During the infusion a high resolution (≥100,000) MS1 survey scan cycled through
m/z “windows” (75-250 m/z, 250-400 m/z, 400-600 m/z, 600-800 m/z, and 800-1800 m/z). The
top 5 most intense ions from each scan were selected for fragmentation, after an ion had been
selected for fragmentation twice it was excluded from further MSMS selection.
The MSMS data was used to classify and identify individual ions (see below). The MS1
survey scan spectra summed across the entire acquisition period were used for quantification. All
the data files were analyzed separately using in-house developed module for the MSPIRE
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proteomics package28 which compared the fragmentation pattern against expected fragments for
the lipids within the LIPID MAPS29 database. Data was filtered according to absolute mass
accuracy (< 3 ppm), comparative peak inclusion (must appear in at least 2 of the 3 technical
replicate runs), and possible modifications to adduct additions, in order to keep the most
confident peak identifications. For quantitation data was normalized using the internal standards.
The normalized summed spectral intensity for each sample was considered a single quantitative
data point for an identified lipid. This process was run in biological triplicate, so each cell line or
tissue type had at least 12 instrumental runs to compile and assess data statistics.
Verification of lipid identities:
The typical data acquisition measured approximately 2000 different ions. Initial lipid
identifications were assigned for each ion based on the parent mass of ion in the primary survey
scan. To increase accuracy, the m/z of each ion was corrected according to the standard curve of
the internal standards (supplemental methods). The instrumental noise was determined as the
baseline detection level across all spectra. Only those peaks that are estimated to be at least
twice the level of the instrumental noise are included. Ions which differed from the theoretical
mass by more than 3 ppm were removed from the data set. Next, putative lipid classifications
from the LIPID MAPS30 database are checked against the fragmentation data. Fragmentation
data was not available for every putative lipid observed in the primary survey data, but it was
used to test the identifications and test that the alignment is accurate (Figure S4). An identified
lipid species was included in the high-confidence list only if it met criteria in two-thirds (8/12) of
the sample spectra. Finally, manual evaluation of putative identities was conducted to evaluate
the fragmentation chemistry. For example, if a peak is identified as a triacylglyceride, but only
matches the spectra with an impossible modification, like neutral loss of ammonia, the peak is
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eliminated or the next best match is evaluated. The curated list of high-confidence identifications
was used to define the ions compared in the MS1 quantitation.
Western Blot Analysis:
Frozen cell pellets were lysed in RIPA lysis buffer supplemented with protease and
phosphatase inhibitors (Pierce Thermo Scientific). Lysates were incubated at 4°C with gentle
rotation for 15 min. Lysates were passed through 25G needle 10 times and centrifuged at 20,000
G for 10 min. Clear lysates were mixed in SDS sample buffer and 80ug of total protein were
resolved on a 10% SDS-PAGE. Resolved proteins were transferred to Odyssey nitrocellulose
membrane (Li-Cor) and blocked with 5% milk in TBS. Western blots incubated with primary
antibody at 4oC overnight and visualized using infrared fluorescent secondary antibodies and LiCor Odyssey system.
Flow cytometry cell death assays:
Cell death assays were completed by plating cells in T-75 flasks (~10,000 cells/cm2) in
log-phase growth and allowing a minimum of 6 hours for growth and adhesion before drug
treatment. Growth media was replaced with fresh media prior to injection of drugs into culture
flasks or plates. Cells were then treated for 12-24 hours with drugs. At the end of drug treatment,
dead cells were removed and collected in a new plate. Cells were washed with 1x PBS and this
was collected and combined into the new plate. Living adhered cells were removed from growth
plates using 0.05% pH balanced trypsin at 37oC and then transferred to the new plate. Under dark
conditions on ice a 1 mg/100 mL solution of propidium iodide was mixed with light shaking into
the cell mixture and allowed 15 minutes to stain. Cell counts were then collected on a red/blue
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acoustically focused Applied Biosciences Attune flow cytometer at a scan rate of 200 µL/min
using BL2-PI blue laser and BL1 blue laser. Data was analyzed with the Attune software.
Data analysis and statistical tests:
Normalization and lipid identification was conducted using in-house developed modules
from MSPIRE module28, MSPIRE-lipidomics written in the Ruby programming language.
Statistical tests were conducted using Excel, and MatLab. Component plots were generated by
assigning identities to MS identified peaks with their corresponding quantitation data using
Perseus31 and visualized with MatLab. The multi-dimensional data sets were reduced to 3
principle components and grouped for each cell sample that was completed.
Results:
Development of lipidomics based activity assay:
Lipidomics lags behind proteomics because of the relative difficulty of identifying
specific lipids relative to protein sequences. We refined both sample preparation and data
analysis methods to measure a large breadth of the lipidome. Several published extraction
methods were evaluated to determine which method would best sample each of the major lipid
classes and introduce the least amount of bias into our mass spectrometry analysis (supplemental
Table 1). The evaluation of extraction methods was conducted using a spiked tissue homogenate
containing eight lipid standards from seven lipid categories (recipe in supplemental). All
methods had differential extraction efficiency with differences in the observed lipid categories
and classes. Another complication is that mass spectrometry requires a charged molecule to
make measurements. Many lipids do not have an intrinsic charge, but addition of ammonium
acetate in the extraction protocol increased the coverage of lipids from all categories in both
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positive and negative ion modes. Based on the initial lipid classifications we determined that a
modification to Bligh and Dyer25 extraction with addition of isopropanol and an ammonium
acetate adduct resulted in the most reproducible, broad coverage of the major lipid categories
(Figure 2, Supplemental Table 1). In order to verify reproducibility of the measurements, we
completed data collection from all samples with a minimum technical triplicate. Total unique
lipid identifications that met our criteria were compared for each of the extraction methods. We
repeatedly identified a total of 3301 lipid species using the modified Bligh and Dyer, which
dropped to 2264 species with other methods. The specificity of the identification varied based
on the quality of the fragmentation data and the information available in the publically accessible
databases32, 33.
Sphingosine-1-phosphate and C16-cerimide levels are perturbed in pancreatic cancer cells.
For this study, we utilized a panel of ductal pancreatic cancer cells and compared them
against an immortalized healthy line. A principle component analysis of the lipidome changes
between cancerous and non-cancerous cells showed that among the ~3000 identified lipids,
significant variations were observed in several lipid categories (Figure 2 A). Of particular
interest, the pancreatic cancer cell lines all displayed severely depleted C16-ceramide levels with
a corresponding increase in the levels of sphingosine-1-phosphate (S1P) relative to control
(Figure 3). Levels of S1P in all pancreatic cancers were at least double that in the immortalized
cell line. C16-ceramide and S1P are both potent cellular signals that form from a common
sphingosine precursor (Figure S1). This suggests that the enzymes controlling sphingosine
metabolism between C16-ceramide and S1P may be regulated differently in pancreatic cancer
cells.
Sphingosine Kinase (SphK1) expression and activation is elevated in pancreatic cancer.
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We tested whether the modified lipid profile observed in these cells was connected to
SphK1 regulation. We observed that there was a measureable increase in the total SphK1
concentration for multiple cancer cell lines relative to an immortalized control cell line (Figure
4). The increase in SphK concentration was very similar to the trend for S1P and the inverse of
the C16 ceramide (Figure 3). SphK1 is known to be activated by phosphorylation on serine 225.
Western blot of phosphoserine 225, showed that all the cancerous lines had an increase in the
amount of phosphorylation relative to the immortalized control (Figure 4B). Interestingly,
CAPAN1 which did not have a measurable increase in SphK1 concentration (Figure 4A), had the
highest levels of activating phosphorylation of all the cell lines. This suggests that individual
cancer cell lines have used different mechanisms to increase SphK1 activity.
Inhibition of SphK slows growth and sensitizes cells to apoptotic signals.
We tested the effect of SphK1 inhibition (SKI-II) on multiple cell lines (Figures S5, S6).
With flow cytometry, we used propidium iodide staining to count dead cells for plates treated for
12 hours with inhibitor versus control. The sensitivity to SKI-II as measured by EC50 (Figure
5C) was almost exactly inverse to the relative expression of SphK1 measured by western blot
(Figure 4). When pancreatic cancer cells (PSN1, PANC1, CAPAN1, BxPC3) were treated with
SKI-II at 1/10th the EC50, the growth rates were greatly reduced. Growth rates were also reduced
to a lesser extent in the already slower growing immortalized control, hTert-HPNE.
We tested how SKI-II changed the efficacy of inducers of apoptosis in these cells.
Gemcitabine, a nucleoside mimetic commonly used to treat pancreatic cancer34, induces
apoptosis by inhibiting DNA polymerization to the next inbound nucleoside. The sensitivity to
gemcitabine was independent of the SphK1 expression and/or phosphorylation and appeared to
be more closely related to the growth rate of the cells with the fastest growing cell requiring less
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gemcitabine to be effective35, 36. In the presence of SKI-II, the percent of dead cells increased up
to approximately ten percent potentially due to increased cell death signaling capacity although
the gemcitabine induced DNA damage was presumably less due to the slowed growth. This
increase was modest but reproducible, and statistically significant (p ≤ 0.06 in the students t-test
(n=3)) across all cell lines (Figure 5). We interpreted these results to mean that there was a
counterproductive relationship between the mechanisms of action for gemcitabine and SKI-II.
SKI-II slows slowed the growth of the cells, which protected them from gemcitabine treatment.
We subsequently tested how SKI-II affected cellular response to a BH3 domain-only
peptide activator of mitochondrial mediated apoptosis (BH3I-1). The BH3 domain is a direct
inducer of apoptosis via activation of pro-death Bcl-2 family members and therefor doesn’t rely
on DNA damage checkpoint activation to kill the cell. Similar to the gemcitabine treatment, the
sensitivity to the BH3I-1 alone, as measured by the EC50, did not directly correlate with SphK1
quantitation and activation. However, the combined effect of added SKI-II and BH3I-1 was
more robust than that observed with Gemcitabine for every cell line (p ≤ 0.02 in the student’s ttest (n=3)) (Figure 5), and did correlate with total S1P/C16 ceramide quantitation with the
greatest effect of inhibition observed in the cell lines with highest S1P expression.
Discussion:
Lipids serve multiple functions in the cell and are common cellular signals used to
promote the cancer phenotype (Figure 1). There have been many advances in the analysis of
biological lipids. It remains a complex problem because lipids with high structural similarity can
have very different biological roles. For example, a cis versus trans desaturation in a fatty acid is
very important biologically, but can be very difficult to distinguish analytically. The scientific
community is just beginning to develop the techniques to monitor the complex array of
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biological lipids (lipidome). For example, liquid chromatography is an effective method to
separate complex mixtures, but in our hands it was difficult to use on complex lipid samples.
These issues were overcome by using a direct-injection based intra-source separation. We
separated lipids based on the ionization potential in the mass spectrometer; positive and negative
modes, with and without adduct additions. This doesn’t achieve the same level of separation as
effective chromatography, but was relatively fast, allowed detection of low abundance species,
and was (in our hands) more robust than chromatographic techniques for lipids.
The lipidomics assay tested activity of multiple enzyme pathways simultaneously,
monitoring substrate and product concentrations. We identified altered regulation of SphK1 in
the sphingomyelin metabolic pathway based on changes in relative lipid distributions. We found
that multiple pancreatic cancer cell lines had achieved lower C16-ceramide and higher S1P
concentrations, through a combination of greater Sphingosine kinase (SphK1) enzyme
expression and/or phosphorylation.
Inactive SphK1 is generally found in the cytosol away from its lipid substrates. After
activation through phosphorylation at Ser-225, the enzyme relocates to the plasma membrane
where it localizes onto functional lipid-raft subdomains for its catalytic activity.37 Activating
levels of SphK1 were high in all cancer lines with the fastest growing pancreatic cancer cell
lines, PSN1 and PANC1, 2.5 fold higher than control (Figure 4). Interestingly, CAPAN1 which
had the highest levels of activation, had the lowest amount of enzyme (Figure 5). This suggests
that multiple mechanisms were used in this small panel of cell lines to shift the balance in
ceramide versus S1P. CAPAN1 demonstrated a spreading growth pattern and BxPC3 often grew
in small colony clusters. This could in part be explained by a dependence of cell-to-cell
proximity for improved SphK1 signaling efficiency in BxPC3 where both quantitation and
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activation of SphK1 is less than in the cell lines with independently activated SphK1 either
through expression, activation, or both.
Pancreatic cancer has historically been very difficult to treat 38, 39. Traditional
chemotherapeutics have only offered limited success due to the resistant nature of the cancer and
the treatment-refractory environment that the tumors establish40, 41. Here we show similar to
previous studies42, 43 that pancreatic cancer cells are resistant to apoptosis and chemotherapeutics.
Our data suggest that depleted levels of the signaling lipid C16 ceramide prevent successful selfelimination. Even worse the cancer cells are actively producing and excreting pro-growth, prosurvival signals, S1P, due to the unregulated increase in sphingosine kinase activity.
Sphingosine kinase enzymes do not share homology with other lipid kinases44.
Interestingly they do not show any homology with other lipid-binding proteins or contain
previously known lipid binding domains.45 Sphingosine Kinase 1 is a highly conserved kinase
that can act independently to induce tumor growth by phosphorylating sphingosine to form
sphingosine-1-phosphate. Overexpression of human SphK1 in NIH3T3 fibroblasts has
demonstrated its ability to independently affect morphological changes and severely alter growth
patterns. Transformed NIH3T3 cells with high SphK1 expression grown in serum exhibited
enhanced growth patterns when compared to the empty vector control cells. Even when the
transformed cells were cultured in nutrient deprived conditions they continued to exhibit elevated
growth. The SphK1 cells continued to grow beyond saturation density thereby gaining the ability
to escape the effects of contact inhibition. SphK1 transformed cells also acquired the ability to
form anchorage-independent colonies in growth media.46 Sarkar et al. were able to show that
activation of SphK1 is required for migration, proliferation, and survival of MCF-7 human breast
cancer cells.47 SphK1 was cemented as a critical component of EGFR signaling. SphK1 was
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shown to be activated through EGF and PDGR stimulation. This induced its translocation to the
plasma membrane where it can act on its substrate, sphingosine. Down-regulation of SphK1
expression almost completely blocked cell migration and metastasis47.
Interestingly, in the presence of SKI-II, there was a very modest increase in cell death for
gemcitabine. We hypothesize that reduction of S1P has an anti-proliferative effect, and slower
cell growth reduced the efficacy of the Gemcitabine. In order for a nucleoside analogue like
gemcitabine to have maximal effect cells should be proliferating rapidly34. Based on these
results, we chose to shift focus to a class of emerging chemotherapeutics, BH3 mimetics, that
target the mitochondrial apoptotic machinery directly. The BH3 mimetic, BH3I-1, was a more
effective companion to SK1-II than gemcitabine. This result may be explained by the role of
S1P in increasing the ratio of anti-apoptotic to pro-apoptotic Bcl-2 family proteins at the
mitochondria48, 49. Thus, a reduction in S1P would reverse the ratio and effectively pave the
way for BH3 mimetic-induced mitochondrial outer membrane permeabilization.
The efficacy of reducing S1P levels to increase apoptosis may also be explained by the
paracrine signaling roles of S1P. Olivera et al. showed that the proliferative response to
exogenously added S1P is partially sensitive to pertussis toxin50. Pertussis toxin prevents Gproteins from interacting with their respective receptors thereby interrupting intracellular
communication. This suggests the likely involvement of G-protein coupled cell surface receptors
in the mechanism of S1P.
Several G-protein coupled receptors (GPCRs) respond to S1P: EDG-1, -3, -5, -6, and -8.
Most GPCRs specific to S1Ps have nanomolar binding affinities. Although it requires
micromolar concentrations of S1P to have any observable effects on most cancerous tumor
types46, there are a few cancer cell lines such as T lymphoblastoma and HTC4 hepatoma cells
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that can respond to nanomolar concentrations of S1P. These cells are protected from apoptosis
and even continue to proliferate in nutrient deprived conditions. Indeed, the addition of
nanomolar concentrations of exogenous S1P was sufficient to activate ERK, induce c-Jun, and
inhibit caspase-3 activity22.
Additional research has shown that sphingosine kinase is activated and acts in an antiapoptotic role when in hypoxic conditions that induce expression of hypoxia-inducible factor-1
(HIF-1).51 Tumors that are nutrient poor and in hypoxic conditions have always led to a poor
prognosis. High expression levels of sphingosine kinase have been found in A549 cancerous
lung cells in hypoxic conditions with high levels of chemoresistance. When short interfering
RNA against sphingosine kinase are introduced the cells lose their chemoresistance and become
sensitive to cell death. Introducing lipid extracts from cells that were cultured in nutrient poor
hypoxic conditions to non-chemoresistant cells was sufficient to protect cells from etoposide
induced apoptosis.
Stopping the signaling cascade that promotes the cancer phenotype may be simplest by
inhibiting production of the initial signal like S1P. Additional promising lipid targets in
pancreatic cancer were also observed in this study. We observed a significant increase of
lysophosphatidic acids (LPAs) in cancer cells, which are also important signaling lipids involved
in oncogene regulation. There was also a reduction in acidic membrane anchoring lipids involved
in regulating oncogenes such as the farnsyl-tail containing K-Ras4B.
We propose that lipidomics assays similar to this one can be used to identify modified
enzymatic pathway activities, which drive the cancerous phenotype. This may lead to the use of
combination therapies where inhibiting the pro-survival signals while promoting an apoptotic
signal would represent a supremely effective technique for cancer treatment. Importantly, this
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methodology could be used to test tumor biopsies in order to personalize treatment options and
test efficacy.
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Figure 1: Lipids in Cancer and Our Global Lipidomics Workflow. A) General localization of
lipid classes in the cell and roles promoting cancer. B) Lipidomics workflow used in this study
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Figure 2: Categorical Composition Results from Global Lipidomics. A) Global lipidomic
identification study involving two primary ductal adenocarcinoma cell lines, PSN1 and PANC1,
and an immortalized pancreatic cell line, hTert-HPNE was conducted. Many differences were
observed between all cell lines but with observable correlation of lipid identifications between
cancer cell lines and fewer identification matches to the immortalized cell line. B) PCA analysis
of pancreatic cancer cell culture lipidomes compared to the immortalized healthy (oncogene
negative) pancreatic cell cultures. Using a three-dimensional PCA gave clear lipidome
fingerprinting separation between healthy and cancerous cell types.
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Figure 3: C16 Ceramide and Sphingosine-1-Phosphate Quantification in Pancreatic Cancer
Cell Lines. A) All tested pancreatic cancer cell lines displayed severely depleted C16 ceramide
concentrations in comparison to the immortalized healthy (oncogene negative) pancreatic cell
line. B) Conversely all tested pancreatic cancer cell lines had elevated concentrations of
sphingosine-1-phosphate when compared to the immortalized pancreatic cancer cell line. (p ≤
0.05 students t-test compared to hTert-HPNE)
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Figure 4: Western blot analysis of SphK1 expression and phosphor-activation in pancreatic
cancer. Quantitative analysis of SphK1 was completed using lysates from pancreatic cell culture.
A) Expression of SphK1 was elevated in each of the cell pancreatic cancer cell lines when
compared to the immortalized pancreatic cell line. B) Activation of SphK1 through
phosphorylation of residue Ser-225 was also observed to be elevated in comparison to the
immortalized pancreatic cell line. * Represents where p ≤ 0.05 in t test comparison to control
(hTert-HPNE). ** Represents where p ≤ 0.05 in Dunnett’s test for comprehensive comparison.
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Figure 5: Sensitivity to Drug Treatment Increases with Sphingosine Kinase 1 Inhibition.
Tissue cultures of PSN1, PANC1, CAPAN1, BxPC3, and hTert-HPNE were treated for 12 hours
with apoptosis inducers alone or with a combination of apoptosis inducer and sphingosine kinase
inhibitor. Dead cells were then stained with propidium iodide and run through a flow cytometer.
Sensitivity to chemotherapeutic treatment was increased in the culture treated with the inhibitor.
Significantly greater changes were observed with BH3I-1 as this targets mitochondrial mediated
apoptosis directly and doesn’t require fast cell growth as does gemcitabine. Treatment with
sphingosine kinase inhibitor significantly slows cell growth rates. Samples were measured in
biological triplicate (n=3) and normalized to vehicle controls. A) Treatment of PSN1 cell line
with the following concentrations: SKI-II Only (1 μM); Gemcitabine Only (9 μM); BH3I-1 Only
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(7 μM); Gemcitabine (9 μM) & SKI-II (1 μM) Combination; BH3I-1 (7 μM) & SKI-II (1 μM)
Combination. B) Treatment of PANC1 cell line with the following concentrations: SKI-II Only
(2 μM); Gemcitabine Only (9 μM); BH3I-1 Only (8 μM); Gemcitabine (9 μM) & SKI-II (3 μM)
Combination; BH3I-1 (8 μM) & SKI-II (2 μM) Combination. C) Treatment of CAPAN1 cell line
with the following concentrations: SKI-II Only (4 μM); Gemcitabine Only (5 μM); BH3I-1 Only
(3 μM); Gemcitabine (5 μM) & SKI-II (4 μM) Combination; BH3I-1 (3 μM) & SKI-II (6 μM)
Combination. D) Treatment of BxPC3 cell line with the following concentrations: SKI-II Only (8
μM); Gemcitabine Only (5 μM); BH3I-1 Only (4 μM); Gemcitabine (5 μM) & SKI-II (6 μM)
Combination; BH3I-1 (4 μM) & SKI-II (8 μM) Combination. E) Treatment of hTert-HPNE with
the following concentrations: SKI-II Only (13 μM); Gemcitabine Only (10 μM); BH3I-1 Only (1
μM); Gemcitabine (10 μM) & SKI-II (13 μM) Combination; BH3I-1 (1 μM) & SKI-II (13 μM)
Combination. (Note: gemcitabine treatment of the slow growing hTert-HPNE line was
ineffective. F) Dot plot of drug concentrations to achieve EC50 in each cell line with the
exception of hTert-HPNE gemcitabine combination treatment was ineffective.
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Figure 6: Signaling Lipids in Pancreatic Cancer. Signaling lipids play a major role in the
development and regulation of cancer. Without C16 Ceramide the cells ability to apoptose
becomes severely handicapped. Up-regulated signaling by S1P can impart many of the resistant
and aggressive characteristics of pancreatic cancer.
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Lipidomic profiling identifies modified sphingosine kinase 1 regulation and cell-fate
signaling in pancreatic cancer: Supplemental Information

Lipid standards: As described in the methods, this standard mix was added to the diluent
immediately preceding sample injection. N-heptadecanoyl-D-erythro-sphingosine (C17
ceramide) 30 μL from 5 mg/500 μL stock solution. 1,2-Di-O-Phytanyl-sn-Glycerol 20 μL from 5
mg/500 μL stock solution. 1-dodecanoyl-2-tridecanoyl-sn-glycero-3-phosphoethanolamine 30
μL from 5 mg/1 mL stock solution. Cholest-5-en-3beta-ol (d7) 30 μL from 0.5 mg/100 μL. 1heptadecanoyl-2-tetradecanoyl-sn-glycero-3-phosphoserine 30 μL from 2 mg/200 μL stock
solution. Retinoic acid 30 μL from 5 mg/500 μL stock solution. Di[3-deoxy-D-mannooctulosonyl]-lipid A (Kdo2-Lipid A) 20 μL from 5 mg/500 μL stock solution. Arachidonic acid
20 μL from 10 mg/1 mL stock solution. All stock solution bases were 2:1 chloroform:methanol
(v/v) Folch reagent with trace toluene. Standards were purchased from Avanti Polar Lipids or
Sigma Aldrich.

Mspire-Lipidomics Command Workflow:
Several Ruby scripts were used iteratively to generate lipid identification assignments.
All scripts can be executed through command-line interface using Ruby-1.9.3 (or similar) with
mspire (https://github.com/princelab/mspire) and mspire-lipid
(https://github.com/princelab/mspire-lipid) gem packages and their corresponding dependencies.
Each script will generate a usage/help screen when run without any options selected.
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The first step is to execute the “quant_compare_direct_injections.rb” script. In order to
function, the raw data files must first be converted to .mzML format with centroided peaks and
only inclusive of high-mass-accuracy MS1 (survey scan) peaks. This will combine each of
intensity values for each bin across the entire data collection run for each file into one tab
separated file (.tsv) with rows corresponding to each m/z bin value. A simple baseline mass
correction can be completed at this step to correct for mass deviations that are a result of current
instrumental calibration deviation. The best base line correction requires that internal standards
were added to the sample prior to data collection as described in col_to_file.rb step below.
quant_compare_direct_injections.rb uses the following options. (Example:
“quant_compare_direct_injections.rb -o quant_compare_first_iteration.tsv -b 3 -m mzs -p -3 -v
*.mzML”)
--outfile, -o <s>: write results to this file (default: quant_compare.tsv)
--bin-width, -b <f>: width of the bins for merging (default: 5.0)
--bin-unit, -i <s>: units for binning (ppm or amu) (default: ppm)
--split, -s <s>: share|greedy_y|zero method used to distinguish peaks (default: share)
--sample-ids, -a <s>: a yml file pointing basename to id
--mz-prefix, -m <s>: use this prefix for mz values (default: mz)
--round-mz, -r <i>: round the final m/z values to this place (default: 6)
--round-intensity, -u <i>: round the final int values to this place (default: 6)
--simple-calibrate, -p <f>: adjust the m/z values by that amount (default: 0.0)
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--verbose, -v: talk about it
--help, -h: Show this message
The next step uses the Ruby script “col_to_file.rb”. This script requires the .tsv file
created in the earlier step. This will extract only the binned masses from the .tsv in preparation
for lipid identification into a new text (.txt) file. This script also allows for more advanced mass
baseline correction which will be used later for lipid standard alignment in the high-massaccuracy lipid identification assignment.
col_to_file.rb uses the following options. (Example: “col_to_file.rb
quant_compare_first_iteration.tsv mzs -p 3.246”)
--ppm-recal, -p <f>: vals deviate this amount (default: 0.0)
--linear-interp, -l <s>: begin,end,m,b[:...]
--interp-bins, -i <s>: x,y:x,y...
--help, -h: Show this message
The next step uses the Ruby script “find_nearest_lipid.rb”. This script requires the .txt
file created in the previous step and also the .tsv database file from LIPIDMAPS with high-massaccuracy m/z’s, LIPIDMAPS IDs, class, common name, and systematic name. This database file
is available from LIPIDMAPS http://www.lipidmaps.org/resources/downloads/index.html.
(Modification of this file using Notepad++ or similar program to eliminate lipid IDs not native to
the organism of study can be completed to increases assignments based on the organism type.
I.E. limited or no polyketides in mammalian samples.) During this step the allowable chemical
and ion modifications can be added in as options. For example, water loss, protonation or adduct
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addition can be included in this step. The number of top hits with the closest mass hit can also be
selected in this step. Results can then either be shown on screen or pushed into a new .tsv or .csv
file (via > command).
find_nearest_lipid.rb uses the following options. (Example: “find_nearest_lipid_massshift.rb
LMSD_20120412_All.tsv -e quant_compare_first_iteration.3.246ppm.ONLY_MZS.txt -t 5 -s 1 a 1 -p 2 > Lipid_IDs_First_Try.tsv”)
--top-n, -t <i>: how many closest ions to print (default: 3)
modifications: (at least 1 charged mod is required)
--lithium, -l <i>: search for i down to 1 lithium adducts (default: 0)
--sodium, -s <i>: search for i down to 1 sodium adducts (default: 0)
--ammonium, -a <i>: search for i down to 1 ammonium adducts (default: 0)
--ammonia-loss, -m <i>: search for i down to 1 ammonia losses (default: 0)
--carbon-dioxide-loss, -c <i>: search for i down to 1 CO2 losses (default: 0)
--proton-gain, -p <i>: search for i down to 1 proton additions (default: 0)
--proton-loss, -r <i>: search for i down to 1 proton losses (default: 0)
--water-loss, -w <i>: if used, *all* mods are also considered with i down to 0 water losses
(default: 0)

other:
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--textfile, -e <s>: a text file with m/z values, one per line
--lower-bound, -o: use lower bound searching (requires m/z's to be in sorted order)
--sort: sorts the m/z's
--help, -h: Show this message
The next step involves a spreadsheet viewer of choice which supports .tsv file formats
(We used Microsoft Excel). The original .tsv file created during the
quant_compare_direct_injections.rb step must be opened and the final .tsv (or .csv) file created
after the find_nearest_lipid.rb step must be opened. The quantitation numbers for each m/z bin
can then be copied over to the corresponding m/z bin with the top matches. At this point of the
workflow the new spreadsheet is searched for the lipid standards that were spiked into the
sample prior to data collection. If the standards are found at the correct masses with low m/z
deviation and the standard shows up with similar intensities across all samples in which it was
spiked then we can check the raw spectra for fragmentation at that mass. If fragments match the
suspected ID we can assign the lipid standard with confidence. Usually there will be some
amount of mass deviation in the spectra when searching for the lipid standards. If this is the case,
the expected mass is evaluated and the quantitation is compared for this m/z bin. The amount of
deviation is calculated and the process reverts back to the col_to_file.rb step where mass
deviation corrections can be made. This process is repeated until all lipid standards are being
identified when find_nearest_lipid.rb is completed. Some analyses will work with only simple
mass shifts and others require more complex linear deviations dependent on m/z or mass window
used in during data acquisition. Normalization for each category of lipid is also completed by
comparing the detected intensities for lipids in a specific category to the lipid standard belonging
208

to the same category that was spiked into the original samples. The detected lipid IDs can then be
combined for each modified state in which they were observed and they can be evaluated across
replicate runs for consistency for inclusion. Confidence filters can also be applied to the data in
the spreadsheet where lipids with mass deviations greater than the desired amount can be
eliminated from further analysis. Also during this step the lipid IDs can be filtered for impossible
modifications (i.e. fatty acid IDs with ammonia loss as their possible modified state, etc…)

Supplemental Figure S1: Ceramide(d18:1/16:0) and Sphingosine-1-Phosphate Quantitation
from immortalized pancreatic cell line compared to many cancerous cell types from pancreas
(CAPAN1, HS766T, MiaPACA2, CfPac1, BxPC3, Hpac, PANC1, PSN1), Lung (H1650), and
Liver (HepG2).
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Supplemental Table 1: Comparison of Common Lipid Extraction Protocols.
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Supplemental Figure S2: Role of Ceramide in Cell Signaling Pathways.

211

Supplemental Figure S3: Role of Spingosine-1-Phosphate in Cell Signaling Pathways.
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Supplemental Figure S4: Lipid Fragment Identifications for C16 Ceramide and
Sphingosine-1-Phosphate. Experimental fragmentation shown for Cerimide (A) and S1P (C)
shown in red. For the important signaling lipids specifically quantified in this study additional
fragmentation was completed to increase confidence in assigned lipid identifications. Using our
searching algorithm both C16 ceramide and S1P were the top ranked matches with the highest
mass accuracy for the given peak mass. A) Additional verification was completed using
LipidBlast for C16-ceramide with matches for all theoretical peaks and a score of 293. B)
Comparisons for C16-ceramide were evaluated to known lipid fragmentation from Kasumov et
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al. (figure adapted from Kasumov et al1.) and Gu et al2. where we had matches for all major
fragmentation peaks. C) At the time of this analysis LipidBlast did not have S1P in its database
and could not therefore be scored in this manner. D) Comparisons for S1P were evaluated to
known purified lipid standard fragmentation from LIPIDMAPS where we had matches for all
major fragmentation peaks.
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Figure S5

Supplemental Figure S5: Cell Death and Cellular Morphology changes due to
Combinatorial Drug Treatment. Cells treated with SKI-II and BH3I-1 were imaged under a
microscope and found to have an observable morphological changes in the PSN1 cell line where
sphingosine kinase activity is elevated. Cells with high sphingosine kinase activity form less
adhered clusters when treated with SKI-II.
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CHAPTER 4:
Development of a Liquid Chromatography Mass Spectrometry (LC/MS) Based Hepcidin-25
Quantitation Assay

Introduction:
The use of mass spectrometry for clinical applications is definitely on the rise. The
advantages of mass spectrometry use for clinical analysis include: 1. One and only one mass
spectrometer can be used to complete hundreds of complex analyses. Using traditional
biochemical techniques requires that you keep expensive specialized reagents for each type of
test you desire to complete. 2. Mass spectrometry based assays don’t expire. Unlike the
traditional ELISA assay, or other chemical based assays that have a limited shelf life, a mass
spectrometer can sit for extended periods and then be used at a moment’s notice without and loss
of fidelity or accuracy. 3. Mass spectrometry based assays are adaptable. If some sampling
condition changes or there is some sort of sample degradation, then this can be detected with the
mass spectrometer. Traditional assays can’t show a degradation pattern like a mass spectrometer
can. If a sample sat too long or became oxidized the methods can be modified to adapt and
record these changes that might not otherwise be detected with other assays. 4. Mass
spectrometry based assays are cheaper. Eliminating the need for specific reagents can make mass
spectrometry based assays cheaper because they use the same, or similar, reagents for sample
preparation. 5. Mass spectrometry based assays can be more sensitive. Many mass spectrometry
based assays have lower limits of detection than traditional assays and can give more information
to a clinician. 6. Data can be researched after experimentation. With traditional chemical based
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assays, you have one shot to collect the information you need and only that information. With a
mass spectrometer you can collect as much or as little information as you desire and this can then
be evaluated for new information that was not in the original search parameters. In this way new
discoveries can be made without needed to go back and collect new samples to re-run specific
experiments.
For the reasons listed above and due to the lack of widely available protocols we set out
to develop a liquid chromatography mass spectrometry based assay for the detection and
quantification of bioactive hepcidin-25 from complex matrices. This allows for us to search for
not only human, but also rat, and mouse isoforms of the peptide hormone for use in evaluated
efficacy of treatment in our studies. While the development of the assay continued longer than
was really necessary the results we obtained we promising for this new assay.
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Whole Blood and Urine Bioactive Hepcidin-25 Determination using Liquid
Chromatography Mass Spectrometry

Summarizing my Contribution: Working in collaboration with the Dr. Richard Watt lab we
determined a need to develop a simple mass spectrometry based measurement technique for a
small signaling peptide known as hepcidin-25. The Watt lab created an animal model for anemia
of chronic inflammation and needed to know the quantitation of this signaling hormone in order
to determine the effectiveness of treatment. An ELISA kit exists for this signaling peptide but the
LLOD and sensitivity of the assay weren’t sufficient for us to determine accurate quantitation
data. In order to address this need, I set out to develop a highly sensitive method of measurement
using an LC-MS/MS based method that could be easily completed using widely available
research equipment. Initially we thought that the method development would be simple but due
to the complex nature of small peptide purification and the poor ionization character of cysteinerich peptides, this method became a much more significant project than was anticipated. I was
the primary driver of this project and determined the technique and direction this experiment
should take.
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Abstract
Hepcidin is a small cysteine-rich signaling peptide that regulates blood serum iron
concentrations1-4. Patients with chronic inflammation are known to have elevated levels of
hepcidin in their blood and urine and often suffer from anemia as a result5-10. Measuring and
quantifying the amount of active hepcidin in blood and urine can help to determine the cause and
severity of the anemia thereby helping physicians determine the correct course of treatment11-16.
We have developed a simple technique to isolate, chemically modify, and concentrate hepcidin
from blood and urine coupled to high-pressure liquid chromatography mass spectrometry that
can accurately and reproducibly measure and quantify the active hormone.
Introduction
Hepcidin is a peptide hormone that is activated under conditions of inflammation and
reduces iron release into the blood. The inactive precursor peptides prohepcidin and
preprohepcidin, which are also found in blood serum, are activated by the proteolytic enzyme
furin17. When cleaved to the 25 amino-acid (aa) length active form, hepcidin binds to ferroportin
thereby causing it to be endocytosed and degraded in the cell18. This prevents further iron release
from the iron-rich cells, and can cause iron deficiency anemia in individuals with high hepcidin25 serum concentrations1, 19, 20.
The need to develop a simple, sensitive, and accurate method to measure hepcidin-25
concentrations from body fluids has been discussed previously21, 22. Several methods for
detecting and quantifying hepcidin have been described in recent years. The first approaches
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involved immuno-chemical techniques such as ELISA assays and Western blot methods23. While
these techniques make it possible to quantify hepcidin from patients, basal hepcidin
concentrations are often below the limit of sensitivity of current antibody based assays (typically
5 ng/mL ≈ 1.8 𝑛𝑛𝑛𝑛)23. More sensitive methods have been developed using matrix assisted laser
desorption ionization mass spectrometry (MALDI-MS)24, 25 and liquid chromatography mass

spectrometry (LC-MS) based techniques24, 26, 27. The use of liquid chromatography is
advantageous because it increases the specificity and sensitivity, but faces the problem of poor
ionization of cysteine-rich peptides using electrospray ionization (ESI).
We have addressed the issue of poor electrospray response due to the cysteine residues by
reducing the cysteine residues and covalently modifying the cysteines. Electrospray response and
efficiency is determined by the ability to confer charge to the molecules of interest and the ability
of the molecules to desorb from the liquid matrix that carries the spray. This can be
accomplished by either adding easily ionizable functional groups to the molecule to add charge
and/or adding non-polar functional groups to aid in desorption from the liquid solvent. We
investigated several chemical covalent modifiers that take advantage of these electrosprayimproving characteristics. Electrospray response improved for all chemical covalent modifiers of
the peptide and allowed for greater sensitivity and a lower limit of detection for blood and urine
hepcidin.
Our sample preparation technique uses widely available laboratory equipment to isolate
and concentrate hepcidin from blood and urine and reduces sample-to-sample variation. Using
this technique, we have shown that it is possible to isolate hepcidin from complex sample
matrices including blood, and urine. The lower limits of detection in this method allowed us to
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confidently measure hepcidin in just 250 L of sample. This allowed us to compare hepcidin
concentrations between healthy subjects in both urine and blood samples.
Materials and Methods
Supplies and instrumentation
Synthetic, purified, human hepcidin-25 standards were purchased to test concentration
responses and for standard curve calculations (China Peptides). For electrospray ionization
response optimization, commercially available iodoacetamide derivative chemical modifiers
(Thermo, Sigma Aldrich) were purchased (Figure 2). Isotopically labeled iodoacetamide (CDN
Isotopes) was also used for testing and quantification. Reduction of cysteine disulphide linkages
was completed using tris(2-carboxyethyl)phosphine (TCEP) (Thermo). 30 kilo-Dalton and 3
kilo-Dalton cut-off (0.5 mL) centrifuge spin-filters were obtained for peptide isolation and
concentration (Millipore Amicon). Mass spectrometry grade formic acid (FA) (Promega) was
used as an ionization aid prior to injection into the mass spectrometer. ELISA Assay
measurements of hepcidin-25 were completed using a commercially available kit from (DRG
Diagnostics). An Agilent 1260 Infinity liquid chromatography system with an Agilent ChipCube
C18 reverse phase column coupled to an Agilent 6530 Q-TOF tandem mass spectrometer was
used for data collection and quantification of human blood and urine samples. A micro BCA
protein assay kit (Thermo Fisher) was used to quantify total protein from urine using the
included tube protocol.
Study participants
The Brigham Young University Internal Review Board (IRB) approved all aspects of the
participant recruiting and sample collection. Blood and urine samples were collected from
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healthy individuals for analysis of healthy basal hepcidin concentration measurements and to
provide complex media for standard curve creation using synthetic hepcidin.
Measurement of urine total protein and creatinine concentrations
Total protein and creatinine measurements were conducted on urine samples to test for
dilution effects and whether or not normalization of hepcidin-25 concentrations would be
required (Supplemental Figure 1). Total protein was measured according to the manufacturer’s
protocol for tube measurement of total protein using the micro BCA protein assay kit. A 1:100
dilution of the urine was required to allow for measurement within the calibration curve. Total
creatinine was measured by centrifuging urine at 18,000 g for 15 minutes and then drawing off
200 μL of supernatant. Supernatant was acidified to 0.5% FA (v/v) and then run on an Agilent
6530 QToF coupled to an Agilent 1260 Infinity with 10 cm C18 column using a 25 minute
gradient. Gradient profiles started at 95% water 5% acetonitrile ramped up to 40% water 60%
acetonitrile over 20 minutes and then ramped up to 5% water 95% acetonitrile over the final 5
minutes. Quantitation was calculated according to the extracted ion chromatogram peak volumes
for creatinine (m/z= 114.3) with fragmentation verification of the creatinine peak (m/z=86.3 &
44.3).
Sample preparation
Collected blood and urine samples were immediately placed in refrigeration at 4 oC and
were centrifuged to complete the first-step filtration within 24 hours. Whole blood, serum, urine,
cell culture media, and purified hepcidin were all analyzed using 250 μL of starting sample. A
finger-prick for blood or small tube for urine provide adequate volumes for hepcidin analyses.
The sample was placed on a 30 kilo Dalton spin filter (Fig 1). The filter separates away the large
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highly abundant proteins while allowing the smaller proteins and peptides to pass through.
Approximately 95% of the peptide was recovered in the flow through when analyzing a purified
synthetic stock solution (data not shown). The large molecular weight retentate proteins were
washed with 100 µL 8 M urea in 0.1 M Tris-HCl at pH 8.5 (urea buffer) to break any proteinprotein interactions and allow any peptides to pass through the filter membrane. Although this
step lysed the cells in whole blood we found that the filter efficiently retained all the protein
components of the lysed cells. The filters were spun 45 minutes at 18,800 g, for each step.
The flow through (solution which passed through the 30kD filter) was treated with TCEP,
50 L of 50mM stock in urea buffer) for 20 minutes to reduce the disulphide bonds and oxidized
cysteine residues in the flow-through fractions. After completion of the reduction step 100 µL of
0.2 M iodoacetamide or one of its derivatives in urea buffer is added to the mixture and allowed
to react for 30 minutes in the dark.
The reduced and alkylated sample was then transferred to a 3 kilo-Dalton cut-off spin
filter and centrifuged at 18,800 g for about 1 hour (more time may be necessary if large sample
volumes are used). The filter was then washed with 50 µL 50 mM ammonium bicarbonate and
spun for 30 minutes at 18,800 g once. This step removes the urea, salts, and lipids from the
sample while retaining the hepcidin above the filter. The spin filter retained 15 µL of the solution
and this concentrates the hepcidin in preparation for mass spectrometry without the need for
speed-vac concentrating of the sample. To recover the remaining concentrated peptides the spin
filter was inverted in a clean collection tube and centrifuged at 2,500 g for 15 minutes (Figure 1).
Completed samples were stored at -20 oC until ready for mass spectrometry at which point the
samples were thawed and formic acid was added to 1% (v/v) prior to sample analysis via LCMS.
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Samples are run on a C18 reverse phase column and eluted using acetonitrile. The
HPLC method was modified based on the column and the derivative used (Figure 2). The
amount of time required to elute the peptide mixture and varied between 10 and 20 minutes.
Although the data presented here was collected using a QToF, individual samples were run on an
Orbitrap mass spectrometer with similar results.
Consistent sample volumes of 0.5-1 µLs were injected into the column and eluted using a
27-minute acetonitrile gradient at a flow rate of 325 nL/min. A target peak list for selected
reaction monitoring (SRM) was included in the method to selectively fragment (MS/MS) peaks
of interest for peptide sequencing/fingerprinting to confirm hepcidin identification in each
sample. For the iodoacetamide derivative (Fig 2A), peaks corresponding to the [M+2H+]2+ at
1397.53 m/z, [M+3H+]3+ at 932.02 m/z, [M+4H+]4+ at 699.27 m/z, and [M+5H+]5+ at 559.62 m/z
were selected for fragmentation (Figure 3 A). A target peak list for selected reaction monitoring
(SRM) was included in the method to selectively fragment (MS/MS) peaks of interest for peptide
sequencing/fingerprinting to confirm hepcidin identification in each sample.
Addition of internal standards
Our assay allows for simple sample to sample comparison of relative hepcidin
concentrations without needing to add a synthetic internal standard. However, to obtain actual
peptide concentration values a synthetic hepcidin-25 internal standard must be used. Several
methods were employed for the addition of the internal standard. For spiked response increase
quantitation a 200 mM stock solution of synthetic hepcidin-25 in water (pH 7.5) was used to
increase the sample hepcidin concentration in a split-reference sample by 5 nM prior to the initial
sample filtration step. When heavy label iodoacetamide modifiers or multiplexed modifiers were
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used in the same sample, the TCEP reduction and cysteine capping reactions were carried out
prior to addition to the sample containing the biological hepcidin-25 to be quantified.
Data analysis
Electrospray ionization usually results in the production of multiple charge states (m/z).
This means that hepcidin was often observed in the +6, +5 (dominant), +4(dominant),
+3(dominant), and +2 charge states (Figure 3 A). For quantitation, we extracted ion
chromatogram intensities for each of the charge states and summed the peak volumes found
during the sample runs. Targeted fragmentation (MS/MS) was collected where possible and was
verified through de novo sequencing and with the use of SearchGUI28/PeptideShaker29 (Figure 3
B). Quantification was completed with the use of in-house developed quantification software and
MassHunter (Agilent). We performed statistical analyses with Microsoft Excel software.
Pearson correlation was used for comparison studies. P values <0.05 were considered significant.
Results and Discussion:
Cysteine rich peptides like hepcidin-25 often have poor ionization in electrospray. Our
method, allows fast, reproducible sample preparation and improved ionizability for hepcidin-25.
We also show that this method is relatively unaffected by sample matrix effects between blood
and urine samples. Our method should also be compatible with commutable secondary reference
materials, such as cyrolyoprotectant treated lyophilized plasma depleted of hepcidin-25 as
demonstrated by harmonization attempts of hepcidin-25 quantification methods30.
Covalent modification of the cysteine residues improves ionization
We tested efficiency of hepcidin ionization using several commercially available
iodoacetamide derivatives to covalently modify the eight cysteine residues found within the
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peptide (Figure 2). We tested the following covalent modifiers: iodoacetamide, D4iodoacetamide, dimethylphenyl iodoacetamide, fluorescein iodoacetamide and pyrene
iodoacetamide. Hepcidin with covalent modifications was quantified in a range of concentrations
from 0.5 nM to 20 nM with linear response curves that had least squares linear fits of R2 ≥ 0.95
across all conditions. We found that each modifier improved ionization relative to the
unmodified peptide. Due to the similar experimental performance, we chose to use standard
iodoacetamide for the subsequent assays due to the wide availability and lower cost. Although
we didn’t test this experimentally, the similar performance also raises the possibility of
multiplexing multiple differentially modified patient samples to determine comparative hepcidin25 concentrations for multiple subjects simultaneously. This would increase throughput and
reduce instrumental run-to-run variation. Therefore multiplexing samples could allow single run
comparisons of multiple individuals. This would be most useful in non-clinical research
applications where absolute concentrations are not as important as the comparative
concentrations.
Summed chromatographic intensity allows accurate quantification
We found that the assay had a linear range of quantitation of more than 500 fold (0.1-50
nM) in buffer (Figure 4 A). We used a chromatographic quantification by monitoring masses
which corresponded to the +5, +4, +3, +2, and +1 charge states of hepcidin-25 (Figure 3A). A
least squares fit linear regression was used for the calibration curve and the coefficients of
determination (R2) were greater than 0.95 in either blood or urine. The lower limit of
quantification (LLOQ) was determined as the lowest regularly detected concentrated calibration
standard, 0.1 nM, with a signal/noise ratio against the background greater than five. Only one
charge state of the modified peptide was typically observed at this low concentration. Our limit
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of detection and the limit of quantification are below the reported values of basal hepcidin in
healthy controls11, 31, 32.
In order to examine matrix effects on the hepcidin measurement, we created standard
curves in blood and urine (Figure 4 B-C). We found that the use of synthesized hepcidin as an
internal standard allowed efficient and accurate quantification from basal concentrations up to 50
nM. We tested two different methods for the assay. First, we split each sample in half, adding a
known reference amount of synthetic hepcidin in one half of the sample. We calculated the basal
concentration as the difference between samples (Figure 5 B,D). Second, prior to adding the
synthetic hepcidin reference, we alkylated it with heavy isotope labeled iodoacetamide (Figure
2B), which we spiked into the sample prior to the filtration steps. Subsequent alkylation of
sample did not affect the previously modified hepcidin. We then compared the signal of the light
and heavy hepcidin (+ 32 Daltons) through summation of total chromatographic peak volumes
within the same sample. Concentration was calculated as the ratio of heavy to light hepcidin
multiplied by the known concentration of the heavy standard (Figure 5 A,C). Simultaneous
elution of the heavy labeled standard was another metric to increase the specificity of the
method. Both methods allow for accurate quantification and when compared against each other,
had statistically insignificant differences in total quantification (Figure 5 E-F).
We determined that absolute quantitation could be determined through either three
measurements (basal and two spiked concentrations) or a single measurement with spiked heavylabeled hepcidin, with a maximum variance between methods of only 0.036. For absolute
quantification, the method only requires the addition of synthetic human hepcidin-25. The
advantage of the heavy isotope labeled standard is that it reduces the number of mass
spectrometry samples.
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Detection of hepcidin-25 in blood
A benefit to our method is that whole blood can be used without the need to separate
plasma or sera from the blood first. The ultra-filters are capable of simultaneously segregating
the very abundant protein components whole blood (hemoglobin, serum albumin, etc.) from the
hepcidin. Previous precipitation methods have been known to cause co-precipitation of hepcidin
along with the abundant proteins in blood thereby biasing the total amount of hepcidin-25 that is
recovered for quantification. Centrifuge times are lengthened due to the high protein content in
whole blood relative to serum, but the sensitivity of the LCMS method allowed us to use small
volumes of whole blood which reduced the required centrifugation time. Also in whole blood,
the complexity of the final sample increased with more compounds co-isolated with hepcidin,
but the chromatographic and mass separation were sufficient to allow specific and sensitive
detection of hepcidin. The increased sample complexity did required a higher amount TCEP (0.2
M) to reduce fully all of the cysteines of the hepcidin peptide due to the overall higher cysteine
concentrations in blood.
Spiking in covalently modified hepcidin-25 into whole human blood and then extracting
the peptide using our method resulted in linear correlations with R2 > 0.99 in all samples tested
(Figures 4 C, 5 A-B). Detection of the peptide in blood after preparation of the sample gave
similar instrumental responses as other tested complex matrices. In all patient samples tested
basal hepcidin concentrations were above the LLOQ for our assay. Additionally we were able to
detect concentration increase differences accurately with only 0.5 nM incremental spiked
additions of modified peptide with coefficients of variance less than or equal to 0.076 for all
concentrations when samples were run contiguously. (Figure 4 B-C).
Detection of hepcidin-25 in urine
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Urine does not contain as many complex abundant proteins as blood and is processed
rapidly using the same method as the blood. In our assay, urine hepcidin-25 concentrations
correlate to blood hepcidin concentrations and can potentially be used for clinical diagnostic
purposes if required. According to our measurements, the excreted concentrations of hepcidin-25
are generally less than that found in blood. Among the nine volunteers that were able to donate
time, matched blood and urine samples the mean urine hepcidin concentration was 1.3 ± 0.1 nM
compared to a mean hepcidin concentration of 5.9 ± 0.5 nM in blood. Spiking in covalently
modified hepcidin-25 into human urine and then extracting the peptide using our method resulted
in linear correlations with R2 > 0.99 in all samples tested (Figures 4 B-C). Additionally we were
able to detect concentration increase differences accurately with only 0.5 nM incremental spiked
additions of modified peptide with coefficients of variance less than or equal to 0.045 for all
concentrations when samples were run contiguously. (Figure 4 B-C).
LC/MS assay has a linear correlation with ELISA, but increases range and sensitivity
Using donated blood samples collected through finger prick (minimum sample volume of
400 µL) and time matched urine samples we analyzed 11 blood and 9 urine samples using a
commercially available hepcidin-25 ELISA (DRG Diagnostics EIA-5258) and our LC/MS assay.
The lowest detected concentration of hepcidin in blood was 1.51 nM and 0.349 nM in urine.
Interestingly, all samples contained concentrations of hepcidin-25 that were detected in both the
LC/MS method and in the ELISA. All concentrations were within the known LLOQ for the MS
assay. However, while the ELISA assay was able to detect and quantify lower concentration
levels of hepcidin-25, it was at or near the quantitation limit for the assay. This resulted in a
lower correlation between assays at concentrations near or below 1 nM where
spectrophotometric variations in the ELISA measurements were greatest. Additionally this could
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potentially be due to detection of truncated isoforms of hepcidin in the ELISA with
proportionally higher concentrations of truncated peptide when active isoform concentrations are
low. Overall, similar concentrations were detected in each method with a standard deviation of
1.39 nM at high concentrations in blood and 0.228 nM at high concentrations in urine when
assays were compared side by side using the same samples (Figure 6 A-B).
Biological observations of hepcidin-25 in human body fluids
Comparison of blood and urine hepcidin concentrations from the same individual
suggests that the urine hepcidin concentration is about 25% of the blood concentration (Figure 6
C). Many factors could affect the correlation of hepcidin-25 that is measured in the blood
compared to measurements in urine. Temporal spikes due to transient furin activation in the
blood can occur which rapidly increase concentrations. Removal of the peptide from the blood
into urine may represent the average over a longer time interval when compared to shorter
interval spikes in blood peptide concentration changes.
We tested to see if urine dilution between subjects could explain the variation in our
measurements. Hepcidin-25 concentrations appear to change independent of total protein
detected (Supplemental Figure 1 A). Creatinine concentration which is also used as a
normalizing factor in urine samples33, did not increase the correlation between blood and urine
(Supplemental Figure 1 B). Of note for application of this assay, recent research indicates that
normalization to creatinine concentrations in urine under conditions of prolonged inflammation
may be inappropriate.34
Interestingly, all of our human sample donors (n=11) had detectable levels of hepcidin-25
in both blood (>1.51 nM) and urine (>0.349 nM). This was surprising as we expected the
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possibility of donors with no detectable hepcidin present. No significant difference was observed
between male (n=6) and female donors (n=5) from our sample set.
Conclusion
This method detects and quantifies hepcidin in complex samples using a simple isolation,
modification, and quantification technique that can be used effectively on widely available LCMS/MS instruments. Our assay also showed a linear correlation with ELISA results and is very
robust to sample matrix effects. Human blood and urine samples evaluated with our method
produced reproducible linear standard curves for all modified compounds tested and are capable
of differentiating sub-nano molar concentration changes of hepcidin-25 in complex matrices.
Three orthogonal methods were used for confident identification of hepcidin-25: accurate mass
detection of multiple hepcidin charge states, simultaneous chromatographic elution profiles for
the different hepcidin charge states, and fragmentation sequencing through MS/MS based on the
amino acid structure of the peptide. This method can be used for small single sample analysis or
for high throughput multi-sample analysis. These techniques may also be applicable to other
small cysteine rich peptides that have traditionally been hard to detect because of their low
concentrations and poor ionizability.
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Figure 1: Sample Preparation Protocol. 1. Sample collection from blood, or urine. 2.
Ultrafiltration with 30 kDa cut-off filter to remove abundant large proteins. Washed with urea to
break protein-protein interactions. 3. Filtrate contains small proteins and peptides without the use
of precipitation. 4. Filtrate transferred to 3 kDa cut-off filter and then treated with TCEP and
iodoacetamide covalent modifier. 5. Ultrafiltration with 3 kDa cut-off filter retains modified
hepcidin-25 peptide. Washed with ammonium bicarbonate (ABC)/methanol to remove salts and
lipids. 6. Filter recovery of modified hepcidin-25 peptide using inverted filter collection. 7.
Sample transferred to mass spectrometry vial and acidified to 1% (v/v) formic acid prior to LCMS analysis.
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Figure 2: Iodoacetamide Based Chemical Covalent Modifiers. Chemical compounds used to
modify the eight cysteine residues in hepcidin-25 in order to aid in electrospray response. (A)
Standard iodoacetamide (IAM) (B) Heavy label iodoacetamide (IAM-D4) (C) Dimethylphenyl
IAM (D) Fluorescein IAM (E) Pyrene IAM (F) Comparison of Chemical Covalent Modifiers
used to aid Electrospray Response. All of the tested chemical modifiers improved the ionizability
of hepcidin-25. Unmodified and unreduced hepcidin-25 remained undetected.
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Figure 3: Detection of Hepcidin-25 by Mass Spectrometry and Confirmation through
MS/MS Sequencing and Chromatographic Profiling. Three orthogonal methods for confident
identification of hepcidin-25: mass fingerprinting of multiple charge states, MS/MS
fragmentation sequencing, and chromatographic separation profile. (A) Multiple charge states
used for quantification of hepcidin-25 modified with iodoacetamide. (B) Fragmentation
sequencing through collision-induced dissociation (CID) MS/MS used to verify the identity of
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hepcidin-25. Spectra generated using PeptideShaker with a 0.5 Da 90% confidence interval. (C)
B and Y ion series fragments of the peptide detected from fragmentation. (D) Extracted ion
chromatograms for 2 detected charge states, 699.27 m/z [M+4H]4+ and 932.02 m/z [M+3H]3+,
at basal detection level in healthy human blood (see Figure 4 C).
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Figure 4: Lower Limit of Detection and Low Level Concentration Determination from
Complex Matrices. (A) Calibration curves detecting hepcidin-25 at low concentrations in
human urine. Linear differentiation of hepcidin-25 concentrations was achieved with as low as
0.5 ± 0.1 nM concentration increase increments in urine. (B) Synthetic hepcidin-25 was spiked
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into human whole blood and collected using our protocol. Response across all samples was
linear with predictable ion intensity increases for each spiked amount. Linear differentiation of
hepcidin-25 concentrations was achieved with as low as 0.5 ± 0.1 nM concentration increase
increments in whole blood.
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Figure 5: Comparison of Spiked Standard Ion Intensity EIC Peak Volume Quantitation
versus Isotopically Heavy Labeled Internal Standard Quantitation. Blood and urine samples
from 4 patients were analyzed for quantitation using two methods. The first method involved
splitting one sample and spiking in a known concentration of synthetic hepcidin-25 (5 nM
concentration spike)(China Peptides). These two samples were run in tandem and the EIC peak
volume difference was determined for the increased spiked sample. This was then used to
determine the EIC peak volume signal increase per nM increase of hepcidin-25. The second
method involved spiking in known concentrations of isotopically heavy labeled IAM modified
hepcidin-25 in order to generate a standard curve by which the natural isotopically light
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hepcidin-25 EIC peak volume can be used to calculate a concentration. (A) Standard curve
generated from heavy isotope modified Hep-25 IAM in blood. (B) Standard curve generated
from spiked in unmodified Hep-25 IAM in blood. (C) Standard curve generated from heavy
isotope modified Hep-25 IAM in urine. (D) Standard curve generated from spiked in unmodified
Hep-25 IAM in urine. (E) Comparison of measured hepcidin-25 concentrations from heavy label
standard vs comparative spiked standard in human blood. (F) Comparison of measured hepcidin25 concentrations from heavy label standard vs comparative spiked standard in human urine.
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Figure 6: Comparison of MS Detection Protocol versus Standard Hepcidin-25 ELISA. (A)
Comparison of measured hepcidin-25 concentrations from ELISA and LC-MS/MS Assays in
human blood and (B) in human urine (analyzed with biological duplicates). Volunteers gave
blood and urine samples that were prepared in parallel for ELISA and for the MS Assay.
Quantitation was determined for the ELISA by generating a standard curve with purified
synthetic hepcidin-25. Quantitation for the MS assay was completed by aliquoting one of the
samples and spiking in a known concentration of hepcidin-25 for comparative ion-count-perconcentration quantitation. Samples were run in duplicate. (C) A correlation can be made
between time-matched blood and urine samples. The concentration of hepcidin-25 in urine is
approximately 4-fold less than in blood. All concentrations were within the known LLOQ for the
MS assay. However, while the ELISA assay was able to detect and quantify lower concentration
levels of hepcidin-25, it was near the quantitation limit for the assay. This resulted in a lower
correlation between assays at concentrations near or below 1 nM where spectrophotometric
variations in the ELISA measurements were greatest. Additionally this could potentially be due
to detection of truncated isoforms of hepcidin in the ELISA with proportionally higher
concentrations of truncated peptide when active isoform concentrations are low.
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Supplemental Figure 1: Total protein and creatinine normalization evaluation. (A) Total
protein concentration measured in urine did not show a statistically significant correlation to
detected hepcidin-25 concentrations. (B) Normalization of detected hepcidin-25 concentrations
can also be determined by measuring creatinine concentrations using established methods
described previously although may not be necessary or appropriate.
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CHAPTER 5:
Development of an Ultra-High Pressure Liquid Chromatography (UPLC) System for High
Performance Separations

Introduction:
In order to maximize the number of identifications of peptides and proteins in a complex
sample you must separate them into simpler mixtures. There are several methods by which this
can be accomplished but the most common by far for proteomics is liquid chromatography.
Using the inherent chemical properties of the peptides in a complex sample they can be attached
to a surface through non-covalent interactions. These interactions will change based on the
ionizability of the peptide, its size, its hydrophobicity, and by its charge. Once a peptide is
attached then additional small molecules can be used to compete away these interactions to make
it so that only a small portion of the peptide will detach from the surface based on the
concentration of the small molecule that is competing the peptide away. By using a gradient this
concentration can change gradually and result in the release of peptides in a controlled manner
and in a way so that only a few similar proteins will be observed in the mass spectrometer at any
given time instead of all of them at once.
The performance of the liquid chromatography system can also be improved by changing
a few parameters as well. Greater separation of peptides can occur if the there is more surface
area for peptide binding and less room for the peptide to get through a matrix without contacting
a binding surface. This is usually accomplished by using very small beads with high surface area
packed into a small diameter column. As the bead size decreases and the surface area increases
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the amount of pressure required to push the peptides and solvent through the column also
increases. Sometimes these pressures are so great they require special instrumentation to give it
enough push to actual get the solvent and peptides into and ultimately through the column.
This is where the next project came in. I helped develop a system that can not only
provide enough pressure to push peptides into a small efficient column but is also small enough
to be easily portable. Many of the previous pump systems available were much to large to be
easily transported and also lacked the performance that the pump system we developed can
achieve. We tested the instrument with great success with purified peptide mixtures and tryptic
digests using very small sample volumes. This was able to show the utility of the system in
providing portable high performance in the field of proteomics.
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Compact Ultra-high Pressure Nano-flow Capillary Liquid Chromatograph Coupled to an
Orbitrap Mass Spectrometer for Proteomics

Summarizing my contribution: This project initially began to restore functionality to the LTQ
Velos Pro Orbitrap Elite because of the failure in our Eksigent HPLC system we had been using.
As it turned out the new experimental portable HPLC system mentioned in this publication was
still in development and still required many additional modifications and revisions. I was
involved in the final set-up, rotor modification, method development and performance analysis
of the pumping system. I directed and collected all of the relevant mass spectrometry data using
a compound mixture that I designed as well as a method that I proposed, developed, and
executed. I assisted in the writing, editing, and layout of the final paper.
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Abstract:
A compact ultra-high pressure nano-flow liquid chromatograph (LC) was developed
specifically for coupling to mass spectrometry (MS) for proteomics studies. The system utilized
innovative nano-flow pumps, integrated with very low volume stop-flow injector and mixing tee.
The system weighed only 5.9 kg (13 lbs) and could hold up to 1100 bar (16,000 psi) pressure.
The total volume pump capacity was 60 µL. In this study, the sample injection volume was
determined by either a 60 nL internal sample loop machined in a high pressure valve rotor or by
a 1 µL external sample loop, although other sample loops could be selected. The gradient dwell
volume was approximately 640 nL, which allowed significant reduction in sample analysis time.
Gradient performance was evaluated by determining the gradient step accuracy. A low RSD
(0.6%, n = 4) was obtained for day-to-day experiments. Linear gradient reproducibility was
evaluated by separating a three-component polycyclic aromatic hydrocarbon mixture on a
commercial 150 µm inner diameter capillary column packed with 1.7 µm particles. Good
retention time reproducibility (RSD < 0.17%) demonstrated that the pumping system could
successfully generate ultra-high pressures for use in capillary LC. The system was successfully
coupled to an Orbitrap MS in a simple and efficient way; LC-MS of a trypsin-digested bovine
serum albumin (BSA) sample provided narrow peaks, short dwell time and good peptide
coverage.
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Introduction
Ultra-high pressure liquid chromatography (UHPLC) has been around for almost two
decades, introduced to overcome the pressure limitations of conventional pumping systems and
to allow the use of very small particles as stationary phases.1-3 Due to its excellent separation
efficiency, short analysis time, low solvent consumption and easy coupling to mass spectrometry
(MS), UHPLC has become a very popular and green analytical tool, and is becoming widely
used for environmental, biochemical and pharmaceutical analysis.4-10
Very small particles (sub-2 µm) can result in improved performance in LC, as well as
high speed separations.1,11-14 However, without shortening the column length, the use of small
particles requires high pressures. Operating at high pressures can create frictional heating, which
can impact the retention of solutes and, in some cases, cause decomposition,1,14 eventually
destroying the column efficiency.15,16 Heat dissipation can be facilitated by reducing the column
diameter.1,12,17 Small diameter packed fused silica columns allow fast heat dissipation, low
organic solvent usage and minimal waste generation.
The first UHPLC system for capillary columns packed with 1.5 µm nonporous silica
particles was a home-built system reported by Jorgenson’s group.1 The same group also
constructed a gradient UHPLC system and separated a tryptic protein digest using 1.0 µm
particles at 9000 bar.2 However, the system was very large, inconvenient, and not amenable to
routine use. A subsequent UHPLC system was constructed by modifying a Waters Model 6000
pump, which was coupled to a tandem MS using a capillary packed with 1.5 µm nonporous
particles.18 This system demonstrated a high duty cycle, good signal-to-noise and full
automation. This work led to the introduction of commercial UHPLC instrumentation in 2004.19
Currently, more than 20 different UHPLC systems are commercially available, with upper
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pressure limits between 600-1500 bar.4,20,21 However, these commercial instruments are still
primarily constructed by modifying conventional HPLC instrumentation, and they remain
somewhat bulky. They are limited to laboratory operation, and cannot be easily used for field
applications. Additionally, when coupled to MS in the laboratory, long connecting tubing is
needed, which greatly reduces the performance of the UHPLC system.
Compared to standard columns, e.g., 4.6-1.0 mm i.d., extra-column band broadening
becomes much more critical when using smaller internal diameter columns.21 Fekete et al.
compared the extra-column peak variance contributions of several commercially available LC
systems, and concluded that losses in efficiency can reach 30–55% with these UHPLC systems,
even when optimized.22 Further improvements in instrumental design could be achieved by using
smaller volume capillary fitting, smaller and shorter connecting capillary tubing and smaller
volume detector cell to reduce detrimental extra-column dead-volume.22-26 Furthermore, small
dwell volume is also highly desirable for UHPLC.21
The injection system for UHPLC should hold extremely high pressure, deliver a
reproducible small volume, eliminate all carryover and minimize brand spreading.27 Static-split
injection technology was reported by Jorgenson’s group, which withstood high pressures.1,2,28
Wu et al. used a pressure-balanced injection method to introduce sample, and found it to be
effective and reproducible.3 A commercial system (Waters ACQUITY UPLC) uses a flowthrough-needle injector.29 The gradient passes through the needle during injection, ensuring
complete sample transfer. In addition to the above-mentioned concerns, the detector dataacquisition rate is also very important. Narrow peaks (as small as 1 s in some cases) require at
least 10-15 data points per peak to accurately specify resolution.21
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Significant effort has been made in the past to miniaturize LC.30-34 However, little effort
has been made to miniature UHPLC. Recently, we reported a compact gradient LC system with
an LED UV-absorption detector (260 nm).31 This system meets many of the requirements for a
field-portable LC, i.e., light-weight (9 lbs), low mobile phase consumption and waste generation,
and battery operation. The pressure generated by this pump could reach up to 8,000 psi.
Although nano-flow UHPLC systems are commercially available, they are not portable.
One of the most popular applications for UHPLC is mass spectrometry-based
proteomics.35 Due to the complex nature of protein/peptide samples, integrated UHPLC-MS is
commonly used to analysis these samples. UHPLC is used prior to MS to separate complex
peptides or proteins for accurate identification and quantitation. High separation power, fast
analysis, small sample volume and easy coupling to MS are some of the key requirements for an
UHPLC system used for proteomics. A simplified portable UHPLC system would reduce the
footprint of the system, increase the duty cycle, simplify maintenance, reduce costs and even
improve the separation power.
In this work, a small, portable gradient ultra-high pressure nano-flow pumping system
was developed and evaluated using an on-column LED-based UV-absorption detector reported
earlier, 36 as well as with an Orbitrap MS. The system was designed specifically for capillary
columns. Gradient performance and separation were evaluated using this new integrated
UHPLC-UV system. Efficient coupling of the nano-flow UHPLC to an Orbitrap MS for
analyzing trypsin-digested BSA for proteomics was demonstrated.
Experimental section
Chemicals and reagents
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Water, methanol, propyl paraben, and three polycyclic aromatic hydrocarbon (PAH)
standards (fluorene, anthracene, and benzo[a]pyrene) were purchased from Sigma-Aldrich (St.
Louis, MO, USA). Acetonitrile (ACN) was purchased from Fisher Scientific (Pittsburgh, PA,
USA). All solvents and chemicals were HPLC or analytical grade. Chromatographically purified
bovine serum albumin (Sigma-Aldrich) ≥ 95% was prepared for bottom-up mass spectrometry
analysis using a filter aided sample preparation (FASP) technique.37 Approximately 500 μg of
protein were loaded onto a 30 kDa cut-off ultra-filtration spin filter (Vivicon) for the FASP
protocol. Due to the high concentration of the final BSA peptide mixture, it was diluted 100 or
1000 fold and cleaned once more with a C-18 solid phase extraction cartridge (Sigma-Aldrich)
prior to injection into the LC.
Instrumentation
The pumping system for the new gradient nano-flow UHPLC instrument (Figure 1) was
engineered at VICI Valco Instruments (Houston, TX, USA). Compared to our previous gradient
pumping system, several important modifications were made as follows: (1) the “Y” design (i.e.,
two pumps and one valve) was changed to two individual pumps (each with stepper motor and
high-pressure valve), which were connected to a separate injection valve (Figure 1);38 (2) a new
sealing material was used to seal around the piston; and (3) smaller i.d. tubing was used to
reduce the dwell volume.
Overall, the pumping system included two pumps, each with separate high pressure valve
and stepper motor, a three-way static mixing tee connected to a serpentine tube for solvent
mixing, and another high pressure valve (18,000 psi) with a stop-flow injector. The pumping
system weighed 5.9 kg (13 lbs) and could hold up to 1100 bar (16,000 psi) pressure. Each pump
volume capacity was 30 µL. The stop-flow injector contained a sample groove in the rotor,with
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sample volume of 60 nL or a 1 µL external sample loop; however, the groove or external sample
loop could be engineered to deliver sample volumes anywhere between 5 nL and the low µL
range. Zero dead-volume (360 µm) fittings especially designed for capillary columns were used
for all connections, and no splitting was employed. This system provided accurate non-split flow
in the low nanoliter to microliter per minute range, and was fully software-controlled. An oncolumn deep UV LED (260 nm) absorption detector described earlier,36 or an orbitrap MS
(described later in this section) was used for detection.
System evaluation
The methods used to determine the dwell volume and gradient step accuracy were
reported earlier.31 In brief, methanol and propyl paraben in methanol were used as mobile phases
A and B, respectively. A linear gradient was programmed through a hollow capillary (150 μm
i.d.) from 0 to 100% B in 10 min with an isocratic hold at 100% B for several min. An injection
of uracil was used to determine the capillary dead volume. The dwell volume of the system was
calculated by subtracting the capillary dead volume from the gradient delay volume.
For evaluating step accuracy, the system was programmed from 0% B to 100% B 10%
intervals. The gradient was stopped every 10% step for several minutes to record the UVabsorption signal. The absorbance record by the detector increased as the proportion of B in the
mobile phase increased, and reached a maximum at 100% B. Every measurement was repeated at
least four times to determine the precision of the results. The recorded absorbance value at each
step was divided by the absorbance recorded at 100% B, which served as a reference.
Injection carry-over was studied by recording the signal obtained by first injecting uracil (0.33
mg/mL in an ACN/water mixture, 70:30 v/v). Then, the injector was thoroughly cleaned by
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purging with mobile phase, and a blank injection (mobile phase) was made. Isocratic elution was
used (ACN/H 2 O, 70:30 v/v), and the flow rate was 2 µL/min. These experiments were repeated
three times, and the detector signals were recorded. For each experiment, the peak area in the
blank divided by the peak area of an analyte signal, multiplied by 100%, was reported as the
percent carry-over.
Chromatographic performance was evaluated using a packed capillary column
(ACQUITY BEH130 C18, 1.7 µm, 100 mm × 150 µm i.d., Waters, Milford, MA) to separate a
PAH mixture under gradient programming conditions. The post-column capillary was removed
and replaced by a UV-transparent fused silica capillary (150 µm i.d.), which was used as a
detection window. Gradient elution was programmed from 50% A to 100% B in 11.6 min.
Solvent A was water and solvent B was ACN. The flow rate was 2 µL/min. The retention time
reproducibilities (n = 4) of components were calculated.
Coupling to Orbitrap MS
Polyimide coated fused silica tubing (75 µm i.d. × 365 µm o.d.) was used to prepare a
column for coupling to the MS. Before packing, one end of the capillary was melted using a
small butane micro torch, and pulled into a narrow tip (approximate 25 µm i.d.) to be used for
electrospray ionization (ESI). Then, the capillary was packed with 1.7 µm BEH C18 particles
(Waters, Milford, MA) by slurry packing. After the desired length was packed, the column was
flushed with ACN before being used for MS analysis.
A hollow capillary (25 µm i.d. × 365 µm o.d., 15 cm total) was used for the transfer line
between the column with integrated ESI tip and injection valve. A VICI zero dead volume union
was used to connect the transfer line and the column as well as to apply the high voltage for
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electrospray (photographs of the all connections and column with integrated electrospray tip
ware shown in the Supplemental Information, Figures S1-S2). MS detection was carried out after
ESI in the positive-ion full-scan mode. An LTQ Veles Pro Orbitrap Elite tandem MS from
Thermal Fisher (Waltham, MA USA) was used, and the settings of the MS were as follows:
spray voltage, 2.5 kV; capillary temperature, 325oC; and scan range, 150-2000 m/z. Nitrogen
was used as sheath gas (3 arb. units). Data acquisition and analysis were performed using
Thermo Xcalibur software Version 2.2.
Results and Discussion
Pump operation
The UHPLC system contained a four-port injection valve to switch between sample
loading and injection (Figure 2). Each port served a specific purpose as described in the
following: S is the sample injection port, W is the waste port, C is the column port, and M is the
port through which the mixed mobile phase flowed to the internal sample loop and then to the
column and detector. SG represents the sample groove in the rotor for loading the sample.
Software controls the pump to switch automatically between the “load” and “inject”
positions. In the load position, the pumps were automatically refilled with their respective mobile
phases A and B at the preset rate of 20 µL/min through a 200 µm i.d. tube. At the same time, the
sample was introduced manually into the 60 nL sample loop. After the valve was switched to the
inject position (i.e., the rotor rotated by 90o), solvents from the pumps were mixed at the tee to
form a gradient flow. Then this gradient flow was used to carry the sample in the sample loop
through the analytical column to the detector for analysis.
Dwell volume
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The dwell volume is defined as the volume from the solvent mixing point to the head of
the analytical column.39 The sample experiences undesirable isocratic broadening in the dwell
volume. When performing fast separations in LC, there are two main concerns related to large
system dwell volume: (1) unreliable gradient method transfer between columns of different
geometries, and (2) greater than expected separation time.21 Small dwell volume is highly
recommended for fast analysis, especially when small i.d. columns are used, such as capillary
columns. Knowing the dwell volume of a new system is also very critical for transferring
methods from conventional LC to UHPLC.
The dead volume was calculated by subtracting the capillary dead volume from the
gradient delay volume. The dead volume was 1.91 µL (1.91 min × 1.0 µL/min), so the dwell
volume of this system was calculated to be 0.64 ± 0.008 µL. This value is less than half of the
dwell volume measured for our previous nano-flow gradient system (1.3 µL),31 and less than the
delay volume of a Waters NanoACQUITY UPLC system (< 1 µL).
Gradient profile
Good gradient accuracy and precision is a prerequisite for achieving reproducible
separations. To test the accuracy of the gradient, experimental step errors were plotted against
their corresponding theoretical step percentage values as illustrated in Figure 3A. Deviations
from predicted values were less than 0.8%. A gradient step accuracy of ± 1% is considered to be
acceptable for an LC system.31 In order to evaluate the precision of the gradient, experimental
RSD values were calculated for a series of step percentages and plotted against their respective
theoretical step percentages. As shown in Figure 3B, the RSD values (n = 4) were less than
0.6%, which is comparable to commercial instruments. Therefore, the gradient performance of
this system was found to be excellent in terms of step accuracy and precision.
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Low carry-over is important for quantitative analysis in LC. Uracil was chosen as test
analyte because a non-retained marker is commonly used to evaluate the injector performance.
Data from this work showed that the nano-flow pump injector had low carry-over (0.20 ± 0.1%).
This indicated that the flow-through injector is very reliable for quantitative work.
Reproducible retention time is a fundamental requirement for chromatographic
separations. Under gradient conditions, high reproducibility comes from high gradient accuracy.
As shown in Figure 4, highly reproducible retention times of PAHs were obtained by using the
UHPLC system. The RSD values were calculated to be less than 0.12%, which is better than the
value (1.42%) obtained from our previous “Y” design gradient pumping system.31 Day-to-day
reproducibility was also measured from experiments conducted over three days with three
injections per day. The RSD was less than 0.17% for these PAH compounds. It should be noted
that there was still some dead-volume between the column and UV detector, so separation
performance could be further improved if this dead-volume was removed.
Performance under high pressure and coupling with MS
Another nano-flow UHPLC system with 1.0 µL sample loop was coupled to an Orbitrap
MS for proteomic analysis. Due to the small particle size (1.7 µm) used in the analysis, higher
backpressure (>10,000 psi) was required. Under high pressure, solvents compress to a certain
extent, which leads to inaccurate flow rate and distorted gradient. Most commercial pumping
systems use reciprocating designs, while some use flow and feedback control to solve this
problem.
In our system, for simplicity, no flow and pressure sensors were employed. In order to
obtain a good gradient, we evaluated two different ways to solve this issue. In the first approach,
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at the beginning, both pumps were moved at the same speed until pressure was built up, and then
the pump for solvent A (water) was programmed to pump at full speed while the other pump was
temporarily stopped to wash all of solvent B (acetonitrile) out of the line. Sample was then
injected into the flow stream and a normal linear gradient was started. For the second approach, a
serials of gradient steps were generated at the first of the run to compensate for the solvent
compressibility. As shown in Figure 5A, without an initial compensation procedure, the gradient
was not linear, but jumped rapidly from 0 to 40% solvent B (uracil was added to solvent B for
easy detection) with a steep slope at the beginning. By adding two gradient steps (gradient
solvent B at 25% for 10 min and then 5% for 10 min), a near linear gradient from 5% to 40%
was obtained as shown in Figure 5A. Both of these approaches were used to separate a trypsindigested bovine serum albumin (BSA) sample. Using the method of delay injection, a 25 min
gradient from 5% to 45% acetonitrile was used, for the chromatogram shown in Figure 5B. The
FWHM peak width was approximately 10 s, the dwell volume was less than 2 µL, and an
identified peptide coverage of over 90% was obtained using Mascot.40 Similar results were
obtained using the stepwise gradient compensation as shown in Figure 5C, with a gradient from
5% to 30% in 30 min and FWHM of approximately 15 s. These results were comparable to
previously reported LC results. Further work is currently being done to implement an initial
solvent compression routine into the operating software.
Conclusions
Ultra-high operating pressures for capillary LC were made possible using a newly
developed LC pumping system. This new nano-flow gradient system showed excellent gradient
performance, and gave highly reproducible retention times of PAH compounds on a capillary
column packed with sub-2 µm particles. Efficient gradient separation of peptides was also
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demonstrated when coupled to an Orbitrap MS. The advantages demonstrated in this study
include: (1) fast analysis with minimum solvent consumption, (2) easy positioning of the small
pumping system and analytical column close to the electrospray source, which greatly reduced
band broadening and analysis time, and improved detection limits, and (3) simple and powerful
separation systems for MS-based proteomics analysis.
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Figure 1: UHPLC system. (A) Cut-away drawing of a single nano-flow pump; (B) photograph
of the nano-flow UHPLC with LED detector.
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Figure 2: UHPLC valve operation. Operating schematics of the nano-flow UHPLC injection
valve. (A) load position, (B) inject position.
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Figure 3: Gradient accuracy. (A) Gradient step accuracy (±% B) and (B) precision in gradient
step accuracy.
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Figure 4: Reproducibility in retention time of a mixture of PAHs.
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Figure 5: Chromatograms of a peptide mixture by UHPLC-Orbitrap MS: (A) total ion
chromatogram of five target peptides, (B) extracted ion chromatogram of [Asn1, Val5]angiotensin II ([M + 3H]3+, 345 m/z), (C) extracted ion chromatogram of angiotensin I ([M +
3H]3+, 432 m/z), (D) extracted ion chromatogram of angiotensin II ([M + 3H]3+, 349 m/z); (E)
extracted ion chromatogram of leu-enkephalin ([M + 3H]+, 556 m/z), and (F) extracted ion
chromatogram of Angiotensin fragment 1-7 ([M + 3H]2+, 450 m/z). Experimental conditions:
column with integrated ESI tip, 12 cm (75 µm i.d. × 365 µm o.d.); mobile phase A, 0.1% formic
acid in water-ACN (95/5, V/V); mobile phase B, 0.1% formic acid in ACN; gradient program,
100% A for 5 min, then ramp to 100% B in 20 min with a flow rate at 500 nL/min; injection
volume, 60 nL.
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Figure 6: Comparison of gradient profiles and tryptic BSA base-peak resolved
chromatography. (A) Comparison of gradient profiles (uracil was added to monitor the
concentration of solvent B, acetonitrile); blue: no compensation step from 0% to 40% B; red: two
step compensation, 10 min at 25% B and then 10 min at 5% B. (B and C) Chromatograms of a
trypsin-digested BSA sample using coupled UHPLC-Orbitrap MS: (B) sample injected 20 min
after 10 min 50:50 (A/B, water/ACN) and 10 min 95:5 wash (total-ion and extracted-ion
chromatograms, m/z = 632). (C) Sample injected at 0 min, compensation steps of 75:25
(water/ACN) for 10 min and 95:5 for 10 min before linear gradient of 5% to 30% (total-ion and
extracted-ion chromatograms, m/z = 654). Experimental conditions: column with integrated ESI
tip, 12 cm (75 µm i.d. × 365 µm o.d.); mobile phase A, 0.1% formic acid in water/ACN (95:5
v/v); mobile phase B, 0.1% formic acid in ACN; flow rate, 500 nL/min; injection volume, 1.0
µL.

Figure 7: Abstract graphic UHPLC performance.
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Supplemental Information
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B

Supplemental Figure S1. Column with integrated electrospray tip. (A) Column packed with 1.7
µm C18 and (B) pulled electrospray tip.
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Supplemental Figure S2. Interface between the nano-flow UHPLC system and Orbitrap
MS. (A) Connection between the injection valve and electrospray source and (B) zero-dead
volume union used for connecting the column and transfer line from the pump.
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CONCLUSION:
I have shown that in biological systems, small changes can have significant impacts.
Through the process of my doctoral research I was able to demonstrate that very simple small
molecules can make tremendous changes to an organism. Whether these changes are the result of
inflammation signaling and the proteolytic activation of bioactive hepcidin-25 in iron transport
control or changes in ceramide concentrations resulting in mitochondrial function impairment or
insulin signaling impairment or cell-fate signaling due to lipids in cancer the outcome is
significant. The new techniques and new pathways I helped elucidate help to further our
understanding of disease and the way in which we can measure and diagnose them.
Mass spectrometry has proven to be a very useful tool in elucidating biological changes
even at a very small scale. My proteomics based techniques have been critical in identifying and
quantifying proteins and peptides in complex systems and have allowed us the ability to track the
efficacy of treatment in pharmacological studies. This work resulted in the development of a
scalable method to detect and quantify the small iron-regulatory hormone known as hepcidin
from a variety of samples such as blood, urine, and cell-culture media. I showed that our
improved high-resolution mass spectrometry based lipidomics techniques are capable of
identifying small changes in diseased states that are associated with inflammation, mitochondrial
shape and function, and cancer. Without this knowledge there were few ways to confidently and
quantitatively know whether or not our hypotheses regarding the biological systems were
actually true. I was also able to show the discovery of a new oncogenic pathway in pancreatic
cancer that had never been observed before. The new knowledge about this pathway and the
lipidomics technique I helped develop may allow for new treatment options that can be explored
and the assay I developed can also be used as a companion diagnostic to track disease
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progression and treatment efficacy. Our techniques we have been able to extract, identify, and
quantify several thousand unique lipid species from complex samples with confidence.
I was also instrumental in evaluating and revising a new ultra-high pressure liquid
chromatography (UHPLC) system that allows for better separation of analytes from complex
mixtures for identification and quantification. Development of these technologies will help to
dispense the availability of powerful instrumentation for use in more areas where this would
have otherwise been impossible.
Through these advances we hope to aid researchers and clinicians to enable them to
further our knowledge about the small but significant changes that regulate complex biological
systems through the use of direct injection and liquid chromatography mass spectrometry.
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